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ABSTRACT
The explosion of high-throughput Omics assays in past 15 years has led to a rev-
olution in the quantity of data and the number of data types which are available to
biological researchers. This has necessitated a second revolution in the development
of analytical tools to handle this wealth and variety of data. No longer is it practical
for a researcher to simply examine a list of differentially expressed compounds and
draw meaningful insight about the biological processes at hand; these differentially
expressed compounds must be put into context with each other, and integrated with
existing biological knowledge. Co-expression techniques, where the simultaneous ex-
pression of two or more compounds is analyzed, have become a powerful tool for
biological insight in high-throughput Omics settings.
The primary goal of this dissertation is to develop techniques for identifying and
characterizing patterns of co-expression. In our first project, we develop a Differ-
entially Weighted Factor Model for estimating covariance matrices related through
structured experimental design. Our factor model allows us to estimate common
structural elements using all available data, and to estimate unique structural el-
ements in a condition specific manner. We develop a method for visualizing the
resulting estimates, and implement the method in an R package, DWFM. The sec-
ond project presents a method using the Prize Collecting Steiner Tree algorithm
to integrate and identify modules in lipid and untargeted metabolomic assays in a
data-driven manner. These assays are integrated over a co-expression network spe-
cific to the applied setting in question, allowing us to capture modules unique to
this setting. Our final project presents a second technique for identifying modules
xii
of co-expressed biomolecules. This technique addresses a major limitation of PCST
based approaches, namely that one is required to choose a cutoff to obtain a list of
differentially expressed compounds used as input into the algorithm. Additionally,
this second method utilizes a meta-analytic inspired approach to identify patterns of
co-expression across multiple data sets, thus reducing the impact of a single noisy
assay.
xiii
CHAPTER I
Introduction
1.1 Background and motivation
1.1.1 Co-expression networks
Over the past decade, co-expression networks have proven themselves to be a
powerful tool for analyzing high-dimensional Omics data. In such settings, the nodes
correspond to biomolecules (genes, proteins, metabolites, lipids), while the edges cap-
ture statistical associations between them. These networks can be drawn from well
annotated biological or pathway databases; it has been noted, however, that networks
comprising of genome-wide (proteome-, metabolome-) interactions derived from ex-
perimental or observational data may contain novel interaction information not cov-
ered annotated in existing databases [2]. Studying such associations has enhanced our
understanding of a number of biological phenomena, including dynamics of human
disease [3], transcriptional changes associated with aging [4], and condition-specific
alterations to metabolic pathways [5].
A number of techniques are available in the literature to estimate networks from
data, including correlation based methods [6, 7, 8] and partial correlation ones [9,
10, 11]. The former are straight forward to calculate, but focus on highly connected
compounds which may not be particularly informative, being potentially driven by
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artifacts [12], while also not differentiating between direct and indirect interactions
between compounds. Partial correlations have been used extensively in Omics set-
tings, but require large sample sizes to calculate (see discussion in [10].)
Coexpression networks on a single dataset have been used to identify hub genes and
pathway associations in retinoblastoma [13], to functionally annotate long noncoding
RNAs (lncRNAs) and identify their potential cancer associations [14], and to identify
potential treatment targets of peripheral arterial disease [15].
Differential analysis of co-expression networks, where the networks themselves are
tested for differences between conditions, have been used to identify novel glioblas-
toma linked gene sets [16] and capture changes in functional interactions resulting
from genetic/epigenetic changes that affect co-expression, but not expression, in the
molecular pathogenesis of multiple sclerosis [17].
Co-expression networks aggregated over multiple related data sets have been used
to gain insight into the ways in which cancer affects perturbs co-expression relation-
ships [18], illuminate the role of indirect connections in gene networks [19] and identify
functional modules of genes in a meta-analytic fashion [20].
1.1.2 Metabolomics
Metabolites are small molecules which are chemically transformed during metabolism;
the metabolome is the collection of these metabolites in an organism. The metabolome
is closely linked to phenotype [21], more so than the genome or proteome, as metabo-
lites are direct signatures of biochemical activity. We are particularly interested in
a subset of metabolites known as lipids - a group of organic compounds which are
crucial for understanding cellular physiology and pathology. Both targeted and un-
targeted mass spectrometry assays are used in metabolomics and lipidomics studies;
targeted assays seek to detect and measure a single metabolite or a select group of
metabolites, while untargeted assays seek to measure any metabolite feature present
2
in the data.
Advancements in mass spectrometry, coupled with the development of more so-
phisticated data processing tools and comprehensive spectral libraries, have enabled
researchers to probe deeper into the metabolome and lipodome; thousands of metabo-
lite features can be measured simultaneously, necessitating the development of new
techniques for functional interpretation of such data. In some ways, the field of
metabolomics stands at a similar point to where the field of genomics stood 15 years
ago, when gene set enrichment and pathway analysis became the tool of choice for
gaining insight into the underlying biology of differentially expressed genes [22].
Just as Gene Set Enrichment Analysis (GSEA) [23] and Gene Set Analysis [24]
approaches were developed to analyze high throughput genomics data, so various
metabolite set enrichment analysis methods have been developed to understand high
throughput metabolomics data [25, 26, 27]. Many of these methods, for any Omics
data types, rely on canonical pathways or other knowledge drawn from existing bio-
logical knowledge bases, such as KEGG [28] or Gene Ontology [29].
This reliance on prior biological knowledge for gaining insight poses a particular
problem in analyzing the lipidome, which is essentially unannotated to canonical
features. Additionally, there are certain lipid classes which are tightly linked, as
lipids in one class serve as precursors for those in another class; for example, there is
the association between the lysophospholipid, diacylglycerol, and triglyceride classes
that are involved in the triglyceride synthesis pathway. Such biochemical constraints
give rise to more structured co-expression patterns which, if appropriately leveraged,
can provide insight into disease processes.
1.2 Dissertation Overview
The primary subject of this thesis is identifying and characterizing patterns of
co-expression; each remaining chapter presents a variation on this theme. We focus
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on Omics applications where prior biological knowledge is lacking (e.g. lipidomics and
untargeted metabolomics), and in each chapter the results of the method are used to
generate hypothesis about the broader biological phenomenon at play.
In Chapter 2 we introduce a differentially weighted factor model capable of jointly
estimating the structure of multiple related covariance matrices. Studying co-expression
networks from high dimensional Omics data has been used to enhance our understand-
ing of a wide range of biological phenomena. Often the data from such studies can be
partitioned intro groups corresponding to experimental conditions or disease states.
Traditional approaches analyze these groups separately, and thus do not make full
use of all sample information. Our method uses all available data for the identifi-
cation of common structural elements and group/condition specific data to estimate
differential weights across conditions. We also introduce a method of visualization to
aid in summarizing and interpreting the results of our method. The method’s utility
is demonstrated on lipidomics data from breast cancer patients.
The proposed method and visualizations have been implemented in the R-package
DWFM available at https://github.com/tguidici/DWFM.
Chapter 3 presents a data-driven method utilizing the Prize Collecting Steiner Tree
(PCST) algorithm to integrate and identify modules of differentially abundant lipids
and untargeted metabolites, while also also incorporating relevant, non-differential
compounds. We apply our method to data from a controlled feeding study and use
condition specific co-expression networks to identify dietary linked modules of lipids
and small polar molecules. We then confirmed that the identified modules were altered
in an animal model of differential metabolite utilization.
The method we present in Chapter 4 addresses one of the limitations of the method
in Chapter 3. As PCST methods rely on choosing a significance cutoff, biologically
meaningful features which miss this cutoff could be missed. Identifying modules based
only on patterns of co-expression between variables helps overcome this limitation.
4
We present a method for identifying modules based on co-expression patterns across
multiple datasets. The method is applied to the data set used in Chapter 3, and the
discovered modules are used to illuminate systems level changes in a second, more
complex data set.
5
CHAPTER II
A Differentially Weighted Factor Model for
Estimating Multiple Related Covariance Matrices
with Applications to Lipidomics
2.1 Introduction
There has been much work in recent years on estimating co-expression networks
from high-dimensional Omics data. In such networks, the nodes correspond to biomolecules
(genes, proteins, metabolites, lipids), while the edges capture statistical associations
between them. Associations can correspond to Pearson correlations or more robust
variants such as Spearman’s ρ or Kendall’s τ , or partial correlations [30]. As noted
in [31], networks comprising of genome-wide (proteome-, metabolome-) interactions
derived from experimental or observational data, may contain novel interaction in-
formation not covered by the standard pathways. Studying such associations has
enhanced our understanding of a number of biological phenomena, including dy-
namics of human disease [3], transcriptional changes associated with aging [4], and
condition-specific alterations to metabolic pathways [5]. Patterns of co-expression
are also important in studies involving metabolomics and/or lipidomics data, since
changes across experimental conditions or disease states can provide insights into the
flow of metabolites through latent metabolic processes. Further, since most lipid
6
species are not currently mapped to canonical pathways, studying their co-expression
can provide useful information of identifying sets of lipids, possibly from different
classes (see Appendix Section A.4 for a very brief primer on lipid classes), that can
be the focus of downstream analysis. Note that in the case of lipids, there are certain
lipid classes which are tightly linked, as lipids in one class serve as precursors for
those in another class; for example, there is the association between the lysophos-
pholipid, diacylglycerol, and triglyceride classes that are involved in the triglyceride
synthesis pathway. Thus, such biochemical constraints give rise to more structured
co-expression patterns which, if appropriately leveraged, can provide insight into dis-
ease processes. Such a setting arises due to the dietary and enzymatic influences that
affect lipid metabolism [32, 33].
The data from many biomedical studies involving Omics data can be naturally
partitioned into groups, corresponding to either different experimental conditions or
disease states. The standard way to conduct analysis of co-expression patterns in this
setting would be to estimate from the Omics measurements a separate co-expression
network for each group and subsequently examine them for common patterns. Under
the assumption that the groups exhibit similarities in their co-expression due to
relationships between the experimental conditions or disease states, a better strategy
would be to develop a statistical model that would enable joint estimation of all co-
expression networks, thus utilizing the sample information across all groups efficiently,
but at the same time allow for differences across groups to manifest themselves.
The motivation for such a modeling framework comes from examining co-expression
lipidomics data for a set of women with early stage breast cancer being treated with
aromatase inhibitor (AI) therapy. The subject’s lipidomes are assayed before begin-
ning the therapy, and 3 months into treatment. Half of the women were unable to
tolerate the AI therapy for more than 6 months due to significant side effects (more
details in Section 2.3.3 and Appendix Section A.4). A visual exploration of the co-
7
Figure 2.1: Scaled first and second eigenvectors from each condition in AI dataset.
Eigenvectors taken from the eigendecomposition of the sample covariance
matrices. Metabolites are colored by class. The TGs, colored in grey,
provide a good illustration of the overall similarities and condition spe-
cific differences between the four conditions. They are relatively similarly
placed in the four plots, but different subgroups of the TGs expand or
contract from condition to condition.
variance matrices for the four groups shows a number of striking similarities across
all of them, but also group specific patterns within each individual data set. These
are depicted in Figure 2.1, where the first two principal components of each data set’s
covariance matrix are plotted, with the points colored by lipid class. It can be seen
that a common structure is shared amongst the data sets, but the patterns are ex-
panded or contracted in each data set; i.e., the group specific co-expression patterns
are roughly proportional to some common structure shared across the data sets.
To formalize this finding, we propose a factor analysis model, wherein the factor
loadings are decomposed onto a common set of loadings, shared across all groups,
but which we allow to be differentially weighted within each group. Thus, when esti-
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mating the common loadings, information from all samples in the study is utilized, a
particularly attractive feature in the analysis of data sets with a small number of sam-
ples in each group (a common enough setting for Omics data), while the differential
weights are calculated based on the sample information from each group.
This modeling framework can inform biomedical researchers of the set of variables
(biomolecules) which are acting in a concordant manner and characterize the under-
lying biological processes in the data, while their differential weighting sheds light on
how these common patterns of association are modulated or disrupted in a specific
group. Such information could then suggest avenues for further investigation into
potential mechanisms underlying the observed differences between groups.
This problem has received some attention in the bioinformatics and biostatistics
literature. A number of approaches focuses on data sets representing different Omics
modalities (genomics, proteomics, etc.) but acquired on the same set of samples and
the goal is either to remove idiosyncratic variability [34], or find common signatures
across Omics modalities for subsets of samples [35, 36]. These approaches use matrix
decompositions (e.g. principal components analysis or non-negative matrix factor-
ization) appropriately constraining their parameters across data sets; for a review of
related approaches see also [37]. When the statistical associations in the co-expression
networks correspond to partial correlations, one has also to contend with the issue
that there are more variables present than samples, and therefore such networks can
only be estimated from Omics data only if additional structural assumptions are im-
posed; the most common and popular assumption being that of sparsity - namely,
that most interactions are non-present. There is an expanding body of literature on
this topic -see e.g. [38, 39, 40] and references therein. Finally, [41] focuses on the
problem of testing for differences between two covariance matrices defined on the
same set of variables, obtained from two different data sets, without assuming any
structural similarities between them.
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In this work, the focus is on identifying common, but “differentially weighted” co-
expression patterns, which shares some conceptual commonalities with the work on
partial correlation networks mentioned above. However, the technical framework and
developments are different. Finally, it should be noted that the proposed methodol-
ogy is capable of identifying data driven strongly interacting modules of biomolecules,
that can be of interest to test for enrichment, as discussed in [31]. This feature is par-
ticularly useful in studies involving lipidomics data, where as previously mentioned,
canonical pathways are not well delineated. Hence, their enrichment analysis has
the potential to provide a systems perspective which can lead to deeper biological
insights.
2.2 Methods
2.2.1 Differential Weighted Factor Model
We start the presentation by providing some basic background on the factor
model for a single data set, before generalizing to the K-group setting. Let X
denote a data set of size n × p, containing Omics measurements on p variables
(biomolecules) collected from n samples. Since the focus is on understanding co-
expression/co-variation patterns amongst variables, a factor model represents a stan-
dard tool for this task. Formally, let x be a p-dimensional vector of random vari-
ables with distribution function H representing the p Omics measurements. Hence,
the n samples are independent and identically realizations from the distribution H.
The classical factor model [30] posits that the i-th variable can be expressed as a
linear combination of m latent common factors {fj}mj=1 and an idiosyncratic error;
namely xi =
∑m
j=1 λijfj + i, where λij is a weight and i an error term. Since
both the factors and the errors are unobservable, for identifiability purposes it is
assumed that F = [f1, · · · , fm]′ and E = [1, · · · , p]′ satisfy E(f) = 0,E(E) = 0,
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E(FF ′) = I,E(EE ′) = Ψk,E(F ′E) = 0, where Ψ is a diagonal matrix containing
the variances of the error term. Therefore, the common factors and the idiosyncratic
components are uncorrelated and also uncorrelated between them. Then, some stan-
dard algebra gives that Cov(x) ≡ Σ = (Λ)(Λ)′+Ψ, where Λ is a p×m matrix of factor
loadings with elements {λij}p,mi=1,j=1. The latter equation can be used to estimate from
the data set X, the corresponding model parameters (Λ,Ψ) by applying for example
an eigenvalue decomposition on the sample covariance matrix S = (X ′X) [30]. Note
that Λ is identified up to rotations, since for any orthonormal matrix Φ, we have that
Σ = Λ˜Λ˜′ + Ψ, where Λ˜ = ΛΦ and F˜ = ΦF .
Our objective is to model jointly the co-expression/co-variation of the K groups.
To that end, we posit the following model for the p random vector xk that generates
the observed data in set Xk comprising of nk samples:
(2.1) Xk = ΛkF k + k = BkQF + k, k = 1, · · · , K,
where Λ = BkQ, with Q being a p×m matrix of common factor loadings and Bk, a
p×p diagonal matrix, being a set of differential weights. Further, the assumptions on
the factors F k and idiosyncratic components Ek are as in the single model case, and
further we assume that E(F k(F `)′) = 0,E(Ek, (E`)′) = 0,E(F k(E`)′) = 0, ∀ k 6=
` = 1, · · · , K. Similar calculations as above yield that each group specific covariance
matrix Σk = Bk(QQ′)Bk +Ψk. Note that the model reduces significantly the number
of loading related model parameters to (p × m) + Kp from k × (p × m), in the
unconstrained version above.
To complete the model formulation, we need to impose a further identifiability
constraint on the differential weight matrices Bk; otherwise, we can inflate all of them
by a factor c, deflate the elements of Q by the same factor c and the model would
not change. To that end, we propose the following two identifiability constraints.
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The first is
∑K
k=1 B
k = Ip (ID1), where Ip denotes the p-dimensional identity matrix.
According to it, the weights for each variable i must sum to 1 across the K conditions.
The second one is motivated by applied settings where the K groups can be naturally
arranged according to the levels of a two-way factorial design. For example, suppose
we have K = 4 groups of disease and normal, female and male patients. Hence, our
two grouping factors are disease status with K1 = 2 levels and sex with K2 = 2 levels.
The second identifiability constraint is then given be
∑K1
k=1B
k = Ip (ID2) for those
groups k, where one of the grouping factors is fixed at a certain level (e.g. normal)
and we are normalizing over the levels of the other grouping factor.
Remark II.1. The model formulation assumes that the factors F k for each group
span different (orthogonal) subspaces, and their coupling comes from the structure
imposed on the factor loading matrices Λk. An alternative would have been to allow
the factor F = [F 1, · · · , FK ]′ to have correlated elements between the various F k’s,
but not within. That is E(F k(F k)′) = 0 for all k = 1, · · · , K, but E(F k(F `))′ 6= 0. In
this case, to identify the model parameters we would require that the factor loading
matrix Λ containing the loadings for all K factors F k, k = 1, · · · , K be block diagonal.
The most restrictive model formulation assumes that F k = F˜ , ∀ k = 1, · · · , K, that
is there is a single latent space explaining the co-variation structure of all the K data
sets, but this proves excessively stringent, since this would suggest to put all K data
sets together and analyze them as a single one.
2.2.2 Estimation Procedure
Since we assume that the data Xk span different subspaces, we can estimate the
model parameters by the following two stage procedure:
1. Estimate Λk through the eigenvalue decomposition of Sk the empirical covari-
ance matrix of Σk.
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2. Estimate the model parameters by solving Λk = BkQ subject to the identifia-
bility constraints (ID1) or (ID2).
Specifically, since we require a rank-m solution, an application of the Eckart-Young
theorem gives that the best rank-m approximation (in squared Frobenius norm) of
S˜k = Uk[1:m]D
k
[1:m](U
k
[1:m])
′, i.e. the eigenvectors corresponding to the largest m eigen-
values of Sk. Therefore, a rank(m) estimate for Λk is Λ̂k = Uk[1:m]
√
Dk[1:m]. Then, from
step (2) above, we get using (ID1) that
(2.2) Q̂ =
K∑
k=1
Λ̂k
or under the (ID2) constraint, the estimate is given by Q̂ = 1
K1
∑K
k=1 Λ̂
k or replacing
K1 by K2.
Then, the estimates for the differential weights are obtained under both normal-
ization constraints by
(2.3) B̂kii =
1
m
m∑
j=1
Λ̂ij
Q̂ij
.
Next, we briefly discuss two implementation issues. The first has to do with
selecting the number of factors; one can use the standard strategies employed in
factor and principal components analysis for each Σk, namely employ the scree plot
and spot where the knee in the eigenvalues occurs, or require that the total variance
explained by the first m factors exceeds a certain percentage (e.g. 60% or 70%). The
final selection for m would be that value that is most compatible across all K groups.
The second issue deals with the rotational invariance of the factor model discussed
above, which is also a feature of the eigenvalue decomposition [30] used to obtain Λ̂k.
Since the Q̂ is an average of K Λ̂k’s, we need to ensure that all of them have the same
”orientation”. The latter is addressed through a Procrustes rotation (see [42].)
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Extension to Sparse Factor Models: For many data sets, the factor structure
may be sparse, wherein different subsets of variables load on different factors. The
estimation of sparse Λk’s becomes more involved. There are a number of propos-
als in the literature that address this issue, including (i) sparse principal component
analysis (SPCA) [43, 44] that employs an elastic net (a combination of a lasso and
a ridge) penalty to obtain sparse principal components, while relaxing their orthog-
onality constraint commonly assumed in classical PCA, (ii) the standard eigenvalue
decomposition used in Step 1 of the proposed estimation procedure, where the eigen-
vectors are truncated by magnitude [45] (EDTM) and (iii), a novel method presented
here, similar to (ii) but the eigenvectors are truncated by the cardinality of their
support (EDTC).
Note that approaches (i) and (ii) require careful selection of tuning parameters;
specifically, for SPCA the regularization parameters the control the lasso and ridge
penalties, while for EDTM selecting a universal threshold value. Without a priori
knowledge of the sparse patterns in Q, tuning these methods directly proves chal-
lenging, as manifested in our simulation studies. Instead, we developed an alternative
approach that provides good estimates of the number of factors m together with their
support using a community detection algorithm. Each covariance matrix is regarded
as a graph, with edge weights given by the absolute value of the covariance matrix.
The leading eigenvector community detection algorithm (LEVCD) [46] is used to find
groups of highly connected nodes (correlated variables). These communities corre-
spond to the columns of Q and the size of each community roughly corresponds to the
number of non-zero components (the cardinality of the support) for a given column
of Q. This last fact is key - we could have estimated the number of factors from a
scree plot, but it would not have provided the support size for each factor. We set the
number of factors, m, equal to the smallest number of communities within a data set,
across all K data sets. The cardinality of non-zero support in each factor is set to the
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cardinality of these communities s = (s1, · · · sm), where si > si+1. These estimates
for m and s, can then be used to estimate Λ̂k via either SPCA (Appendix Algorithm
4) or EDTC (Appendix Algorithm 3).
All algorithms are detailed in full in Appendix A.1, along with a performance
review on selecting the tuning parameters, and a comparison of all three methods in
Appendix A.2.
2.2.3 Illustration of the Method through a Toy Example
An intuitive understanding of how the method works can be gained via the follow-
ing small example. Suppose we have data from an experiment with 3×1 experimental
design. The data have 2 common latent factors, 2 variables are observed across data
sets. The Bkii are equal across all data sets (B
k
ii = 0.33), but the noise in the ob-
served data (Ek) increases with each condition. The error terms are generated so
that cor(X11 , X
1
2 ) ≈ 0.9, cor(X21 , X22 ) ≈ 0.75 and cor(X31 , X32 ) ≈ 0.6.
We can compare the results of our method with the standard approach of separate
eigen-decompositions by computing the reconstruction loss in Equation A.5. We
expect our method to perform well when the sample size is large; we also expect
gains over the standard approach when the sample size is small. In panel (a) of
Figure 2.2 we can see that this is indeed the case.
We can also see in panel (b) of Figure 2.2 and Table 2.1 that our estimation of
Bk and Q moves closer to the truth as sample size increases.
2.2.4 Visualization
Note that the output of the proposed model comprises of the common factor load-
ings Q̂ and the differential weights {Bk}Kk=1. The common factor loadings can be rep-
resented as in any standard factor or principal components analysis through a scatter-
plot of its elements. Similarly, the reconstructed covariance matrices Σ̂k = B̂kQ̂Q̂′B̂k
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(a) Λ̂k estimated with different sample sizes (b) true Q and estimated Q̂
Figure 2.2: Toy Example: (a) Both our method and separate eigen-decompositions
improve with increasing sample size. Our algorithm (top row) does a
better job of estimating the Λ̂k similarly, while the estimates from separate
eigen-decompositions are spread further apart, reflecting the influence of
increasing noise in the data. Left to right by row, the reconstruction loss
values are: 0.153 (method, n=15), 0.108 (method, n=100), 0.161 (eigen-
decomp, n=15), 0.109 (eigen-decomp, n=100). (b) As the sample size
increases, Q̂ moves closer to the true Q.
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B1 B2 B3
true Bk11, B
k
22 0.33 0.33 0.33
n = 100, B̂k11 0.25 0.34 0.41
n = 100, B̂k22 0.24 0.35 0.41
n = 15, B̂k11 0.25 0.30 0.46
n = 15, B̂k22 0.21 0.33 0.46
Table 2.1: Toy Example Performance. B̂k for n = 100 and n = 15. True Bk11 = B
k
22 =
0.33,∀k.
can be visualized through heatmaps. For the differential weights, we propose to com-
pute a quantity similar in spirit to the traditional log-fold-change. For comparing
groups k and `, we define rk`i = log(B̂
k
ii/B̂
`
ii), i = 1, · · · , p. This ratio provide informa-
tion about how the loadings Q̂·i for variable i are modulated between groups k and `;
for example, if rk`i is close to 0, then the patterns of association involving variable i
are similar in both groups. As rk`i moves away from 0 and becomes more positive, the
associations involving i become, on average, stronger in group k relative to `, while if
it becomes increasingly negative, the associations become weaker in group k relative
to `. The ratios rk` are visualized as bar charts, with bars extending to either side of
the central axis (representing 0). A visualization of synthetic data corresponding to
4 groups organized according to two experimental design factors with two levels each
are depicted in Figure 2.4.
Figure 2.3 illustrates our approach to visualization in a setting with 3× 1 experi-
mental design structure.
2.3 Results
Next, we provide an in depth performance evaluation of the proposed methodology
based on synthetic data. We start with a comparison over estimating K separate
models, and then focus on the performance of the method under different settings
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Figure 2.3: Visualization for 2×2 experimental design. Visualization for results from
a simulated 2×2 setting with the following selection of model parameters;
m = 2, p = 30, n = 100. Latent factors account for 75% of observed vari-
ance, while Q1 has 20 non-sparse entries and Q2 has 10. Reconstruction
loss is 0.1486. The reconstructed covariance matrix heatmaps are inter-
preted in the usual manner. The bar charts are oriented so that longer
bars extending in the direction of a specific reconstructed covariance ma-
trix k indicate that those Bk values are larger than the same values in
the condition the bars are pointing away from. We can see that the
visualization allows us to see the common block structure, as well as spe-
cific differences between conditions (compare, for example, the lower right
block and the relevant sections of the bar charts between all 4 heatmaps.)
This figure also allows us to observe the impact of the experimental de-
sign on the normalization - B̂1 and B̂2 are normalized together, as are B̂3
and B̂4. This can be seen in the figure, where Σ̂1R and Σ̂
2
R have patterns
of light and dark cross-hatching which are complimentary to each other,
and very different from the patterns present in Σ̂3R and Σ̂
4
R
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Figure 2.4: Visualization for 3×1 experimental design. We observe that the visualiza-
tion allows us to see the common structure present in all of the covariance
matrices - they all share a block diagonal structure, with a large block in
the upper left (representing the first factor), and a small block in the lower
right (the second factor). Differences between the conditions can be seen
in both the color and intensity of the individual cells in the heatmaps, and
in the bar charts. We can see this concretely by regarding the lower right
block in Σ̂1R. This represents the variables which load onto Q2. Overall
this square is darker than the equivalent square in Σ̂2R and lighter than
the one in Σ̂3R. This relationship between Σ̂
1
R and the other two datasets
is also reflected in the bar charts - in r12 the bars corresponding to the
second factor point towards Σ̂1R, but in r
13 these same bars point away
from Σ̂1R and towards Σ̂
3
R.
involving the key model parameters p, n,m,K and the noise level.
2.3.1 Comparison to performing separate analyses
Using synthetic data across a range of simulation settings: 3× 1, 2× 2 and 5× 1
experimental design settings, with 2 latent factors, 50 or 100 variables, and a range of
sample sizes. Further, the latent factors account for 50% of the observed variation. We
compare the reconstruction error from using K separate scaled eigen-decompositions
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or using the proposed method to estimate Λk. We compute
1
K
K∑
k=1
||Λ˜k − Λk||
||ΛK ||(2.4)
where Λ˜k is either Λ̂k, or B̂kQ̂. The ratio of this reconstruction error for the two
approaches is given in Table 2.2. In general, the proposed method outperforms un-
dertaking K separate analyses. The greatest gains are observed when the experi-
mental design necessitates constraint ID2 (the 2× 2 experimental design setting), or
when noisy entries of a modest size (cutoff = 0.05) are removed. In settings where
ID1 is used (3 × 1 and 5 × 1), and the cutoff is too large (0.2), our method slightly
under-performs. This is primarily due to the fact that the selected threshold 0.2 sets
some true non-zero entries to zero (a common practice in classical factor analysis to
aid interpretation), and the additional steps included in the algorithm to deal with
noisy entries slightly decrease the accuracy in these scenarios.
3× 1 2× 2 5× 1
cutoff = 0 0.9516 0.8903 0.9221
cutoff = 0.05 0.9498 0.8860 0.9264
cutoff = 0.1 0.9772 0.8925 0.9987
cutoff = 0.2 1.0223 0.9416 1.0092
Table 2.2: Average loss ratio: (method based reconstruction loss)/(separate eigen-
decomposition reconstruction loss). Results are averaged over 500 error
realizations, all n and all p. Entries with magnitude less than the cutoff
are set to 0.
2.3.2 Performance evaluation based on Synthetic Data
Next, we consider a large set of scenarios to test the performance of the model
and the corresponding estimation strategies for both sparse and non-sparse Q, with
varying experimental design structures. For each simulation setting, we measured the
algorithm’s performance on estimating a range of model elements. Here, we present
the algorithm’s performance in computing B̂k, for a subset of simulation settings that
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give an overall sense for the algorithm’s behavior.
This performance can be measured by B-loss, calculated as
B-loss :
||B − B̂||F
||B||F(2.5)
where B is a p × K matrix whose kth column is the diagonal entries in Bk. Figure
2.5 shows this loss for 3×1 experimental design structure (a single design factor with
3 levels), with non-sparse Q settings in panel (a) and sparse Q settings in panel (b).
See figure legend for complete simulation details.
It can be seen that the algorithm behaves in an expected manner; specifically, loss
decreases as the percentages of variance explained by the latent factors increases, or
as sample or variable size increase. We also observe that the standard deviations of
the loss values are quite small - indicating that the algorithm consistently exhibits
good performance.
When Q is sparse, these trends still apply, but the loss values are generally higher
and the range of loss values is broader. This can be attributed to the challenge of
identifying the sparse support of Q with a very high degree of accuracy. In the non-
sparse case, mean B-loss is always less than 0.233, with half of the instances even
below 0.11. For the sparse case, the mean B-loss is higher, ranging from 0.042 to
0.24, but in the majority of the settings the loss values remain below 0.15.
In Appendix A.3results on the model’s performance in estimating Q̂ and recon-
structing Λ̂k, across additional simulation settings (2 × 2 experimental design struc-
tures are also tested) are provided. Further, a discussion of a scaling factor, sij,
included to adjust for noisy entries and complete technical details on the simulation
procedure are also given.
21
(a) B-loss with non-sparse Q (b) B-loss with sparse Q
Figure 2.5: B-loss for 3 × 1 experimental design. We consider m = 2, 3, and Ψ such
that Λk explains 50% or 75% of the variance present in the simulated
data. For the non-sparse Q (each column in Q is fully populated with
non-zero entries), we consider p = 100, 250 with n = 50, 100, 250, de-
pending on p. When Q is sparse, we test p = 100 and n = 75, 150. For
both 2 and 3 factors in the sparse scenario, we also vary the amount
of sparsity in each column of Q. The first column of Q always has the
greatest number of non-zero entries, followed by the second column and
so on. Every row in Q has a single non-zero entry, giving the columns
of Q distinct, non-overlapping support. For m = 2 we look at Q having
(0.55p, 0.45p) and (0.7p, 0.3p) non-sparse elements, while for m = 3 we
testQ with (0.39p, 0.33p, 0.28p) and (0.5p, 0.3p, 0.2p) non-sparse elements.
These patterns of loading are referred to as ”Qload: 1” and ”Qload: 2”.
All scenarios are run for 500 error realizations with a single realization
of Q and Bk, ∀ k. Our preferred method for estimating sparse Λ̂k is the
EDTC method, as it yielded the best results (see Appendix Algorithm 3
and Appendix Section A.2 for more details.)
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2.3.3 Application to lipidomics data
We further illustrate the usefulness of the proposed model by analyzing the fol-
lowing lipidomics data set. Aromatase inhibitor (AI) adjuvant therapy is effective
in reducing the recurrence early stage hormone receptor-positive of breast cancer by
inhibiting the conversion of androgens to estrogen, interrupting estrogen-dependent
cancer cell growth [47]. AI use is associated with adverse events, including muscle
and joint pain that occurs in up to 50% of treated patients [48]. These side effect can
affect quality of life and lead to discontinuation of the drug in a significant proportion
of symptomatic patients [49] .
Dietary fatty acid intake, especially ω3- and ω6-fatty acids, can affect overall in-
flammation by altering the production of pro- and anti-inflammatory cytokines [50].
An earlier study showed that women treated with daily ω3-fatty acids showed no
difference in incidence of AI side effects when compared to soybean/corn oil supple-
mentation [51]. However, it was noted that both groups showed a significantly higher
improvement during the intervention phase than had been seen in other intervention
trials to modulate side effects following AI inhibition. One potential explanation for
this finding is that the ”placebo” soybean and corn oil have over 50% content of
ω6-fatty acids, which also can have anti-inflammatory effects [52].
Given the above, we employed the proposed model to identify potential differences
in patterns of co-variation of lipids in the serum lipidome of women who developed
symptomatic arthralgias following treatment with AI (Cases n = 24) compared to
women who remained asymptomatic (Controls n = 25). Samples were derived from
a prospective clinical trial (more details in Appendix A.4.) Cases were defined as
women who were unable to continue treatment for more than 6 months due to the
development of musculoskeletal pain, whereas controls remained symptom free (de-
fined as pain ≤ 2/10) for at least 24 months. Clinical characteristics of the women
were not different between cases and controls (Appendix Table A.1) nor were there a
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Figure 2.6: Visualization of results for AI data (a) Q̂ for AI data. Metabolites are
colored as in Figure 2.1, and are grouped according to their loadings onto
Q̂. (b) Σ̂kR and r
kk′ for AI data. Variables in each heatmap are sorted by
group assignment from (a). Clockwise from upper left, the reconstructed
heatmaps are: Cases at baseline, Cases at 3 months, Controls at 3 months,
Controls at baseline. In the same order, the bar charts are: Case at
baseline vs Cases at 3 months, Cases at 3 months vs Controls at 3 months,
Controls at baseline vs Controls at 3 months, Controls at baseline vs Cases
at baseline.
difference in the type of AI used.
Subjects’ lipidomes were assayed at baseline, and 3 months following initiation
of AI treatment; a total of 442 lipids in 15 classes were identified and their relative
levels determined by LC/MS. We also measured a small set of eicosanoids which are
potential modulators of inflammation [53], and free fatty acids (FFA).
A description of the normalization procedure used, as well as pre- and post-
processing steps for the method and wet lab lipidomics methods can be found in
the Appendix A.4.. In short, after normalizing and selecting samples which were
present in all three analytical platforms, there were 24 subjects who could not con-
tinue receiving the drug (cases) and 25 subjects who could continue being on the
drug (controls). For these 49 subjects, data were available on 467 compounds (lipid
species, FFA and eicosanoids).
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In preliminary analysis of the data, paired and unpaired t-tests were used for iden-
tifying differentially expressed compounds related to the following comparisons: (i)
cases at baseline vs cases at 3 months, (ii) controls at baseline vs controls at 3 months,
(iii) cases vs controls at baseline and (iii) cases vs controls at 3 months. After cor-
recting the resulting p-values for multiple comparisons using the Benjamini-Hochberg
False Discovery Rate adjustment procedure [1], there were only 3 metabolites (CE
22:6, TG 62:13, TG 62:14) with an adjusted p-value less than a 0.1 threshold, in the
controls at baseline vs controls at 3 month comparison. No statistically significant
differential abundance was found for any other comparison.
We then turned our attention to co-variation patterns exhibited across the four
groups, using the proposed factor model. Based on scree plots, we set the rank to
be m = 2. The differential weights were normalized based on the (ID2) constraint
applied to the samples in the controls and the cases, respectively. To enhance interpre-
tation, we thresholded small values of Q̂ (removing values between −0.2 and 0.2) and
the results are depicted in Figure 2.6, where the coloring scheme of the compounds
corresponds to their class. Based on their location on this plot, each compounds can
be assigned to a group; this assignment is reflected by the plotting symbols used in
Figure 2.6.
The common factor loadings reflect the association of each variable with the la-
tent factors, with a positive value indicating that the specific compound is positively
associated with the corresponding factor. This fact provides a data driven strategy
for grouping variables (compounds) for further analysis, in settings where canonical
pathways are not defined, or well studied.
With the compounds divided into groups, we tested those groups for over-representation
of each lipid class, and saturation level. Similar to the approach often taken in the
analysis of gene expression data organized into canonical pathways, we also tested
each group for differential abundance using the GSA technique [24]. More specific
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methodological details and full results for these tests can be found in Appendix Sec-
tion A.5, and Appendix Tables A.2 and A.3.
We found that group 1 enriched for saturated compounds, group 2 for monounsat-
urated, and both groups 3 and 4 strongly enriched for polyunsaturated lipids. Group
1 included many FFA and eicosanoids, having over half of the FFA and all of the
eicosanoids. Group 2 mainly contained the DG and TG lipid classes. Group 3 was
enriched for the lysoPC and PC lipid classes, while Group 4 was enriched for the
plasmenyl-PE and TG lipid classes.
Using GSA we tested all 2-way comparisons of interest (described above), and
found that only group 4 showed any differential abundance, with the controls ex-
hibiting lower abundance of the respective compounds at month 3, vs the controls at
baseline. As previously mentioned, group 4 contains mostly polyunsaturated lipids,
which have polyunsaturated fatty acid (PUFA) tails. Since longer chain PUFA species
with multiple double bonds are primarily derived from the elongation and desatura-
tion of dietary essential fatty acids [54], the significant decrease in Group 4 lipids
following AI treatment in Controls could be due to differences in PUFA intake or
metabolism.
Women have higher levels of the ω3-fatty acid, docosahexaenoic acid (DHA) than
men due to estrogen, but these levels fall in the absence of estrogen due to decreased
conversion of dietary ω6-fatty acids to DHA [55]. The fall in the levels of the very long
chain fatty acids in women who remained asymptomatic could be due to a decrease
in the intake of ω3-fatty acids with an increase in the relative intake of ω6-fatty acids,
including α-linoleic acid. Accumulating evidence suggests that dietary α-linoleic acid
may have potent anti-inflammatory effects and reduces cardiovascular risk factors.
Given the greater than expected response from the ’placebo’ arm which contained
high levels of α-linoleic in studies testing the efficacy of fish oil to alleviate arthralgias
in AI treatment may due to salutary biological effects of lipids in soybean/corn oil in
26
the placebo.
2.4 Discussion
There is increased interest in studying co-variation patterns across multiple data
sets, as in routinely done with analysis of variance for examining mean changes. The
proposed method fills in this gap. As extensive numerical work shows, the method
performs well across a range of simulation settings in identifying common co-variation
patterns in complex experimental settings and can also accommodate sprase factor
structures.
As the AI case study shows, the resulting estimates of the common factors and
their differential weights prove useful for gaining deeper biological insights. To do so
effective visualization strategies are needed and this work provides plots that success-
fully summarize the bulk of the information produced by the algorithm.
At present, the model serves as an exploratory analysis tool. If one is interested
in a more confirmatory approach, it would be possible to do hypothesis testing on
the elements of Bk. Bootstrapping could be used to generate confidence intervals for
Bk. Fox example, if one’s experimental design allowed for constraint (ID1), and one
had K total data sets, a tight confidence interval around 1
K
for Bki would imply that
there is no (or little) condition-specific modulation for the ith metabolite across the
K conditions. Further, permutation tests could be used to test ||Bk − Bk′|| for two
conditions k, k′, where || · || is an appropriate norm that reflects well the magnitude
of the differences in the two conditions. If ||Bk −Bk′|| was not significantly different
from zero, then one could consider treating k and k′ as the same condition - allowing
the researcher to pool the data and increase sample size for that condition. This
would, of course, change the calculations for the normalization constraints, and could
even change which normalization constraint was applied. This pooling would need to
be done with care, as would consideration of the label swapping in the permutation
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test. Additionally, one could test ||Bki − Bk′i ||, over a subset of metabolites, such as
those with high loadings on a particular column of Q̂.
At a technical level, the model can be used with more complicated experimental
designs (such as a 5×4 design). Visualization in these scenarios is less straightforward
and more advanced tools such as those provided in [56] and Shiny [57] need to be
employed to enable researchers to fully explore the results and understand co-variation
patterns in their data.
Finally, the model assumes that all patterns of co-variation observed in the data
are up or down modulations of common motifs when, in truth, there could be additive
differences in these patterns as well. Additionally, in a biological context, it is much
more likely that the columns of Q would have sparse, overlapping support, rather
than the non-overlapping sparse scenarios investigated here. In the case where the
conditions do not all have the same number of factors, the model will still be suitable,
but one would need to be careful about the interpretation of the results. For example,
an experimental condition having 4 factors, while the remaining ones only have have
2 could indicate that that dataset is more variable than the others and should be
treated with care.
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CHAPTER III
Integrative data-driven module discovery of
metabolic perturbations induced by diet
3.1 Introduction
Advancements in mass spectrometry, coupled with the development of more so-
phisticated data processing tools and comprehensive spectral libraries, have enabled
researchers to probe deeper into the metabolome and lipodome. This has allowed
new insights into biological mechanisms and disease progression, such as creating
measurements of internal body time [58], integrating metabolomics and genomics to
identify features associated with poor prognosis in neuroendocrine cancers [59], or
illuminating metabolic profiles predictive of future diabetes [60].
While primary and secondary metabolites are well mapped to canonical pathways
(such as KEGG [28]), and this prior knowledge can be leveraged for biological in-
sights, the lipidome remains essentially unannotated in this way. Metabolites in the
blood have notable interconnectedness which can result in substantial co-expression.
This holds true both for metabolites sequentially formed and consumed in metabolic
pathways, and metabolites that are metabolized by the same enzymes. The high
correlation of various lipids within and across lipid classes is due to both step-wise
metabolic anabolism and multiple lipid species competing as substrate. Because
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metabolomics analysis of small polar compounds and lipidomics are often done on
separate platforms, integration of these data sets is important to gain broader in-
sights into how a physiological or disease state affects the interconnected domains of
intermediary metabolism. The presence of unannotated features in the ”untargeted”
metabolomics profiles also limits the utilization of all information derived from mass
spectrometry analyses [12]. Recent studies have demonstrated that networks beyond
those defined by canonical pathways can provide novel biological insights [2, 61, 62].
These factors make network based methods particularly attractive in studying Omics
data in general, and metabolomics data in particular. Recent applications of network
based methods include detecting novel candidate drivers in melanoma [63], illuminat-
ing a link between pre-existing cellular phenotype and certain genetic alterations in
glioblastoma [64] and identifying relevant unannotated compounds in a longitudinal
study of women’s aging [10].
A number of techniques are available in the literature to estimate networks from
data, including correlation based methods [6, 7, 8] and partial correlation ones [9,
10, 11]. The former are straight forward to calculate, but focus on highly connected
compounds which may not be particularly informative, being potentially driven by
artifacts [12], while also not differentiating between direct and indirect interactions
between compounds. Partial correlations have been used extensively in Omics set-
tings, but require large sample sizes to calculate (see discussion in [10].) A common
analytic pipeline leveraging such data driven networks is to first calculate (partial)
correlation networks from metabolomics (or other Omics) profiles and subsequently
extract strongly connected components from them. These components are then con-
sidered as sets and examined for enrichment using one of the numerous methods
available in the literature [65, 66, 25].
In this paper, we employ the PCST algorithm that integrates the above two-step
process and simultaneously considers differential expression/abundance and interac-
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tions between compounds. This algorithm requires as input a network (nodes and
their corresponding edge set) together with a cost associated with each edge and a
prize associated with a subset of the nodes. Its output comprises of a tree that max-
imizes profit (total prizes - total cost). It has been successfully applied to identify
relevant modules (subnetworks) across a range of Omics data types. For example,
Bailly-Bechet et al. [67] used it to uncover the role of a previously uncharacterized
protein, leveraging a yeast protein interaction network (edge costs) combined with
p-values obtained from testing for differential expression across experimental condi-
tions related to response to yeast (prizes). A human protein interaction network
was also employed in Balbin et al. [68] together with differential abundance (prizes)
between non-small cell lung cancer phenotypes in transcript, protein and phospho-
protein datasets to help discover a protein in the KRAS pathway that could serve
as a drug target. More recently Pirhaji et al. [69] used a network of protein-protein
and protein-metabolite interactions, constructed from integrating multiple databases,
while the prizes reflected the significance of a metabolomic feature’s disregulation be-
tween conditions in a Huntington’s disease cell-line model.
This brief literature overview shows that the PCST is used in conjunction with a
network of physical interactions (protein-protein, protein-DNA, protein-metabolite)
obtained from curated biological databases. However, as argued in Creixell et al. [2]
such interactions may not reflect the current physiological state, since different phys-
iological or pathological conditions may directly or indirectly alter the interactions,
limiting the technique’s potential. Indeed, in earlier studies we found that the relative
correlations of metabolite can be affected in individuals prone to type 2 diabetes [10].
Metabolites in the blood have notable interconnectedness which can result in
substantial co-expression patterns [70]. This arises from the metabolites sequentially
formed and consumed in metabolic pathways, and metabolites that are metabolized
by the same enzymes. A high correlation of various lipids species, within and across
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lipid classes, is due to both to step wise metabolic anabolism and multiple lipid species
competing as substrate. For example, glycerol-3-phosphate acyltransferase (GPAT)
enzymes catalyze the conversion of multiple diacylglycerol species to triacylglycerol
[71] resulting in high co-expression of diacylglycerol with triacylglycerols in plasma.
Increased dietary carbohydrates (CHO) intake result in increase in de novo lipogenesis
of saturated and monounsaturated fatty acids [72] while polyunsaturated fatty acids
(PUFA) from the diet correlate with fat intake [73]. These correlations extend to a
variety of other metabolites such as amino acids and acylcarnitines [10].
In the present study, we performed a controlled feeding study to assess the al-
terations in the metabolome as a first step in developing an objective assessment of
dietary intake. Our goal is to identify modules of co-varying lipids and small po-
lar molecules by analyzing the results of LC-MS based lipidomic and untargeted
metabolomics profiles, integrating these platforms to gain insights into both the
metabolic pathways that are affected by the diets and the metabolite signature of
each diet.
In the application, we exploit the high degree of interconnectedness amongst
molecular entities in metabolomics datasets, especially those derived from lipidomics
profiling and take an agnostic approach using networks with data driven edge weights,
instead of those based on physical interactions obtained from curated biological
databases. We combine these networks with node prizes based on differential abun-
dance and apply the PCST to identify biologically relevant modules in the plasma
metabolome from individuals fed two different diets, one high on polyunsaturated fats
(PUFA) and another high on carbohydrates (CHO). The proposed approach yields
insights into both the metabolic pathways that are affected by the diets and the
metabolite signature of each diet. We further show that identified modules can be
coordinately altered in the plasma of an animal model of altered fatty acid oxidation,
suggesting that the intimate association of metabolites may provide a statistically
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tractable way of identifying variable interactions amongst metabolites that provides
both biomarkers for dietary intake, but also may provide insights into alterations in
underlying physiological processes in physiological or disease states.
3.2 Integration Methodology
The Prize Collecting Steiner Tree algorithm [74] is employed to integrate, in a
condition specific manner, lipidomic and untargeted metabolomic data sets, with a
focus on lipids and metabolites that are significantly changed across dietary condi-
tions. As mentioned in the introductory Section, the PCST algorithm requires as
input an undirected network G(V,E, c(e), p(v)), with node set V , and edge set E.
The function p(v) assigns a prize, p(v) ≥ 0 to each node v ∈ V , and nodes with
p(v) > 0 are referred to as terminal nodes. The function c(e) > 0 assigns a cost
to each e ∈ E. The aim is to find a tree T (VT , ET ) that maximizes the objective
function:
profit(T ) =
∑
v∈Vt
βp(v)−
∑
e∈Et
c(e)(3.1)
Nodes with p(v) = 0 which are returned in VT as part of the solution will be referred
to as Steiner nodes.
Effectively the PCST algorithm is used to sparsify a condition-specific co-expression
network, where the latter is sparsified around nodes of interest (often those which
show differences between experimental conditions or groups). Further, in a setting
where the co-expression network itself is substantially different between conditions,
such as the feeding study, our method enables researchers to utilize this condition-
specific connectivity information to generate hypothesis about systems level differ-
ences in behavior.
To ensure robust results, the algorithm is run multiple times while applying a
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small amount of noise to the cost function. The results are then used to create
consensus graphs in which the approach identifies modules of metabolites that are
strongly linked by their patterns of co-variation. The resulting stable modules can
then by characterized by testing for enrichment or depletion in relevant characteristics
and compared across conditions in order to obtain a ranking of their contribution.
This workflow is outlined graphically in Figure 3.1.
Figure 3.1: Method Schematic: Differentially abundant lipids and untargeted metabo-
lites are designated as terminal nodes and assigned prizes. Condition spe-
cific correlation matrices are used to calculate edge weights. The Prize
Collecting Steiner Tree Algorithm is run with noise over an undirected
network as described in main text. Consensus graphs are created from
PCST output; modules are identified in these graphs. Modules are tested
for enrichment in relevant characteristics and compared across experimen-
tal conditions.
In the discovery phase of this work, we analyze data from a controlled feeding study
on humans. Twelve healthy adults (6M/6F) were fed a diet high in polyunsaturated
fatty acids (PUFA) for 3 weeks, immediately followed by a diet high in carbohydrates
(CHO) for 3 weeks. Each subject’s plasma lipidome was assayed at days 0, 2, 7, 21,
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23, 28, and 42, while their plasma metabolome was assayed at days 0, 21 and 42. For
additional details see Methods.
3.2.1 Prize Collecting Steiner Tree algorithm
The PCST algorithm employed is implemented in the OmicsIntegrator software
[75] (local copy, downloaded on 2/2/2017) which solves a modified version of the
Prize Collecting Steiner Forest (PCSF) problem. Formulated similarly to the PCST
problem, the PCSF allows the solution set to be comprised of disjoint trees. OmicsIn-
tegrator further incorporates additional tuning parameters into the objective function,
most of which we set to their default values. For complete details of the formulation,
see Tuncbag et al. [75].
We supplied the node and edge sets, edge weights, and terminal prizes (detailed
below), using forest.py with the forest-only and doRandom options. We modified
the original forest.py file so that betweenness was not calculated when merging the
results from noisy PCST runs. Forest parameters were as follows: w = 4 (controls the
number of trees), b = 20 (controls the trade off between including more terminals and
using less reliable edges), D = 10 (controls maximum depth of trees), processes= 1
(number of processors to spawn when doing randomization runs), threads= 2 (number
of threads to use in optimization algorithm), noise= 0.005 (the standard deviation
of the Gaussian noise added to edge costs). All other parameters were set to their
default values. For robustness, the algorithm was run 50 times over the same set of
terminal nodes and prizes for each network, with a small amount of noise added to
the edge weights each time.
The four networks considered - labeled as
G21u(V,E21, c(e), p21u(v)), G42u(V,E42, c(e), p42u(v))
G21d(V,E21, c(e), p21d(v)), G42d(V,E42, c(e), p42d(v))
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- are described fully below. Each network has the same node sets and cost function,
while the edge weights and prize functions differed.
3.2.2 Terminal prizes
To determine terminal nodes and the corresponding prizes, we used a linear model
to test for differences in abundance levels between any two time-points assayed. We
modeled the abundance of the kth lipid (or metabolite) Lk as
Lk = d+ u(3.2)
where d is a factor, with levels, di, representing each day assayed in the study
(di, i ∈ {0, 2, 7, 21, 23, 28, 42} for lipids or i ∈ {0, 21, 42} for untargeted metabolites.)
The random effects u for the nth subject on day k of diet j are specified as: un+unj +
unk; note that d0, d2, d7, d21 are classified as diet 1, PUFA; the remainder of the days
are classified as diet 2, CHO.) TThis specification allows us to account for overall
subject level variation, as well as differences in the way each subject processes each
dietary intervention across time.
Differential abundance between any two levels i and j of d were then tested using
contrast vectors based on the R-language implementation in the lme4 and pbkrtest
packages. Formally, the hypothesis of interest is given by
H0 : di − dj = 0
Hα : di − dj 6= 0(3.3)
While we included all of the data in our linear model, our analysis focused on
the dynamics between days 0, 21 and 42 as these time points captured the most
meaningful differences between dietary interventions.
We identified three different terminal node sets of interest: 21d, the lipids and
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metabolites for which there is a significant difference between d0 and d21; 42d, the
lipids and metabolites for which there is a significant difference between d21 and
d42; and 21u = 42u, the union of those two sets. Significance was defined for
lipids as a False Discovery Rate corrected (via the Benjamini-Hochberg procedure)
p-value of p < 0.1; for untargeted metabolites a p-value of p < 0.2. Let p0v21 de-
note the FDR-corrected p-value from testing d0 − d21 = 0, and p21v42 be the corre-
sponding p-value for testing d21 − d42. Terminal prizes for 21u and 42u were set to
p21u(v) = p42u(v) = −log(min(p0v21, p21v42)). For 21d, p21d(v) = −log(p0v21) and for
42d, p42d(v) = −log(p21v42).
3.2.3 Network Edge Weights
Edge weights for the diet specific networks were generated by applying Fisher’s
z-transformation [76] to the 603 × 603 matrix of correlations between all lipids and
metabolites at a single time point. We employ Fisher’s z-transformation to test
whether correlation amongst lipids and/or metabolites is zero or not. Specifically,
letting r denote the sample correlation between two lipids, then z(r) = 1
2
log(1+r
1−r ) =
arctanh(r). Further, if the measurements of the two lipids are assumed to be indepen-
dent and identically distributed from a bivariate normal distribution with correlation
ρ, then z(r) ∼ N(1
2
log(1+ρ
1−ρ),
1√
N−3), where N denotes the corresponding sample size.
This allows us to test for correlations that are significantly different from 0.
In our implementation of the OmicsIntegrator, we set edge weights to w(e) = 1−
pe, where pe is the FDR-corrected p-value from testing the null hypothesis H0 : ze = 0
for the pair of lipids defined by edge e, versus the alternative of being different than
0. Hence, the corresponding edge cost is set to c(e) = pe, so that edges with more
significant p-values are more likely to be included in the solution set. Further, the
sample correlation matrix at day 21 was used to create E21, while E42 was created
from the sample correlation matrix at day 42; these correlation coefficients are then
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converted to z values using the above transformation and tested for significance,
yielding p-values for the edge costs.
3.2.4 Consensus graphs, module discovery, enrichment analysis
Inspired by the consensus clustering approach [77], we created consensus graphs
from the PCST results on each graph by selecting nodes which appeared in > 80% of
all noisy runs. Any edge chosen by the algorithm to connect these nodes, regardless of
how frequently that edge appeared in the solution set, was included in the consensus
graph. We we refer to the consensus graph from the results on Gi as CGi.
Modules in each consensus graph were identified via the leading eigenvector com-
munity detection algorithm [46] (LEVCD), which identifies highly connected sub-
groups/modules within a larger network. For this clustering step, an edge between
nodes i and j was given weight equal to |rij|, where rij is the sample correlation
between the nodes at the relevant time point. The kth module from consensus graph
CGi is labeled Mi:k. These modules were then tested for enrichment in relevant char-
acteristics using the hypergeometric test. The hypergeometric test indicates whether,
in a given module, there are more lipids/metabolites with a certain characteristic
than one would expect by chance (in which case the module is enriched in said char-
acteristic), or if there are fewer than one would expect (in which case the module is
depleted.) (see Cao and Zhang [78] for a good review on the hypergeometric test).
Finally, percent density for the consensus graphs is calculated as:
D = 100
2|E|
|V |(|V | − 1)
3.2.5 Validation in Rat data
The discovered modules based on the data from the human feeding study were
subsequently assessed for concordance and biological relevance in metabolomic and
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lipid profiles obtained from the rat model (see details below). For the comparison,
we first identified modules in which at least 70% of the module’s lipids/metabolites
are also present in the rat data. These modules were then tested for differential
abundance between pairs of conditions using the Gene Set Analysis (GSA) approach
[24] implemented in the R package GSA. We used the maxmean method, with s0 = 0,
and without restandardization. The GSA method [24] is a more powerful and robust
version of the popular Gene Set Enrichment Analysis (GSEA) procedure [23]. The
maxmean statistic used in GSA can detect subtle, concordant changes in a group of
biomolecules across a wide range of settings.
3.3 Results
3.3.1 Method Results
To create our list of terminal nodes, we used a linear model to test for DA across
the course of each dietary intervention. Lipids and untargeted metabolites were mod-
eled and tested separately, as the untargeted metabolomics assay was only run on
days 0, 21 and 42.
Lipids showed high levels of activity across all classes - 180 lipids exhibited sta-
tistically significant changes from day 0 to day 21, and 222 from day 21 to day 42.
Out of these, 130 lipids exhibited statistically significant differences under both diets
(FDR adjusted p-value < 0.1.) Untargeted metabolites showed much lower levels of
activity overall - out of 147 metabolites, only 9 showed statistically significant dif-
ferences under PUFA, and 10 changed under CHO (FDR adjusted p-value < 0.2).
Finally, no metabolites were differentially expressed under both diets. These cutoffs
gave G21u and G42u 291 terminal nodes, while G21d and G42d had 189 and 232 ones,
respectively.
As previously mentioned, the PCSF algorithm was applied on the following four
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Graph Nodes in CGi Edges in CGi # of modules
# of modules with
>8 members
G21d 224 619 21 8
G42d 291 1475 16 6
G21u 323 967 20 7
G42u 346 1668 16 9
Table 3.1: Summary of results from PCST and module discovery steps
networks: G21u, G42u, G21d, and G42d. In each case, it always returned the terminal
nodes and a fairly stable subset of Steiner nodes (Appendix Table B.1). We chose
to include Steiner nodes which occurred in > 80% of the solutions in the consensus
graphs. The edge sets were much more variable - relatively few edges were chosen
every time, with many more ”moderately often” chosen edges (Appendix Table B.1.)
This variability led us to include in the consensus graphs all edges chosen by the
algorithm which connected our terminal and selected Steiner nodes.
The resulting consensus graphs are overall quite sparse - only 1.86% dense, 2.79%
dense, 2.52% dense and 3.54% dense for CG21u, CG42u, CG21d, and CG42d respec-
tively. The Leading Eigenvector Community Detection (LEVCD) algorithm identifies
between 16 and 21 modules in each consensus graph (Table 3.1); the jth module from
CGi is referred to as Mi:j (i.e. M21u:2 refers to the second identified module from
CG21u.) Between 6 and 9 modules in each consensus graph had more than 8 mem-
bers. These larger modules were tested for enrichment in the observed lipid classes,
saturation levels, and other relevant characteristics. The enrichment and depletion
results for select modules are summarized in Table 3.2, with complete results for all
modules in CG21u and CG42u available in Supplemental Table A4.
In general, the untargeted metabolites are fairly well integrated with lipids in the
identified submodules. Although many modules do not contain any metabolites, those
that do, also contain lipids from a range of lipid classes. Hence, we conclude that the
approach successfully integrates lipids and metabolites and does not segregate the
two classes of biomolecules into their own modules ((see Appendix C)
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Module CE DG lysoPC lysoPE MG PC PE plasmenyl-PC plasmenyl-PE SM TG SFA MUFA PUFA
M21u:2 0.795 0.106 0.921 0.728 0.595 0.338 0.886 0.523 0.928 0.859 0.000 0.426 0.008 0.366
M21u:3 0.648 0.000 0.921 0.627 0.595 0.558 0.886 0.523 0.928 0.404 0.137 0.977 0.922 0.004
M21u:4 0.441 0.707 0.000 0.361 0.057 0.251 0.886 0.523 0.860 0.429 0.990 0.009 0.017 0.720
M21u:6 0.441 0.735 0.921 0.465 0.282 0.595 0.886 0.523 0.860 0.810 0.000 0.856 0.922 0.001
M21u:20 0.211 0.953 0.921 0.465 0.208 0.131 0.593 0.612 0.000 0.404 0.990 0.856 0.253 0.002
M42u:2 0.485 0.000 0.920 0.602 0.567 0.923 0.950 0.790 0.816 0.965 0.000 0.860 0.192 0.009
M42u:5 0.485 0.225 0.755 0.602 0.192 0.923 0.950 0.320 0.685 0.965 0.000 0.906 0.472 0.000
M42u:14 0.383 0.958 0.000 0.602 0.192 0.923 0.950 0.394 0.224 0.965 0.097 0.823 0.609 0.001
M42u:15 0.485 0.958 0.055 0.000 0.192 0.644 0.950 0.175 0.816 0.965 0.998 0.469 0.472 0.960
M42u:16 0.712 0.958 0.755 0.602 0.567 0.605 0.950 0.790 0.816 0.965 0.000 0.457 0.245 0.029
Table 3.2: Enrichment analysis of identified modules. Selected modules were tested
for enrichment in notable classes and for saturated fatty acids (SFA),
monounsaturated fatty acids (MUFA) and polyunsaturated fatty acids
(PUFA). P -values are corrected column-wise for multiple testing using
the Benjamini-Hochberg False Discovery Rate adjustment procedure [1].
Results for all modules in CG21u and CG42u available in Supplemental
Table A4.
Comparison tested M21u:2 M21u:3 M21u:4 M21u:6 M21u:20 M42u:2 M42u:5 M42u:14 M42u:15 M42u:16
d21 < d0 0.000 0.000 0.000 0.997 0.000 0.000 0.032 0.000 0.000 0.000
d42 < d0 0.993 0.993 0.013 0.993 0.013 0.993 0.993 0.061 0.027 0.993
d42 < d21 1.000 1.000 1.000 0.000 1.000 1.000 1.000 1.000 1.000 1.000
d21 > d0 1.000 1.000 1.000 0.053 1.000 1.000 1.000 1.000 1.000 1.000
d42 > d0 0.107 0.018 0.993 0.200 0.993 0.018 0.064 0.993 0.993 0.190
d42 > d21 0.000 0.000 0.000 1.000 0.000 0.000 0.000 0.000 0.000 0.000
Table 3.3: Differential abundance in modules from CG21u and CG42u tested via GSA.
End of PUFA (d21) and end of CHO (d42) tested against baseline (d0),
and each other. Values presented are fdr adjusted p-values for a subset
of modules. Results from all modules in CG21u and CG42u available in
Supplemental Table A2.
We primarily focus our analysis on a subset of modules from CG21u and CG42u.
3.3.2 Module metabolite participants and dynamics under different di-
etary conditions
We examined the properties of the metabolites that were identified as covarying
under the two dietary conditions. Following consumption of a PUFA diet for 21 days,
several modules were identified that were significantly enriched in some metabolite
classes (Table 3.2). There was a large overlap between M21d:3, M21u:2, M42u:16 (Ap-
pendix C), indicating that these metabolites are dynamically changed under each
feeding condition. We focus first on M21u:2, which was overall decreased by PUFA
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Figure 3.2: All nodes present in either M21u:2 or M42u:16. Nodes in left and right
halves of image arranged identically. Edges on left taken from CG21u:1,
edges on right taken from CG42u:16. Only edges connecting nodes within
the figure are shown. Nodes colored by module label from CG21:u (left)
and CG42:16 (right). Clockwise from upper left, A: M21u:2, B: Nodes
in M21:3 that are brought in as a group when transitioning to CHO, C:
Subset of nodes shed as a group into M42u:2 when transitioning to CHO D:
M42u:16, E: Subset of nodes shed as a group into M42u:4 when transitioning
to CHO, F: Nodes which are shed into many different modules when
transitioning to CHO, G: Nodes with varying module memberships under
PUFA, incorporated into M42u:16
feeding and increased following CHO diet (select results in Table 3.3, complete re-
sults in Supplemental Table A2). The module was enriched in PCs and triglycerides
(TGs), which we observe to be primarily shorter chain species, with relatively few
saturated fatty acids (Table 3.2), likely reflecting the increase in de novo lipogenesis
seen after consumption of a carbohydrate diet. This module contained 2 untargeted
metabolites, carnitine and 3-hydroxy-3-methylbutryric acid. The latter is generated
during leucine degradation and is found elevated in individuals with insulin resistance
and diabetes [79]. Leucine was not associated with a module under either dietary con-
dition. However, it has been previously observed that carbohydrate can reduced the
oxidation of leucine [80] and dietary carbohydrates also reduce leucine catabolism
[81], suggesting that the higher levels of its intermediate breakdown product is due to
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Comparison tested M21u:3 M21u:4 M21u:6 M21u:20 M42u:2 M42u:5 M42u:14 M42u:15 M42u:16
HCR-AL < LCR-AL 0.011 0.025 0.108 0.000 0.090 0.089 0.040 0.011 0.170
HCR-CR < LCR-CR 0.381 0.278 0.278 0.493 0.278 0.278 0.278 0.278 0.493
LCR-CR < LCR-AL 0.000 0.000 0.033 0.013 0.000 0.017 0.000 0.063 0.033
HCR-CR < HCR-AL 0.213 0.213 0.213 0.870 0.213 0.213 0.200 0.748 0.213
HCR-AL < LCR-CR 0.853 0.511 0.853 0.483 0.853 0.783 0.853 0.133 0.853
Table 3.4: Module dynamics in animal model. Modules from CG21u and CG42u which
had at least 70% overlap with animal data were tested for differential abun-
dance in animal data using GSA. None of the tests in the opposite direction
(HCR-AL > LCR-AL, HCR-CR > LCR-CR, etc) were significant. Values
presented are fdr adjusted p-values for a subset of modules. Results from
all modules in CG21u and CG42u available in Supplemental Table A3.
inhibition of the later part of leucine catabolism (see Discussion). Interestingly, the
single metabolite whose levels covaried inversely to the others in M21u:2 was carnitine.
A previous study observed that carnitine levels rose significantly on a high fat diet
compared to a high carbohydrate diet [82], suggesting that the increased oxidation of
carbohydrates results in greater consumption of carnitine.
The majority of TG species in M21u:2 overlap substantially with M42u:16; the latter
also being highly enriched in TGs (Figure 3.2). The 23 overlapping lipids are almost
exclusively shorter chain, relatively saturated TGs (Figure 3.2, box A). The retention
of a highly connected subset of TGs suggests that these lipids are generated and
consumed in a highly parallel manner, allowing them to be maintained in synchronous
plasma levels despite varying in concentration.
As module M21u:2 transitions to module M42u:16 following CHO feeding, longer
polyunsaturated DGs and TGs, as well as some saturated PCs and TGs are shed
(removed from the module) (Figure 3.2, boxes C and E). These lipids ’join’ two
large modules M42u:2 and M42u:4, the former enriched in DGs and TGs and the latter
enriched in PCs (Table 3.2). These lipids were replaced by some shorter, mostly
low saturated chain PCs and interestingly, some short, unsaturated PCs and TGs
(PC 38:8, PC 40:4, TG 51:4, TG 52:7) (Figure 3.2, box B). Also shed were the two
untargeted metabolites. The addition of the new lipid species in the module after
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CHO diet suggests that these are newly formed lipids which have incorporate de
novo generated fatty acids into a polyunsaturated lipid. A variety of other nodes
have varying memberships after leaving M21u:2 (Figure 3.2, box F) or before joining
M42u:16(Figure 3.2, box G).
Modules M21u:4 and M42u:14 were of interest as they were both enriched only in
LPCs in which nearly half showed reciprocal changes under the different dietary con-
ditions (Appendix C),. Module M42d:7 was also enriched in these LPCs. Paradoxically,
PUFA-diet associated Module M21u:4 was enriched in saturated and monounsaturated
fatty acids while the CHO-associated M42u:14 was statistically enriched in polyunsat-
urated fatty acids. Plasma LPC is thought to be derived from phosphatidylcholine in
lipoproteins acyltransferases and phospholipases [83]. LPC as well as its metabolite,
lysophosphatidic Acid (LPA, generated by the removal of the choline headgroup),
can differentially signal through cell surface receptors by depending on chain length
and degree of saturation [84]. No specific pattern of increase and decrease in the
levels of other LPCs in the data set were found; we do note that PCs populated
Module M42u:14, though it was not significantly enriched in this class. Module M21u:4
also contained 4 notable untargeted metabolites, guanosine and threonine as well as
palmitoylcarnitine decreased between baseline and d21, while cholesterol increased
over the same time. As with leucine, higher levels of threonine are found in insulin
resistance and are reduced by weight loss [85, 86]. The reduction in palmitoylcarnitine
is likely due to reduced entry of palmitic acid into mitochondria during PUFA feeding.
These metabolites were shed in M42u:14. Further exploration of these modules will be
necessary to understand its unique behavior, but we note that the modules were also
perturbed in the rat model (see discussion below).
We also recognized M42u:15 as being unique. This 33 member module, visualized in
Figure 3.3, was enriched in LPE and was devoid of triglycerides (Appendix C). The
module contains long-chain acylcarnitines, derivatives of saturated and mononunsatu-
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rated fatty acids, which decrease in PUFA diet as well as medium chain acylcarnitines,
which increase in PUFA diet. The lower abundance of long-chain acylcarnitines sug-
gests reduced entry of saturated and monounsaturated fatty acids into the mitochon-
dria [87], potentially through competition by polyunsaturated fatty acids. This is
supported by the observed increase in levels of octenoylcarnine, which is derived from
polyunsaturated omega-6 fatty acids. In addition, M42u:15 contained a number of
acetylated amino acids. There is a dearth of literature on n-acetylated amino acids
outside of N-acetylaspartate (NAA), which an abundant metabolite in the brain and
is synthesized enzymatically from aspartate and acetyl-CoA in neurons [88]. We note
that NAA was only found in M42d:3, which also increases following the CHO diet.
Non-enzymatic acetylation of lysine residues in the mitochondrial is well described
[89] and it is tempting to suggest that under higher carbohydrate flux, excess acetyl-
CoA generated in the mitochondria may modify amino acids. Finally, kynurenine,
a product of mitochondrial tryptophan metabolism, is also associated with M42u:15.
Like many of the other metabolites found associated with modules elevated in the
plasma following CHO diet, kynurenine (KYN) and its direct precursor tryptophan
(TRP) are elevated in the plasma of insulin resistant individuals [90, 91]. However,
unlike the other metabolites, KYN terminal metabolic fate is not oxidation, rather
is used for niacin biosynthesis. The reason for an increase in kynurenine in insulin
resistance has been attributed to increased expression of indoleamine 2,3-dioxygenase
1 [IDO1] by chronic inflammation [90, 92], increasing the conversion of TRP to KYN.
The finding that KYN is associated with other presumptively mitochondrially gen-
erated metabolites could suggest that alteration in KYN mitochondrial metabolism
may underlie its association with insulin resistance.
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Figure 3.3: Visualization of M42u:15 Nodes are colored according to their classes -
most notably, the medium chain acylcarnitines in bright green and the
long chain acylcarnitines in red. Terminal nodes are represented as tri-
angles while steiner nodes (those which are not differentially abundant,
but are brought into the consensus graph via their associations with dif-
ferentially abundant nodes) are represented by circles. Note that only
two acylcarnitines, Hexanoylcarnitine and Palmitoylcarnitine are termi-
nal nodes; the other acylcarnitines in this module are brought in by their
associations with these two nodes. Out of 11 acylcarnitines in the entire
untargeted metabolomics dataset, 7 are incorporated into this module,
with the remainder not being incorporated into any module from any
consensus graph.
3.3.3 Module dynamics in animal model of differential metabolite utiliza-
tion
The above results suggest that modules of plasma metabolites and lipids can be
identified that change in a concordant manner following dietary changes. To answer
the question as to whether these metabolite/lipid modules related under divergent
dietary conditions, remain associated in different biological contexts, we examined the
identified modules in a rat model which demonstrates differences in the utilization of
fatty acids and carbohydrates at rest and during acute exercise [93]. Two lines of rats,
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high capacity runners (HCR) and low capacity runners (LCR), were selectively bred
for high and low intrinsic exercise capacity based on untrained aerobic capacity to
create a model for studying aerobic exercise and its relationship to metabolic health
[93]. We have shown that the HCR, compared to the LCR rats, have a higher fatty
acid utilization, both at rest and during exercise. Specifically, the enhanced fatty
acid utilization appears to underlie the enhanced running capacity of the HCR. An
apparent inefficiency in the oxidation of fatty acids likely plays a role in the reduced
weight gain observed in the HCR line [93], and may also play a role in the increase
in lifespan in the HCR compared to the LCR [94]. Thus, to test whether the plasma
metabolome would respond to alterations in fuel utilization (fatty acids v. CHO),
as opposed to alterations in fuel input through dietary consumption, we identified
PCST-identified human modules which had more than 70% of their members observed
in the rat model. These modules were tested for differential abundance in the rat
plasma using the GSA pathway enrichment methodology [24]. In addition, we also
assess enrichment in HCR and LCR rat plasma following a 12-month period of caloric
restriction (CR) to assess whether the lines had a similar metabolomic response.
Few plasma metabolites show differential levels between the HCR and LCR in
either the ad lib fed or CR state. Only 49 lipids/metabolites were differentially abun-
dant between LCR-AL and LCR-CR, having an fdr-corrected p-value ¡ 0.1. Between
LCR-AL and HCR-AL, 26 lipids/metabolites were differentially abundant with the
same cutoff. No lipids/metabolites were differentially abundant between any other
2-way comparison of interest. Each module found in the rats, however, was lower in
the HCR (Table 3.4) and among the comparisons, the most statistically significant
changes were seen in LCR-CR compared to the LCR-AL followed by HCR-AL com-
pared to HCR-AL. The modules identified in the rat comparison are reduced in the
plasma of PUFA diet and increased in the CHO diet. This may suggests that the
increased utilization of fatty acids as fuel (or reduction of CHO utilization), is what
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is impacting the levels of the modules.
Of considerable interest is the finding that none of the modules were changed
between the HCR-CR compared to HCR-AL or the LCR-CR, suggesting that the
perturbation in metabolism induced by caloric restriction ”preexists” in the HCR
such that there is not further change following CR. Importantly, as is found in caloric
restriction in rodents, HCR rats have an extended lifespan in the ad libitum fed state
[94], suggesting biological mimicry in the enhanced utilization of fatty acids in both
high oxidative capacity and caloric restriction, both associated with improved health
and longevity humans [95].
3.4 Discussion
In this paper we present a data-driven method for integrative analysis of lipids
and untargeted metabolites. We focused on named untargeted metabolites as a first
step, but the method can readily be extended to unnamed untargeted metabolites, or
applied to other Omics settings where one wishes to identify modules outside of canon-
ical pathways. Our method identifies modules of biologically relevant biomolecules,
centered around those which are differentially abundant between conditions, while
incorporating related biomolecules which did not reach a significance cutoff. Many
potentially interesting modules were identified beyond the most biologically interest-
ing ones highlighted here. While competing methods based only on the correlation
matrices uncover some of the same features, our method identifies additional subtle
features that other methods do not.
In our controlled human dietary intervention, each of the dietary feeding peri-
ods caused a significant change in the levels of multiple lipid species. Many were
expected due to the anticipated influx of polyunsaturated fatty acids into lipids dur-
ing the PUFA diet and a reduction in saturated and monounsaturated fatty acids;
the converse happening during CHO diet. Additional Steiner nodes were identified
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in each condition through the addition of lipids and untargeted metabolites due to
their consistent interactions with the terminal nodes in each module. Though few
of the metabolites detected in the untargeted platform were significantly different in
transitioning from baseline to PUFA to CHO, the metabolites added to the modules
using the data-driven PCST algorithm were both biologically consistent with previous
observations and provided some potentially novel insights into alterations in whole
body metabolism in people under fat and carbohydrate feeding.
The changes in the untargeted metabolites in modules identified via CG21u and
CG42u were consistent with changes in handling of metabolites in the mitochondria
(Figure 3.4). Our findings are consistent with increasing carbohydrate utilization
following the change from the high fat PUFA diet to CHO. It is known that a rela-
tive increase in flux of glucose-derived pyruvate into the mitochondria increases the
levels of acetyl-CoA which leads to increased malonyl-CoA [96] production and re-
duction of fatty acid uptake through CPT-1 [96, 97], reducing the levels of long- and
short-chain acyl-CoAs. Increased acetyl-CoA production will also reduce oxidation
of branched chain amino acids [80, 98], reflected in the elevated levels of 3-hydroxy-
3-methyglutarate, an intermediate in leucine metabolism (Figure 3.4). Though spec-
ulative, the fall in carnitine levels during CHO feeding may be due to utilization in
formation of medium chain acylcarnitines in the cell, accumulating in the plasma.
Excess mitochondrial acetyl-CoA is associated with an increase in mitochondrial
protein acetylation [98]. Our finding relative increased N-acetylated amino acids in
CHO vs. PUFA diet suggests that excess acyl-CoA formed during CHO diet can lead
to accumulation of n-acetylation amino acids, potentially making N-acetylated amino
acids markers of high carbohydrate intake. Whether this occurs in the mitochondria
or in the cytoplasm or whether they are formed enzymatically is unclear. Finding the
TRP metabolite KYN in a module with the medium chain acylcarnitines and n-acetyl
amino acids is more puzzling. The degradation of TRP is complex and regulated in
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large part by Indoleamine 2,3-dioxygenases (IDO) and as mostly been studied in
relationship to inflammation-related metabolism [99]. One speculative reason for
the finding of increased TRP and KYN in CHO is a an increase in mitochondrial
redox, lowering FAD/FADH and reducing the FAD-dependent conversion of KYN to
3-hydroxykynurenine by IDO1. Our proposed model outlined in Figure 3.4 assumes
that diet-induced alteration in mitochondrial metabolism, produces a signature in
plasma. Studies of plasma following inherited disruption of mitochondrial enzymes
support that this is a reasonable assumption [100].
The changes identified in the module metabolites in the HCR/LCR rat model
under two different feeding conditions show that even across species, the metabolites
identified in humans covary under different physiological states. We note that the
NIH31 diet used in the HCR/LCR studies has a very high CHO and low fat content
(72.2% and 7.4% of calories, respectively), which is similar to the CHO diet provided
in the human studies. Despite this, we observe changes in metabolite modules in
the HCR and during calorically restricted feeding that parallel the high PUFA diet.
This intriguing result suggests that alterations in the modules may be more related
to an increase in fatty acid vs. glucose utilization. Many of the alterations in plasma
metabolites that we observe in individuals under a high carbohydrate diet have been
seen in insulin resistance. Data supports the idea that a principal defect in people
with insulin resistance is an impaired capacity to upregulate muscle lipid oxidation in
the face of high fatty acid supply, principally in skeletal muscle [101, 102]. We suggest
that the insulin resistance signature may be due to alterations in fuel selection that
may be modified by changes in oxidative capacity observed in the HCR/LCR rat
model.
We were limited by the relatively small sample size in defining covariant modules,
but the human studies were aided by the sequential feeding in the same individuals,
reducing inter-individual variations. We also incorporated only annotated metabolites
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in the untargeted metabolomics data set in our analysis. Further studies demonstrat-
ing association of unannotated metabolites in ”modules” in different metabolic states
could potentially help in identifying these unknown metabolites.
Figure 3.4: Schematic of mitochondrial metabolism of untargeted metabolites identi-
fied by PCST. Arrows preceding metabolites indicate the direct of change
from PUFA to CHO diet. TRP = tryptophan; KYN = kynurenine; LEU
= leucine; FAD = flavin adenine dinucleotide; CoA = Coenzyme A; AA
= amino acid
3.5 Methods
3.5.1 Dietary intervention
All studies were approved by the Institutional Review Board of the University of
Michigan and all participants provided written, informed consent. All methods and
procedures were performed in accordance with the relevant guidelines and regulations.
Twelve healthy participants (6 women, 6 men, Table 3.5) were provided two sequential
isocaloric diets for 21 days each. The first diet was enriched in polyunsaturated fatty
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Females (n = 6) Males (n = 6) p-value
Age (yr) 29.3 ± 7.4 27.17 ± 4.1 0.55
Body mass index (kg/m2) 21.9 ± 2.6 27.08 ± 4.0 0.02
Cholesterol (mg/dl) 163.3 ± 24.6 157.00 ± 28.9 0.69
Triglyceride (mg/dl) 68.2 ± 66.0 81.50 ± 57.9 0.72
High Density Lipoprotein Cholesterol (mg/dl) 63.7 ± 9.8 54.0 ± 10.9 0.13
Low Density Lipoprotein Cholesterol (mg/d) 92.3 ± 27.8 86.5 ± 30.2 0.74
Glucose (mg/dl) 86. 3 ± 9.8 86.7 ± 5.0 0.94
Homeostatic Measure of Insulin Resistance (HOMA) 2.5 ± 1.0 3.1 ± 1.4 0.40
Table 3.5: Subject characteristics Values given are mean ± standard deviation.
acids (PUFA) consisting of 12 − 15% protein, 35 − 50% carbohydrate, 40 − 50%
fat (25 − 30% polyunsaturated fatty acids, 5 − 10% monounsaturated and < 10%
saturated followed immediately by a diet enriched in carbohydrate (CHO) with 10−
15% protein, 70 − 80% carbohydrate and 10 − 15% fat (< 10% fat as SFA with 2%
polyunsaturated fatty acids). All meals and snacks were provided by the Nutrition
Assessment Laboratory (NAL) of Nutrition Obesity Research Center at the University
of Michigan. Participants came to the facility at least twice per week during this 6-
week controlled feeding trial for food pick-ups and weigh-ins. The diet was adjusted
to maintain initial body weight. This resulted in a mean relative weight standard
deviation of 0.8% throughout the study period. Fasting blood was drawn in the
morning at baseline (Day 0) and at days 2, 7, 21 (PUFA), and 23, 28 and 42 days
(CHO) and EDTA plasma was collected and aliquoted for analysis.
3.5.2 HCR/LCR rat model
These studies were approved by the University of Michigan Institutional Animal
Care and Use Committee. All methods and procedures were performed in accordance
with the relevant guidelines and regulations. In the present study, generation 20 male
HCR and 20 LCR were randomly selected to receive a fortified NIH31 diet (Taconic,
Rensselaer, NY) ad libitum (ADLIB) or a calorically restricted diet (CR) for 12
months. Plasma was obtained from cardiac puncture between 5 and 6 pm and frozen
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LCR-ADLIB (n = 11) LCR-CR (n = 12) HCR-ADLIB (n = 10) HCR-CR (n = 11)
Start weight (gm) 93.8 ± 5.1 93.6 ± 4.9 78.6 ± 4.2 78.8 ± 4.2
End weight (gm) 517.3 ± 15.9 331.3 ± 10.7 388.5 ± 15.2 286.5 ± 8.6
Body weight gain (gm) 440.4 ± 15.4 245.9 ± 9.3 330.7 ± 14.7 208.8 ± 7.4
Table 3.6: Animal model subject characteristics. Values given are mean ± standard
deviation.
at -80◦C until analysis. Additional details on animals subjects in Table 3.6 and further
details of the entire study are the subject of another publication.
3.5.3 Lipodomic profiling
Lipids were extracted from 50 µl of plasma using a modified Bligh-Dyer Method.
The extraction was performed using water/methanol/dichloromethane (2:2:2 v/v/v)
at room temperature after spiking internal standards. The organic layer was then
collected and dried under a stream of nitrogen before being re-suspended in 100µL
of Buffer B [acetonitrile/water/isopropanol (10:5:85 v/v/v) containing 10mM am-
monium acetate]. The lipid extract was injected onto a 1.8µm particle 50x2.1mm
internal diameter Waters Acquity HSS T3 column (Waters, Milford, MA) that was
heated to 55◦C. Four injections were performed with either 60% or 2% of a solution
of acetonitrile/water/isopropanol (10:5:85 v/v/v) for each sample. This produced
a total run-time of 20 minutes. Data were acquired in positive and negative mode
using data-depended MS/MS with dynamic mass exclusion. Pooled human plasma
sample and pooled experimental sample (prepared by combining small aliquots of all
experimental samples) were used to control for the quality of sample preparation and
analysis. Furthermore, a randomization scheme was used to distribute pooled samples
within the set. A mixture of pure authentic standards was used to monitor instru-
ment performance on a regular basis. Lipids were identified using the LIPIDBLAST
computer-generated tandem MS library [103]. This database contains 212,516 spec-
tra covering 119,200 compounds representing 26 lipid classes, including phospholipids,
glycerolipids, bacterial lipoglycan, and plant glycolipids. Quantification of lipids was
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completed using AB-SCIEX MultiQuant software. The nomenclature used for indi-
vidual lipids begins with the abbreviation of the lipid class followed by the number
of carbon atoms in the molecule, and, finally, by the number of double bonds.
3.5.4 Untargeted metabolite profiling
Fasting plasma (50 µl) was extracted by adding 280 µl of extraction solvent (1:1:1
methanol: acetonitrile: acetone) containing internal standards; vortexing for 10 sec,
allowing to rest on ice for 5 min, and then centrifuging at 4◦C for 10 min. The su-
pernatant was dried by vacuum centrifuge at 45◦C and resuspended in 200 µl of 8:2
methanol:water. Metabolites were analyzed by LC-MS using an Agilent 1260 infin-
ity LC connected to an Agilent 6520 quadrupole time-of-flight MS. MS parameters
were as follows: full-scan negative ion mode (m/z 50 to 1,200), acquisition rate 1
spectrum/sec, capillary voltage 3500 V, gas temperature 350◦C, drying gas 10 l/min,
nebulizer pressure 20 psig, and reference mass correction enabled. RPLC was per-
formed using a Waters Acquity HSS T3 column, 1.8 µm particle size, 2.1 x 100 mm
i.d. (Milford, MA), with a flow rate of 0.25 ml/min. The gradient consisted of a
7-min linear ramp from 0 to 99% B, 3 min at 99% B, and 5 min of re-equilibration
at 0% B. Mobile phase A was 0.1% of formic acid in water and mobile phase B was
0.1% of formic acid in 8:2 of isopropanol:acetonitrile.
Untargeted feature peak areas were initially quantified using Profinder version
B.08.00 (Agilent Technologies, Santa Clara, CA) and re-quantified using Agilent
Masshunter Quantitative Analysis software for quadrupole time-of-flight MS version
B.07.00. Peaks were re-quantified by peak area using the ”Agile2” or ”spectrum sum-
mation” peak integrator. Untargeted metabolite identification was performed using
accurate mass and retention time from authentic standards by MS or using MS/MS
fragmentation pattern referenced from
www.lipidmaps.org/resources/lipidmapspresentations/EB2009/BrownEB2009.pdf. Un-
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targeted metabolite annotation was performed using Human Metabolome Database
(www.hmdb.ca) and LIPID MAPS Lipidomics Gateway (www.lipidmaps.org).
3.5.5 Data normalization
Lipidomics data were normalized to remove batch and run order effects. Each
lipid was normalized individually, without the use of internal standards. Positive and
Negative modes treated separately, until the final step of removing duplicate lipids.
Pooled samples are the pooled samples from the test data. Lipids which were missing
excessive data from either the pooled samples or the subject samples were removed.
Robust regression on the pooled data was used to calculate an adjustment ratio
between batches; this ratio was then used to remove batch effects. For each lipid i,
we calculate a batch-adjustment factor βi. If there are two batches, this is essentially
the slope from the robust regression of one batch on the other, without an intercept.
Let b1i be the measurements for lipid i in batch 1 and b
2
i be the measurements for
lipid i in batch 2. We want to calculate b2i = βib
1
i .
If there are more than two batches, then one batch is picked as the reference, and
all other batches are regressed against the reference batch, one at a time. We use the
lmrob function from the R package robustbase for calculating the adjustment ratio
between batches. Once the adjustment factors have been calculated, missing data
are imputed using the knn function from the R pamr package. Imputation takes into
account the batch number, run order and sample label. Then, the adjustment factor
is used to remove batch effects by updating b2i to be
1
β
b2i .
Next, loess smoothing is used to remove the remaining effects of run order. Loess
tuning parameters are calculated on the pooled samples, and then used to smooth
the original samples. Once all batch and run order effects have been adjusted for,
positive and negative modes are combined and repeated lipids are removed. If a lipid
is present in only one mode, but with multiple ions, we keep the ion with lowest
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variability as measured by relative standard deviation (RSD), where RSD of the ith
lipid, li, is equal to 100stdev(li)/mean(li). If a lipid is present in both modes, we pick
the mode that has the most lipids of that lipid’s class, and keep the ion w/ the lowest
RSD within that mode. If a lipid is present in both modes, and there are the same
number of ions/lipids in both modes, we keep the ion with the lowest RSD across
both modes After normalization and the elimination of duplicates, there were 458
lipids in the controlled feeding experiment. All data was then log2-transformed.
The untargeted metabolomics were normalized similarly. We started with 1588
untargeted metabolites, run in one batch. We removed metabolites that had fewer
than 5 pooled samples, had an RSD over 30, or were missing more than 25% of
their samples across all timepoints. Where there were multiple instances of a single
metabolite, we retained the instance with the lowest RSD and discarded the oth-
ers. Additionally, we chose to analyze only named, non-lipid untargeted metabolites.
Selected exogenous compounds (acetaminophen and caffeine) were removed. The re-
sulting set of untargeted metabolites had 147 members. Missing data were imputed,
positive and negative modes were combined, the data was median centered by subject
and finally log2 transformed.
Animal data (lipids and untargeted metabolomics) were normalized with the
lipidomics normalization workflow. After normalization, the data had 478 lipids and
188 untargeted metabolites, out of which, 304 and 75 overlapped with the human
data, respectively.
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CHAPTER IV
Consensus Correlation Modules for Discovery and
Insight
4.1 Introduction
In this chapter, we present a variation on the method presented in Chapter III.
Previously, we showed that condition specific modules could be discovered by using the
Prize Collecting Steiner Tree to integrate differentially abundant lipids and untargeted
metabolites via a data driven network, while also incorporating a small number of
related biomolecules that were not differentially expressed. This new method creates
a robust, consensus co-expression network by combining information from multiple
correlation matrices. Modules are then identified in this new network, and treated
similarly to the modules in Chapter III.
The method presented here has two main differences compared to the method of
Chapter III. The first being that instead of anchoring the modules with differentially
abundant biomolecules, we examine the entire interactome for modules, considering
only the biomolecules’ patterns of co-expression. Focusing on differentially abundant
variables requires one to impose a significance cutoff, which could leave important
and relevant features out of a module simply because they were not differentially
abundant. Analysis techniques that consider only biomolecules having the largest
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differences between conditions have several major limitations. The most pertinent to
this chapter is that after correcting for multiple testing relatively few features may
be differentially abundant, especially if the biological differences are small relatively
to the noise in the assay. A range of techniques have been developed to counter this
problem, such as Gene Set Enrichment Analysis (GSEA) [23] and GSA [24]. These
techniques also address a related problem - many biological processes involve a set of
biomolecules working in concert. In such a setting, a small increase in the abundance
of many members of a biological pathway could result in a more meaningful biological
difference than a very significant increase in a single member of that pathway. Our
method is similarly motivated, though we start with the aim of summarizing patterns
of co-expression, not differential expression.
The second main difference is that instead of creating a co-expression network
from a single dataset, we use a variation on the Hedges-Olkin method [104] for com-
bining estimates of correlation coefficients to create a consensus correlation network
on which modules are identified. Combining correlation coefficients in this fashion
allows one to find common patterns across datasets while decreasing the influence
of noise in a single dataset. Examples in the literature include Lee et al [20], who
perform a large-scale analysis of 60 human mRNA microarray datasets, combining
the co-expression profiles to create a high-confidence network of genes which contains
functionally coherent modules of genes. Choi et al [18] use gene expression datasets
from cancers of 13 different tissues to construct 2 distinct co-expression networks
(tumor and normal).They compare these networks to elucidate the ways in which
cancer affects many co-expression relationships leading to functional changes in en-
ergy metabolism, promotion of cell growth and immune activity. Gillis and Pavlidis
[19] present another variant of this concept, summing individual co-expression ma-
trices from microarray data to illuminate the role of indirect connections in gene
networks in predicting function.
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Protein Carbohydrate Fat SFA MUFA PUFA
PUFA, n=35 15.42 (2.38) 40.54 (2.02) 44.02 (2.02) 5.55 (0.86) 11.38 (2.04) 24.24 (2.13)
CHO, n=36 15.37 (2.15) 71.66 (3.33) 13.06 (2.67) 4.17 (1.31) 4.2 (0.94) 3.22 (0.83)
B, n=72 14.71 (0.83) 49.48 (0.89) 35.74 (0.96) 14.26 (0.93) 11.19 (0.86) 7.08 (0.75)
HF, n=231 15.21 (1.04) 24.72 (0.84) 60.03 (0.97) 27.87 (1.87) 18.16 (1.85) 8.89 (2.12)
HC, n=273 14.89 (0.65) 74.72 (0.62) 10.38 (0.61) 3.56 (0.52) 3.11 (0.32) 2.35 (0.39)
US diet 15.8 (0.1) 48.5 (0.2) 33.7 (0.1) 10.8 (0.1)
Table 4.1: Summary statistics for percent calorie intake from select macronutrients.
US diet data taken from dietary recall interviews for 2011-2014, reported in
[106]. Remainder of data taken from NDSR output. Values are mean(sd)
or mean(se) for the US diet data.
We are interested in identifying modules in the PUFA/CHO dietary intervention,
described in Chapter III, based only on the common patterns of co-expression between
lipids across all days of each dietary intervention. We use this new method to identify
consensus modules in PUFA and CHO, which are then used to identify differences in
the lipidomes of subjects on a second dietary intervention. This second intervention
has some notable differences from the first - 24 healthy adults are fed for 3 days on a
standardized diet (represented by B), meant to reflect the median standard American
diet [105]. Subjects were then randomized to either a high fat (HF, n=11) or a high
carbohydrate (HC, n=13) diet. While the HF/HC diets are more extreme in the
percentage of total calories from fat or carbohydrates (compared to the PUFA/CHO
diets), the more notable difference comes from the relative proportions of saturated
(SFA), monounsaturated (MUFA) and polyunsaturated (PUFA) fatty acids.
As shown in Table 4.1, the PUFA diet is high in polyunsaturated fatty acids,
while the HF diet has an even greater percentage of calories coming from saturated
fatty acids. While humans cannot make polyunsaturated fatty acids, saturated and
monounsaturated fatty acids can come either directly from dietary intake, or indi-
rectly from dietary intake through de novo lipogenesis when excess carbohydrates are
consumed [72]. As a result, it is anticipated the HF/HC dietary interventions will
present a more complex and potentially subtle signal (relative to each other) than the
PUFA/CHO dietary interventions.
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4.2 Consensus Correlations Networks
4.2.1 Theory background
Let (X, Y ) be a pair of random variables with a bivariate normal distribution and
true correlation ρ,
 X
Y
 ∼ N(µ,Σ)
where
µ =
 µX
µY
 , Σ =
 σ2X ρσXσY
ρσXσY σ
2
Y

Given a set of N sample pairs (Xi, Yi), i ∈ {1, · · ·N}, let r be the sample correla-
tion coefficient,
r =
cov(X, Y )
σXσY
Fisher’s z-transformation [76, 107] of r, fz(r) and the inverse transformation are
defined as
fz(r) = z :=
1
2
ln
(
1 + r
1− r
)
= arctanh(r)(4.1)
r = tanh(z)(4.2)
With (X, Y ) as described above, and Xi, Yi being independent and identically
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distributed, then z is approximately normally distributed z ∼ N(µz, σ2z),
µz =
1
2
ln
(
1 + ρ
1− ρ
)
and σz =
1√
N − 3
where N is the number of samples and ρ the true (population) correlation coefficient.
Also of use is the fact that given zi, i ∈ {1, · · · , K} where zi ∼ N(0, 1), the
weighted sum, Z, has a standard normal distribution -
Z :=
∑K
i=1wizi√∑K
i=1w
2
i
∼ N(0, 1)(4.3)
4.2.2 Consensus Correlation Network
Suppose that one had K related data sets, Xk, k ∈ {1, · · ·K}, each with Nk
observations and sample correlation matrix Sk. These could be multiple datasets
from the same experiment, or datasets from separate experiments investigating similar
phenomena (as in the case of meta-analysis).
Let rkij be the sample correlation between variables i and j in dataset k. Fisher’s
z-transformation is used to transform Sk into Zk by applying Equation 4.1 to each
rkij in Sk. For simplicity, the elements of Zk are standardized.
fz(rkij) = zkij =
arctanh(rkij)− 12 ln
(
1+ρ
1−ρ
)
√
Nk − 3
∼ N(0, 1)(4.4)
We then create a consensus Z matrix, ZK, from the weighted sum of the Zk
matrices.
ZK =
∑K
k=1 wkZk√∑K
k=1w
2
k
The weights wk allow flexibility in how the Zk matrices are combined- all datasets
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could count equally, or emphasis could be placed on certain data sets which were
more important or had more reliable data.
For each zKij , we can test whether this z variable is significantly different from 0.
Formally, the hypothesis of interest is given by:
H0 : ρ = 0(4.5)
Hα : ρ 6= 0(4.6)
which is tested by calculating
p(zKij) = P(zKij 6= 0|zKij ∼ N(0, 1))(4.7)
Testing this hypothesis for each element of ZK gives us p(ZK) = P ′K. This matrix of
probability values can then be corrected for multiple testing. Let PK be the version of
this matrix with p-values corrected for multiple testing using the Benjamini-Hochberg
procedure [1].
The inverse Fisher’s z-transformation can be applied to ZK to give us a consensus
correlation matrix SK := tanh(ZK). SK can be sparsified by setting to 0 any SKij
which has corresponding PKij > c for some significance cutoff c. This sparsified
matrix can be thought of as a network, GK, with nodes corresponding to the original
variables observed in the data. Nodes i and j are connected by an edge with non-zero
weight eij = |SKij | if PKij < c, and are unconnected otherwise. This network is then
used for all future analyses.
4.2.3 Module discovery and analysis
Relevant modules can be identified on GK, the sparse consensus correlation net-
work, by using a community detection algorithm, e.g. leading eigenvector commu-
nity detection (LEVCD) algorithm [46]. By using the entire interactome/graph, the
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method identifies relevant modules based solely on their co-expression patterns. As
there is no pre-selection step (as in Chapter III, where the modules are centered
around a pre-selected subset of biomolecules), the method remains agnostic to any
features of our variables beyond their co-expression patterns.
These modules can then be tested for enrichment in various characteristics using
the hypergeometric test. This test indicates whether, in a given module, there are
more lipids with a certain characteristic than one would expect by chance (in which
case the module is enriched in said characteristic), or if there are fewer than one
would expect (in which case the module is depleted.) See Cao and Zhang [78] for a
good review on the hypergeometric test.
The modules can also be tested for differential abundance DA between pairs of
conditions; our preferred method for this is a custom implementation of the GSA
method [24]. Inspired by the Gene Set Enrichment Analysis (GSEA) procedure of
[23], Efron and Tibshirani developed the maxmean statistic as a more robust means
of detecting group level differences in a wider range of settings. This statistic is
computed in the following way:
Given some test statistic z, define
s(z) = (s(+)(z), s(−)(z)),
 s
(+)(z) = max(z, 0)
s(−)(z) = −min(z, 0)

For some set of biomolecules S, containing m biomolecules g, each having a test
statistic z, the maxmean statistic, Smax is defined as
Smax := max

∑
g∈S
s(+)(z)
m
,
∑
g∈S
s(−)(z)
m
(4.8)
As Smax is divided by the total number of molecules m, many small biomolecule
scores will contribute more than a single large score. The statistic is robust by design,
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and does not allow a few large biomolecule scores (positive or negative) to dominate.
4.3 Results
4.3.1 Module discovery in PUFA/CHO
Initial exploratory analysis of the PUFA/CHO data indicates that many lipids
change quite quickly within the first two days of either dietary intervention, while
others take the full 21 days to reach a significant change (see Section 4.3.2 and Figure
4.1 for complete details). The patterns of co-expression also change over time -
some quickly, and others more gradually. By creating a consensus correlation matrix
from each diet, the significance of co-expression patterns which are always strong is
increased, and influence of noise inherent in a single data set is decreased.
Letting Zdi = fz(Sdi) for any i ∈ {0, 2, 7, 21, 23, 48}, consensus correlation matri-
ces for the PUFA and CHO diets are created from an equally weighted sum of the
days for each dietary intervention.
ZPUFA =
Zd2 + Zd7 + Zd21√
3
SPUFA = tanh(ZPUFA)
ZCHO =
Zd23 + Zd28 + Zd42√
3
SCHO = tanh(ZCHO)
The consensus correlation matrices, SPUFA and SCHO, are sparsified using a sig-
nificance cutoff of 0.05 (controlling FDR at the 5% level) giving GPUFA and GCHO.
LEVCD identifies 4 larger modules in both PUFA and CHO; as can be seen in the
module membership contingency table (Table 4.2) most of the lipids fall into one of
these 4 groups, with a handful of remaining lipids clustered into modules with one or
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C1 C13 C14 C15 singletons/dyads total
P1 90 22 27 8 6 153
P16 26 74 9 30 1 140
P17 20 8 68 8 0 104
P18 10 11 21 1 2 45
singletons/dyads 6 3 5 0 2 16
total 152 118 130 47 11 458
Table 4.2: Contingency table of module membership. PUFA modules are labeled as
Pi and CHO modules as Cj. In each diet, 4 modules with more than 8
members are identified. No module is identical across either diet. Groups
of lipids move together under either diet, joining together with different
other lipid groups to form the larger modules.
two members (singleton/dyad modules).
Table 4.2 also shows us that none of the modules are identical across diets. Rather,
groups of lipids (some quite large, others rather small) move together. These groups
come together with other groups under PUFA to form PUFA modules, then detaching
and associating with other groups of lipids to form CHO modules. This phenomenon
is similar to the one illustrated in Figure 3.2.
Each of the identified modules is tested for enrichment (E) or depletion (D) in
certain classes, saturation levels and behavioral characteristics (Table 4.3). A module
is classified as enriched if it contains more lipids of a particular class of lipid (or
saturation level) than one would expect by chance, and depleted if it contains less of
the same than one would expect by chance. For convenience, the p-values, adjusted
for multiple comparisons using the Benjamini Hochberg procedure [1], are discretized
in the following manner:
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D/E : 0.05 < p < 0.1
DD/EE : 0.001 < p < 0.05
DDD/EEE : 0.0001 < p < 0.001
DDDD/EEEE : p < 0.0001
We can see that P1 is depleted in DGs and TGs, while P16 is highly enriched in
these two classes, as is C13. The PEs and PCs tend to group together in P17 and C14,
but under neither dietary condition do they group with the lysoPCs and lysoPEs.
dd CE DG lysoPC lysoPE PC PE PI plasmenyl-PC plasmenyl-PE SM TG SFA MUFA PUFA
P1 D EEEE EEE D E EEE EEE DDDD EE EE DDD
P16 EEEE DD DDDD DDDD D DD EEEE DD EE
P17 DDD DD EEEE EEEE D DDDD DD DD EEE
P18 D EEEE DD EE DD
C1 EEEE E DDD EEEE EEEE DDDD DD
C13 EE EEEE DDD DDD DD DDDD EEEE
C14 DDD DD EEEE EEEE EEEE DD DD DDDD EE
C15 D DD EEEE DD EEE
Table 4.3: Module characteristics. Modules are tested separately for enrichment (E)
or depletion (D) in each of the classes and saturation levels shown. Classes
with fewer than 9 members observed are not shown (CerP, CL, MG, PA,
PG). P -values, after adjusting for multiple comparisons, are discretized
as follows: D/E:0.05 < p < 0.1, DD/EE: 0.001 < p < 0.05, DDD/EEE:
0.0001 < p < 0.001, DDDD/EEEE: p < 0.0001
4.3.2 Differential Abundance Testing
Using the linear model and hypothesis tests presented in Section 3.2.2, we can test
for differential abundance between any two days measured in the PUFA/CHO exper-
iment. These tests, summarized in Table 4.4, showed us that many lipids changed
quickly, with 28% of the lipids changing significantly within the first 2 days of either
dietary intervention. Most of these lipids decrease over the PUFA dietary interven-
tion ( 35% of the lipids decrease significantly between d21 and d0). In contrast, 35%
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of the lipids increase over the CHO dietary intervention (d42 − d21). We also see
that relatively few lipids change between d42 and d0 (baseline), suggesting that the
individuals were consuming a relatively high carbohydrate diet prior to entry into the
study. Overall, the model in Equation 3.2 does a good job of explaining the variation
seen in the data, with 317/458 models having an adjusted p-value < 0.1.
d2 − d0 d7 − d2 d21 − d7 d23 − d21 d28 − d23 d42 − d28 d21 − d0 d42 − d21 d42 − d0
proportion negative 0.58 0.64 0.68 0.30 0.27 0.83 0.74 0.36 0.54
proportion signif (p < 0.1) 0.28 0.08 0.01 0.35 0.10 0.06 0.39 0.48 0.16
proportion signif & nega 0.21 0.02 0.01 0.04 0.00 0.06 0.35 0.13 0.13
Table 4.4: Summary of time course dynamics in PUFA/CHO. Proportions are calcu-
lated as (# with characteristic)/458.
We can classify the lipids that show a significant change across either PUFA or
CHO as fast or slow, based on how quickly they reach a significant change. Fast
lipids, under either diet, change significantly in the first 2 days, and also change
significantly between the beginning and end of the diet. Slow lipids are classified as
those which do not change significantly within the first 2 days, but reach a significant
change between the beginning and the end of the diet. These labels (PF ,PS, CF , CS)
have a significant association with each other, as can be seen in Table 4.5. We will
use CN and PN to denote the lipids which do not change significantly over the course
of either dietary intervention.
These dynamic changes can be summarized visually in Figure 4.1.
The consensus modules can be tested for enrichment or depletion in these dietary
labels. Table 4.6 shows that modules which are enriched for PF tend to be enriched
for CF , and that some of the modules are enriched for lipids which show no significant
CF Cs CN
PF 62 20 11
PS 25 23 39
PN 39 53 186
Table 4.5: Distribution of DA labels for each diet. PUFA labels have significant as-
sociation with CHO labels (Pearson’s Chi-squared p < 2.2e−16)
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(a) (b)
Figure 4.1: Visual representation of dynamic changes in PUFA/CHO. Tests in each
column are: 1: d2 − d0; 2: d7 − d2; 3: d21 − d7; 4: d21 − d0; 5: d23 − d21;
6: d28 − d23; 7: d42 − d28; 8: d42 − d21; 9: d42 − d0
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changes over either diet.
PF PS PN CF CS CN
P1 DD E DD EE
P16 EEEE DDD EEEE D DD
P17 D E
P18 E
C1 DDDD EE DDD EE
C13 EEEE DD DD EEEE DD
C14
C15
Table 4.6: Module enrichment in dietary labels Modules are tested separately for en-
richment and depletion in the diet labels shown. P -values are summarized
in Table 4.3, after adjusting for multiple comparisons.
4.3.3 Module dynamics
For each consensus module the maxmean statistic, Smax, is computed. P -values
are obtained in the usual fashion by permuting sample labels (see Section 4.6.1 for
additional details). We are particularly interested in whether a given module increases
or decreases between d0 and d21, d0 and d42, and d21 and d42 (results in Table 4.7).
As expected from the linear model results, all modules significantly decrease between
d0 and d21. Likewise, all modules but one, C1, increase between d21 and d42. Module
C1, enriched in lipids which do not change under either diet and several classes of
lipids, decreases significantly across this diet.
In Table 4.4, we saw that relatively few (∼ 16%) of the lipids show a significant
difference between baseline (d0) and the end of the carbohydrate diet (d42). These
modules, however, help us to identify more subtle changes - about half of the identified
modules decrease across the entire course of the experiment, while the other half
increase. Further analysis is necessary to identify which lipids are responsible for
these changes, and what characteristics they might have in common.
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P1 P16 P17 P18 C1 C13 C14 C15
d42 > d0 1 0 1 0.128 1 0 1 0
d21 > d0 1 1 1 1 1 1 1 1
d42 > d21 0 0 0 0 1 0 0 0
d42 < d0 0 1 0.04 1 0 1 0 1
d21 < d0 0 0 0 0 0 0 0 0
d42 < d21 1 1 1 1 0 1 1 1
Table 4.7: GSA analysis in PUFA/CHO data. Modules from PUFA/CHO are tested
for DA using a custom implementation of GSA. End of PUFA (d21) and
end of CHO d42 are tested against baseline (d0) and each other. Values
presented are p-values adjusted for multiple comparisons.
4.4 HF/HC validation
The previous sections illustrate that our method can be used to identify bio-
logically meaningful modules in a controlled feeding experiment where the dietary
interventions are relatively simple and starkly different. In HF/HC experiment, the
dietary interventions are more complex - all subjects are put on standardized diet
for three days, before being randomized to HF or HC conditions. While the overall
mean percent of calories from fat is more extreme in the HF/HC diets than in the
PUFA/CHO diets, the more meaningful difference comes in the percent of calories
from SFA and MUFA. In particular, the HF diet is substantially different from the
PUFA diet in terms of what percentage of calories is coming from SFA vs MUFA
vs PUFA. Given that humans make their own saturated and monounsaturated fatty
acids through de novo lipogenesis when the body takes in more carbohydrates than
necessary, the signal from the HF/HC dietary interventions is more complex and
potentially more difficult to analyze.
4.4.1 Linear Modeling of HF/HC
The dynamics of these dietary interventions can be captured by a linear model
similar to the one used for PUFA/CHO. The abundance of the kth lipid is modeled
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as:
Lk ∼ µ+ r(4.9)
where µ is a factor with 10 levels:
µ levels: µ−3, µ0, µF2, µF7, µF14, µF21, µC2, µC7, µC14, µC21
All subjects have measurements for levels µ−3 and µ0, which represent the stan-
dardized diet on days -3 and 0. Levels µF2, µF7, µF14, µF21 represent the 3 weeks of
HF diet, and the remaining levels correspond to the 3 weeks of HC diet.
The random effects, represented by r, for subject i on diet j are: ri + rij. Each
subject is on two different diets: B (corresponding to the standardized diet on day
-3 and day 0) and HF or HC, corresponding to the remainder of the days assayed.
Out of 562 models, 281 were significant at the model level (adjusted p-value < 0.1).
Linear model results are summarized in Table 4.8, where it can be see immediately
that the time course dynamics are more complex than in PUFA/CHO. The majority
of lipids which change significantly across either of the diets do decrease (comparing
µF21 and µC21 to either µ0 or µ−3), but when µC21 is compared with µF21 a greater
proportion of lipids are significantly decreasing than what was found in the equiv-
alent comparison in PUFA/CHO. It is interesting to note that more lipids change
significantly when transitioning from the standardized diet to the HC diet (µC2−µ0)
than when subjects transition to the HF diet (µF2 − µ0 ). The total percentage of
macronutrients from fat is reduced by over 66%, in the former case, while almost
being doubled in the latter case. Further investigations into this subset of lipids
may yield further insight into the short term response of the metabolome to dietary
perturbations.
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µ0 − µ−3 µC2 − µ0 µC7 − µC2 µC14 − µC7 µC21 − µC14 µC21 − µ0 µC21 − µ−3 µC21 − µF21
proportion negative 0.75 0.60 0.69 0.43 0.68 0.71 0.57 0.44
proportion signif (p < 0.1) 0.02 0.12 0.03 0.06 0.00 0.23 0.13 0.22
proportion signif & negative 0.02 0.08 0.03 0.01 0.00 0.21 0.10 0.12
µF2 − µ0 µF7 − µF2 µF14 − µF7 µF21 − µF14 µF21 − µ0 µF21 − µ−3
proportion negative 0.65 0.68 0.55 0.40 0.77 0.60
proportion signif (p < 0.1) 0.00 0.00 0.00 0.00 0.19 0.10
proportion signif & negative 0.00 0.00 0.00 0.00 0.17 0.08
Table 4.8: Summary of time course dynamics in HF/HC. Proportions are calculated
as (# with characteristic)/562.
C1 C13 C14 C15 singletons/dyads total
P1 30 11 14 3 3 61
P16 11 60 5 22 0 98
P17 10 3 48 5 0 66
P18 3 8 13 0 1 25
singletons/dyads 3 0 1 0 0 4
total 57 82 81 30 4 254
Table 4.9: Contingency table of module membership in HF/HC data set. Module
membership for PUFA and CHO modules, with only lipids measured in
HF/HC
4.4.2 Module dynamics under more extreme dietary perturbations
Out of the 562 lipids measured in the HF/HC dataset, only 254 overlapped with
the PUFA/CHO dataset. Fortunately, the modules are relatively well preserved, and
the missingness is distributed relatively evenly across modules (Table 4.9.)
The modules defined in Section 4.3.1 can be tested for DA as in Section 4.3.3 to
see if there are more substantial changes in HF/HC data at the module level than at
the individual lipid level. As with the PUFA/CHO data, the three comparisons which
are of most interest are: µC21 vs µ0, µF21 vs µ0, and µC21 vs µF21. These results (Table
4.10) complement and magnify the linear model results, while also providing a more
complex picture than what was originally observed in the PUFA/CHO experiment.
We see that when day 21 is compared against day 0, for HF or HC, the modules
which change significantly decrease, with the exception of P16 and C13 which increase
between across the HC diet. These modules, along with C15 increase between d0 and
d42 in the original CHO diet. P18 and C15 decrease over the HC diet, while remaining
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P1 P16 P17 P18 C1 C13 C14 C15
µC21 > µ0 1 0.016 1 1 1 0.016 1 1
µF21 > µ0 1 1 1 1 1 1 1 1
µC21 > µF21 1 0 0 0.896 1 0 0.1184 0
µC21 < µ0: 0 0.998 0 0.0576 0 0.998 0 0.069
µF21 < µ0 0 0 0 0 0 0 0 0
µC21 < µF21 0 1 1 0.875 0 1 1 1
Table 4.10: GSA analysis in HF/HC data. Modules from PUFA/CHO are tested for
DA in HF/HC data set using a custom implementation of GSA. End
of HC (µC21) and end of HF µF21 are tested against µ0 and each other.
Values presented are p-values adjusted for multiple comparisons.
unchanged (P18) or increasing (C15) in the CHO diet.
It is particularly interesting that while P1 increases from d21 to d42, it decreases
over the equivalent comparison in the HF/HC study. These subtle differences in
module level activity may provide insight into more complex systems level dynamics
regarding the metabolism of SFA, MUFA and PUFA.
4.5 Discussion
In this chapter we present an alternative method for identifying modules of lipids,
one which does not rely on an arbitrary DA cutoff, and which combines data from
multiple data sets to create more robust co-expression networks. This method pri-
oritizes differential edges, instead of differential nodes (as in Chapter III). Ideally
this method is suited to a scenario where one has weak mean differentials between
conditions, and where the patterns of co-expression themselves are of primary interest.
We use the method to identify diet-linked modules, in the PUFA/CHO controlled
feeding study, which are then are used to illuminate more complex dynamic behavior
in a second controlled feeding study (HF/HC).
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4.6 Methods
4.6.1 Gene Set Analysis Implementation
Let βˆi be the estimate of the fixed effects from our linear model and Σˆi the
associated covariance matrix from solving the appropriate regression equation for the
ith lipid of the relevant dataset. Given a contrast vector c, we can calculate the
appropriate statistic
Di =
c′βˆ√
c′Σˆc
The test statistics Di are used to calculate Smax (Equation 4.8) for a set S, com-
prised of all the lipids in a consensus module (P1, C16, etc.) To calculate a p-value for
each Smax, sample labels are permuted nperm times (we used nperm = 500.) For paired
data (as in PUFA/CHO, or certain comparisons in HF/HC), the labels are shuffled
in pairs. For unpaired tests, all sample labels are permuted together. Sample labels
which are not directly involved in a test remained fixed (ie: if testing d21 - d0, the
sample labels for the observations from d2, d7, d23, d28 and d42 remain unchanged.)
Smax is recomputed on each permuted dataset, giving permuted values S∗1max,S∗2max,· · · ,
S∗npermmax . For the test di − dj, two p-values are computed:
p− value for di > dj =
nperm∑
k=1
I(S∗kmax > Smax)
nperm
(4.10)
p− value for di < dj =
nperm∑
k=1
I(S∗kmax < Smax)
nperm
(4.11)
P -values are then adjusted for multiple comparisons across all modules tested
using the Benjamini-Hochberg False Discovery Rate adjustment procedure [1].
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4.6.2 Study methods
The diet intervention study was approved the Institutional Review Board of
the University of Michigan (HUM00110543). Participants were recruited through
umclinicalstudies.org website and with posters placed throughout the University of
Michigan community. Subjects were required to have a body mass index (BMI) of
18.5− 27kg/m2 and between the age of 18-45 years. They were required to be weight
stable for 6 months (±5 pounds), have no known food allergies and be willing to
eat provided meals. Exclusions included active cigarette use within the previous 6
months, active cardiovascular disease, diabetes mellitus or other metabolic diseases,
use of any medication known to alter metabolism, such as metformin. After obtaining
informed consent, subjects were randomized within sex to either the a high carbohy-
drate (HC) or high fat (HF) diets (6 HC women, 6 HF women, 7 HC men, 5 HF men).
Subjects were assigned a unique identification number for tracking. All collected data
was de-identified prior to analysis using this unique number.
Plasma sampling. Plasma was collected from all subjects was obtained in three
phases: Baseline, Standard Diet, and. was sampled at baseline, after 3 days of a
Standard Diet and at days 2, 7, 14 and 21 of the HC or HF experimental diet.
Dietary intervention. Standard diets reflected the 50th percentile macronutrient
intake (±2%) for the US population, as available in the 2015 Dietary Guidelines
Advisory Committee Report (Committee, 2015) with the target intake of 15% protein,
35% fat, and 50% carbohydrate. Details of the interventions are detailed in past
MCRU-NAL protocols [108, 109, 110].
Experimental Diets. The HF diet target was 60% fat, 25% carbohydrate and
15% protein while the HC diet target was 10% fat, 75% carbohydrate and 15% pro-
tein. Total calories provided during the Standard diet and Experimental diet phases
was calculated to meet macronutrient requirements of the eucaloric diet for each
individual. Weight varied less than 1% during the dietary interventions.
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Dietary Analysis. For PUFA/CHO MCRU Nutrition Assessment Laboratory
dietitians analyzed recorded the content of the diet over a random sample of 3 days
of each study diet using the dietary analysis program Nutrition Data for Research
(NDSR). Each subject had 3 days analyzed for each dietary intervention, except for
subject 17, which only had 2 days for PUFA due to a processing error. For HF/HC,
dieticians analyzed recorded content for each of the 24 subjects for each of the 3
standard diet days (B), as well as for each of the 21 HF or HC diet days.
4.6.3 Lipidomics methods
Lipidomics methods for PUFA/CHO are described in Chapter III.
HF/HC data were processed similar, with additional classes of lipids added to the
insilico library.
4.6.4 Lipid Normalization
Lipids in both studies were normalized as in Chapter III. In HF/HC data, one
subject sample (male, high carb group at day 0) was removed because of an injection
error. After normalization, PUFA/CHO data had 458 lipids in 16 classes; HF/HC
data had 562 lipids in 23 classes.
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APPENDIX A
Supplementary material for Chapter II
A.1 Algorithm Details
In the algorithm for estimating Q̂ and B̂k, (Appendix Algorithm 1), we include
two additional steps, one of which is optional, to help deal with noisy data. The iden-
tification restriction on the Bkii’s require them to be positive; hence, B̂
k
ii < 0 implies
excessively noisy data for variable i, which in turn can result in the corresponding
entries in the Λ̂k having differing signs. It is possible to have different signs in Λ̂k
without having a B̂kii < 0, if the signal is strong enough. If B̂
k
ii < 0, we pick the
”correct” sign based on a majority rule, and remove from estimation the entries with
the opposing sign.
If Qij is nonzero, then any corresponding entry Λ̂
k
ij which is set to 0 in the course
of the algorithm is done so because of noise. This means that in the calculation of Q̂ij,
this element is not getting the full contribution from each Λ̂kij, and will be artificially
low. This can be partially addressed by an optional scaling factor, sij, which was
found to improve performance in some simulation settings.
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sij =
K
K∑
k=1
I(Λ̂kij 6= 0)
(A.1)
Q̂ij is then updated to be sijQ̂ij.
If all Λ̂kij are nonzero, then the scaling factor is 1. Otherwise, sij > 1, and will
slightly inflate Qij. This adjustment would be included whenever Q̂ was calculated
(immediately after line 1 in Appendix Algorithm 1). A brief discussion of the results
of including this step is included in Appendix Section A.3.4.
Recall that certain constraints are placed on Bk, depending on the overall design
structure, and how one wants to compare data sets. If comparisons between any two
data sets in a 2× 2 experimental design are desirable, one would normalize Bk across
all levels of both design factors. If the first design factor has levels {1, · · ·K1} and
the second {1, · · ·K2}, then
ID0 :
K1∑
k=1
K2∑
j=1
Bkj = I(A.2)
Given a single design factor with unordered levels, this constraint would reduce
to
ID1 :
K∑
k=1
Bk = I(A.3)
If one were primarily interested in comparing across levels of the one design factor
for a single, fixed, level of the second design factor, one might use the following
constraint:
ID2 :
K2∑
k=1
Bik = I (for each fixed i ∈ {1, · · · , K1}.)(A.4)
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Algorithm 1: Estimating Q̂, B̂k
Data: Λ̂k, k ∈ {1, · · · , K};m; d
Result: B̂k, Q̂
begin
1 Q̂← 1
d
∑
k
Λ̂k
1.1 if including sij then
1.2 Q̂ij ← sij(Q̂ij)
2 for k ∈ {1, · · · , K} do
3 B̂kii =
1
m
m∑
j=1
Λ̂kij/Q̂ij
4 if Q̂ij = 0 then
5 B̂kij = 0
6 Normalize B̂k
7 if B̂kii < 0 then
8 for j∈ {1, · · · ,m} do
9 np =
K∑
k=1
I(Λ̂kij > 0), nn =
K∑
k=1
I(Λ̂kij < 0)
10 if np = nn then̂
12 Λkij = 0 ∀ k
13 if np > nn and Λ̂
k
ij < 0 then
14 Λ̂kij ← 0
15 if np < nn and Λ̂
k
ij > 0 then
16 Λ̂kij ← 0
16-21 repeat lines 1-6
where one is interested in comparing outcomes for each of the K1 levels of D1
across all K2 levels of D2.
In Algorithm 1, normalizing of B̂k is according to design structure and these
constraints. d is equal to 1 if using the constraints in equations A.2 and A.3, and is
equal to K1 if using the constraint in equation A.4.
For the the algorithms calculating Λ̂k, we need a few additional functions. Let
φΛ̂k(Λ̂
k′) be the rotation of Λ̂k′ so that it has maximum similarity with Λ̂k (the
Procrustes rotation). The reference condition k can be chosen at random, or with
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some consideration of the experimental design.
Let ψc(Λ̂
k) be the thresholding of Λ̂k where all entries between −c and c are set
to 0.
Finally, let ηs(Λ̂
k) be the function with thresholds Λ̂k by cardinality. Specifically,
let s = (s1, s2, · · · , sm) represent the target cardinality (the target number of non-zero
entries) for each column of Λ̂k. If Λ̂k has p rows, then, for each column j, the p− sj
smallest entries are set to 0.
The estimation of non-sparse Λ̂k via a scaled eigendecomposition is presented in
Algorithm 2. The addition of lines 3.1 and 3.2 are all that is required for a fast,
decent approximation of a sparse Λ̂k via method EDTM. Method EDTC is presented
in Algorithm 3, and the SPCA method for sparse Λ̂k is presented in Algorithm 4.
Algorithm 2: Estimation of non-sparse Λ̂k OR sparse Λ̂k via method EDTM
Data: UkDkUk
′
, the eigen-decomposition of Σk, k ∈ {1, · · · , K};m; c
Result: Λ̂k
begin
1 for k ∈ {1, · · · , K} do
2 Λ̂k ← Uk1:m
√
Dk1:m
3 Pick k ∈ {1, · · · , K}
3.1 if Q is sparse then
3.2 Λ̂k ← ψc(Λ̂k)
4 for k′ ∈ {1, · · · , K}, k′ 6= k do
5 Λ̂k′ ← φΛ̂k(Λ̂k′)
6 for k ∈ {1, · · · , K} do
7 Λ̂k ← ψc(Λ̂k)
In Algorithm 4, Σspca is the diagonal matrix having entries equal to the variance
of each sparse principal component. In this specific case where we are using the spca
function from elasticnet, the entries are equal to the total variance of the decompo-
sition multiplied by the percent explained variance of each component. We use the
varnum option of spca, in which the user supplies the number of non-zero components
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Algorithm 3: Estimation of sparse Λ̂k, via EDTC
Data: UkDkUk
′
, the eigen-decomposition of Σk, k ∈ {1, · · · , K};m; s
Result: Λ̂k
begin
1-3 As in Algorithm 2
4 Λ̂k ← ηs(Λ̂k)
5 for k′ ∈ {1, · · · , K}, k′ 6= k do
6 Λ̂k′ ← φk(Λ̂k′)
7 Λ̂k′ ← ψc(Λ̂k′)
desired for each sparse principal component to be estimated.
Algorithm 4: Estimation of sparse Λ̂k, via SPCA
Data: Σk, k ∈ {1, · · · , K}, m, (s1, · · · sm)
Result: Λ̂k
begin
1 for k ∈ {1, · · · , K} do
2 Λ̂k ← spca(Σk) with m sparse principal components, having (s1, · · · sm)
non-zero elements in each column.
3 Λ̂k ← Λ̂k√Σspca
4 Λ̂k ← ψc(Λ̂k)
5 Pick k ∈ {1, · · · , K}
6 for k′ ∈ {1, · · · , K}, k′ 6= k do
7 Λ̂k′ ← φΛ̂k(Λ̂k′)
8 for k ∈ {1, · · · , K} do
9 Λ̂k ← ηs(Λ̂k)
A.2 Performance review of sparse PCA methods
A.2.1 selecting tuning parameters
For both SPCA and EDTC, we used the leading.eigenvector.community de-
tection algorithm (LEVCD) in the igraph package in R to estimate the number of
latent factors, m, and their cardinalities, (s1, · · · sm). The steps to estimate these
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tuning parameters are presented in Algorithm 5.
Algorithm 5: Number and cardinality of latent factors
Data: Σk ∀k
Result: m, (s1, · · · sm)
begin
for k ∈ {1, · · · , K} do
Convert Σk to an undirected graph with weighted edges, Gk.
Calculate the number, ck and size, s
k
1, · · · skck , (ski > ski+1), of
communities present in Gk.
m = min
k∈{1,···K}
ck
(s1, · · · sm) = (sm1 , · · · smcm)
A.2.2 Performance Review
In the case where we believe that the underlying Q is sparse, our first challenge
is in calculating an accurate sparse eigen-decomposition. We began by investigating
SPCA ([43] [44]), implemented in the spca function of the R package elasticnet.
In principal this method should work well when tuned appropriately. The default
setting uses two different λ penalty parameters;in our investigations we were unable
to come up with a good heuristic for guiding the tuning of these parameters.
The spca function in R has a second option, one which allows the user to put in
the number of principal components to estimate, and the number of non-zero elements
in each. When given the true values for these parameters, the method worked quite
well. This raises another question though - how to estimate the values for those
parameters? It turns out that LEVCD can be used quiet reliably to estimate those
parameters.
The first quantity LEVCD needs to estimate is the number of communities (which
we take as equivalent to the number of latent factors). Over all iterations of all the 2-
factor simulation settings that we ran, LEVCD returned the correct number of factors
99.94% of the time. In the few cases where it mis-estimated the number of factors, it
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added an additional factor.
For the 3-factor simulation settings, the performance was also quite good, return-
ing the correct number of factors 99.6% of the time. Here too the method usually
over-estimated the number of latent factors, most commonly when the factors only
explained 50% of the observed variance and the communities all had similar sizes.
In both the 2 and 3 factor simulation settings, when LEVCD over estimated the
number of factors/communities, the additional community was estimated to be very
small. For the 2-factor settings, this third community was never estimated to have
more than 2 members; for the 3-factor settings, the fourth community was never
estimated to have more than 7 members (the majority of the time it was estimated
as having only one member.)
Across all 2 factor simulation settings, LEVCD estimates the first and second
community within ±1 of their true size 98.3% of the time. In the 3 factor simulation
settings, LEVCD estimates the first, second and third community sizes within ±1 of
their true size over 99.2% of the time.
While SPCA yielded good performance, the algorithm often took some time to
run. Given that we had already estimated the number and cardinality of each of
the factors, we wondered if there was a simpler method for creating the sparse eigen-
dcomposition which could use these parameters, but offered improved performance or
speed over SPCA. For this purpose, we developed an alternative eigen-decomposition
method, where the eigenvectors were truncated by their cardinality (EDTC method,
Algorithm 3), which also yields good results.
After close examination of the results from EDTC method, it was observed that
many of the ”incorrect” values were quite small, and would have been truncated if
a simple cutoff had been used. This led us to test a simple eigen-decomposition,
truncated by magnitude in the usual way (method EDTM). To make a fairer com-
parison, we used the number of communities estimated via LEVCD (so there would
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be the same number of factors as the other methods), but truncated with a simple
0.1 threshold, the same as we used for the non-sparse eigen-decomposition.
Intuitively, whichever method has the best reconstruction of Λ̂k, is also going to
give us the best results for B̂k and Q̂. We used a modified version of the reconstruc-
tion loss (Equation A.5) as a proxy for how well each method would perform in the
algorithm over all.
Reconstruction- loss v2:
1
K
K∑
k=1
|| |Λk| − |Λ̂k| ||F
||Λk||F(A.5)
We can compare this reconstruction loss for the three methods in Appendix Fig-
ures A.7, A.8 and A.9. We note that for the EDTM, we did use the number of
communities generated by the LEVCD method, though this number could also be
obtained from a scree plot. It can be seen that both of the eigen-decomposition
methods outperform the spca method. Closer inspection shows that EDTC slightly
outperforms EDTM, based on this reconstruction loss, but the performance differ-
ences is quite small. In summary, simple eigen-decomposition, truncated by cardi-
nality, yields results just as good as the SPCA, with the advantage of being much
faster to compute. Furthermore, if one did not want to go through the additional
work of estimating parameters via LEVCD, one could get a decent sparse principal
component approximation simply by truncation by magnitude.
A.3 Simulation Results
A.3.1 additional simulation details
For each Bk ∈ {1, · · · , K} we generate a random bk ∼ Unif(0.15, 0.85). The set
of Bk are then normalized according to the design structure, as discussed in Section
A.1.
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The factors F are generated from a N(0, 1) distribution, while the non-zero entries
in Q are generated uniformly from (−1,−0.5) ∪ (0.5, 1).
Once we have generated our Bk, F and Q, we generate our distribution for E.
For each realization of E we sample from a N(0,Ψ) distribution, where Ψ is designed
so that Λk explains, on average, 50% or 75% of the variance in the observed data.
In the context of our motivating example, lipids in a certain class are more likely
to have variances which are more similar to each other than to lipids from another
class, due to technical reasons. With an eye towards this application, we also design
Ψ as a block-diagonal matrix. In all of our simulations, Ψ has three blocks, each
representing approximately 1/3 of the total variables. If the target variance (cal-
culated as described below) is σ2t , then we set the variance within the blocks to be
((σt − 0.05)2, σ2t , (σt + 0.06)2), respectively.
The proportion of variance in our dataset, having p variables, explained by our
factors can be written as:
p∑
i=1
(
ΛkΛk
′)
ii
p∑
i=1
(ΛkΛk′)ii + Ψii
(A.6)
If we want our factors to account for 50% of the total variance in the dataset, then
σ2t =
1
p
1
K
K∑
k=1
p∑
i=1
(
ΛkΛk
′
)
ii
If we instead want our factors to account for 75% of the total variance in the
dataset, then
σ2t =
1
3
1
p
1
K
K∑
k=1
p∑
i=1
(
ΛkΛk
′
)
ii
Each application of the algorithm includes an additional step in which we use
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a procrustes rotation to align the Λ̂k with Λk, so that we accurately measure the
performance of the algorithm, not the accuracy of the eigen-decomposition or spca
in picking the correct orientation. We used the procrustes function in vegan package
in R, with the scale=false option, which ensures that the transformation is only a
rotation, and therefore orthogonal.
The performance of the algorithm is evaluated via the following equations:
B-loss:
||B − B̂||F
||B||F(A.7)
Q-loss:
|| |Q̂| − |Q| ||F
||Q||F(A.8)
Reconstruction-loss:
1
K
K∑
k=1
|| |B̂kQ̂| − |BkQ| ||F
||BkQ||F(A.9)
where B is a p×K matrix whose kth column is the diagonal entries in Bk.
In the non-sparse simulation settings we used a threshold of c = 0.1 for the final
truncation step in estimating Λ̂k (step 7 in Algorithm 2). We ran the algorithm with
and without the sij scaling factor on the same datasets; in general, the adjustment step
decreased the error in estimating B, while slightly increasing the error in estimating
Q. These two effects combined to have a minuscule decrease in the error of Λ̂ in some
settings. Overall, this step was shown to yield no increase in performance in the non-
sparse settings (likely due to the strong signal), while yielding some improvements in
the sparse scenario (possibly due to the difficulty in correctly estimating the sparse
structure.) While the step increases the error in Q̂ slightly, it also serves to decrease
the number of entries in Q̂ which have small loadings. This may be an advantageous
in an application setting, as it was in our application on the AI data. Depending on
which component was of greater interest in an application, Bk or Q, a researcher may
wish to include the adjustment step or not.
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A.3.2 Results for non-sparse Q, without sij
Overall, we have quite good results across all simulation settings, as can be seen
in Figures A.1, A.2, and A.3. We see that in many ways that algorithm behaves
as our intuition tells us it should - loss goes down as the error decrease and as
the percentages of variance explained by the latent factors increases. Loss generally
decreases with increasing sample or variable size, but increases (particularly in Q)
with an increasing number of latent factors. Performance across all metrics tends to
increase as the number of datasets increases, regardless of the experimental design
structure. We also observe that the standard deviations of the loss values are quite
small - indicating that the algorithm consistently has good performance.
The mean B-loss is always < 0.233, with half of the instances even below 0.11.
Mean Q-loss values are also quite good- always below 0.23, with the majority of the
settings having loss values < 0.17, and a quarter below 0.12. Mean Reconstruction-
loss values are slightly higher, but still below 0.29, with half of the simulation settings
having loss values between 0.083 and 0.174.
A.3.3 Results for sparse Q, without sij
Our preferred method for estimating sparse Λ̂k is the EDTC method, as it yielded
the best results, shown in Figures A.4, A.5, and A.6. ”Qload: 1” and ”Qload: 2” refer
to Q having (0.55p, 0.45p) and (0.7p, 0.3p) non-sparse elements respectively, when
m = 2, or Q with (0.39p, 0.33p, 0.28p) and (0.5p, 0.3p, 0.2p) non-sparse elements,
respectively, for m = 3.
Again we have quite good results across all simulation settings. With the addition
of sparsity, the overall picture is somewhat more complex than previously. Overall, we
see similar trends to the non-sparse case - loss decreases as the percentage of variance
explained by our factors increases, or as sample size increases. Now however, we see
that as the number of factors increases, the loss also tends to increase very slightly.
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For two factors and either experimental design structure, the algorithm performs
slightly better in the Qload: 1 settings than in the Qload: 2 settings for all of the
performance metrics. This is also true for most of the three factor settings, but the
performance increase is so slight as to be negligible.
Across all settings, the mean Q-loss ranges between 0.067 and 0.158, with half of
the settings having loss values below 0.1. The mean B-loss is higher here, ranging
from 0.042 to 0.24, but the majority of the settings have loss values below 0.15. Mean
Reconstruction-loss values are similar in range to the B-loss values, 0.766 to 0.269,
with most < 0.17.
A.3.4 Results for sparse Q with sij
The results for the sparse scenarios with the additional adjustment step have the
same general trends as without that adjustment step, as can be seen in Figures A.10,
A.11 and A.12.
There are some slight differences - mean Q-loss ranges between 0.068 and 0.193,
with most of the entries having loss < 0.139. Mean B-loss ranges from 0.042 to 0.183,
with about half of the loss values being below 0.1. Mean Reconstruction-loss values
are still fairly good, between 0.076 and 0.27, with 75% of those being < 0.171.
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(a) 3× 1 design
(b) 2× 2 design
Figure A.1: Q-loss, non-
sparse Q
(a) 3× 1 design
(b) 2× 2 design
Figure A.2: B-loss, non-
sparse Q
(a) 3× 1 design
(b) 2× 2 design
Figure A.3: Reconstruction-
loss, non-sparse
Q
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(a) 3× 1 design
(b) 2× 2 design
Figure A.4: Q-loss with
sparse Q
(a) 3× 1 design
(b) 2× 2 design
Figure A.5: B-loss with
sparse Q
(a) 3× 1 design
(b) 2× 2 design
Figure A.6: Reconstruction-
loss with sparse
Q
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(a) 3× 1 design
(b) 2× 2 design
Figure A.7: Reconstruction-
loss v2, SPCA
(a) 3× 1 design
(b) 2× 2 design
Figure A.8: Reconstruction-
loss v2, EDTC
(a) 3× 1 design
(b) 2× 2 design
Figure A.9: Reconstruction-
loss v2, EDTM
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(a) 3× 1 design
(b) 2× 2 design
Figure A.10: Q-loss with
sparse Q and
sij
(a) 3× 1 design
(b) 2× 2 design
Figure A.11: B-loss with
sparse Q and
sij
(a) 3× 1 design
(b) 2× 2 design
Figure A.12: Reconstruction-
loss with
sparse Q and
sij
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A.4 Materials and Methods
A.4.1 Lipid background
Lipids are small biomolecules comprised of a head group attached to a fatty acid
tail. The structure of the head group separates lipids into classes (such as diglycerides
(DGs), triglycerides (TGs), and sphingomylins (SMs), among others). The fatty acid
tail is comprised of chains of carbon atoms, connected by single or double bonds.
Lipids can be classified by the length of these tails as short, medium or long chain
lipids. They can also be classified as saturated (0 double bonds), monounsaturated
(1 double bond) or polyunsaturated (2 or more double bonds).
A.4.2 Metabolomics methods
Plasma samples were spiked with internal standards lipids (LPC 17:0/0:0, PC
17:0/17:0, PE 17:0/17:0, SM 17:0/17:0, Ce 17:0/17:0, PG 17:0/17:0, PS 17:0/17:0,
PA 17:0/17:0, PI 17:0/20:4, d5-DAG, TG 17:0/17:0/17:0 and D31-TAG, Avanti Polar
Lipids (Alabaster, AL)) and lipids extracted using a modified Bligh-Dyer method [111]
using 2:2:2 volume ratio of water/methanol/dichloromethane at room temperature as
described previously [112]. The organic phase was collected and dried under nitrogen
and reconstituted in 100µL of a buffer (10:85:5 ACN/IPA/H2O) containing 10mM
ammonium acetate and analyzed using LC-MS based lipidomics. The data acquisition
was performed in both positive and negative ionization modes, using a TripleTOF
5600 equipped with a DuoSpray ion source (AB Sciex, Concord, Canada). The lipids
were identified using Lipid Blast [113] [114] ,software by matching MSMS spectra to
different library and the data files were processed using MultiQuant 1.1.0.26 [115]
(ABsciex, Concord, Canada).
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A.4.3 Normalization procedure
Data was normalized to remove batch and run order effects, and log2 transformed.
One case sample had lipid data, but no FFA or eicosanoid data, and so was removed
(giving us 24 cases and 25 controls). There were 442 lipids, 9 eicosanoids and 16 FFA
in the dataset.
Lipidomics data was normalized to remove batch and run order effects. Each
lipid was normalized individually, without the use of internal standards. Positive and
Negative modes treated separately, until the final step of removing duplicate lipids.
Pooled samples are the pooled samples from the test data.
Each batch had 7 pooled samples. Lipids that were missing more than 2 pooled
samples across both batches were removed (35 lipids in the positive mode, 5 lipids in
the negative mode).
Robust regression on the pooled data was used to calculate an adjustment ratio
between batches; this ratio was then used to remove batch effects.
For each lipid i, we calculate a batch-adjustment factor βi. If there are two
batches, this is essentially the slope from the robust regression of one batch on the
other, without an intercept. Let b1i be the measurements for lipid i in batch 1 and b
2
i
be the measurements for lipid i in batch 2. We want to calculate
b2i = βib
1
i
If there are more than two batches, then one batch is picked as the reference, and
all other batches are regressed against the reference batch, one at a time. We use the
lmrob function from the R package robustbase for calculating the adjustment ratio
between batches.
Once the adjustment factors have been calculated, and missing data imputed
(using the knn function from the pamr package. Imputation was done taking into
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account the batch number, run order and sample label (cases at baseline, controls at
3 months, etc). ) we can then use the adjustment factor to remove batch effects by
updating b2i to be
1
β
b2i .
Next, loess smoothing is used to remove the remaining effects of run order. Loess
tuning parameters are calculated on the pooled samples, and then used to smooth
the original samples.
Once all batch and run order effects have been adjusted for, we combine the
positive and negative modes and remove any duplicate lipids which appear more
than once.
If a lipid is present in only one mode, but with multiple ions, we keep the ion with
lowest variability as measured by relative standard deviation (RSD), where RSD of
the ith lipid, li, is equal to 100stdev(li)/mean(li).
If a lipid is present in both modes, we pick the mode that has the most lipids of
that lipid’s class, and keep the ion w/ the lowest RSD within that mode.
If a lipid is present in both modes, and there are the same number of ions/lipids
in both modes, we keep the ion with the lowest RSD across both modes.
The FFA data was normalized in the same way as the lipidomics data. The
eicosanoid data was run in a single batch and was median centered after being log2
transformed.
A.4.4 Case Study Details
A.4.4.1 Patient Characteristics
Samples were derived from a prospective clinical trial - all postmenopausal women,
had completed surgery, radiation, and chemotherapy as indicated, participating in
a randomized clinical trial (Exemestane and Letrozole Pharmacogenomics (ELPh))
comparing two aromatase inhibitors (letrozole and exemestane). Patients were fol-
lowed prospectively during treatment to assess tolerance of medication, completed
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Cases (n=25) Controls (n=25)
Median age (range) 60 (48-79) 60 (44-77)
Race
White 22 (88%) 23 (92%)
Black 3 (12%) 2 (8%)
Body mass index (kg/m2), mean (SD) 30.5 (5.6) 29.3 (5.1)
Aromatase inhibitor (AI)
Exemestane 16 (64%) 15 (60%)
Letrozole 9 (36%) 10 (40%)
Time on AI, months, median (range) 5.5 (2.9-6.0) 24.2 (23.6-25.1)
Prior chemotherapy 12 (48%) 11 (44%)
Prior tamoxifen 13 (52%) 12 (48%)
Table A.1: Baseline Demographic and Medical Characteristics. Data presented as
n(%), n(max,min), or mean (standard deviation)
the HAQ/VAS questionnaire at baseline, 1, 3, 6, 12, and 24 months. Those patients
who discontinued therapy by 6 months because of increased pain were ”cases” and
those who didn’t report a pain level > 2/10 during the 24 month follow-up on AI
therapy were the ”controls” [48]. A summary of subject characteristics can be seen in
Appendix Table A.1. Serum was collected at baseline and after 3 months of therapy
on subjects enrolled on this clinical trial.
A.4.4.2 Application of method
Based on scree plots of the covariance matrices for each of our 4 data sets, we
decided on a 2-factor model with a non-sparse underlying Q. We chose the controls
at time 0 as the reference condition for the Procrustes rotation. The rotated Λ̂k, were
then truncated with a threshold of ±0.1 to remove small loadings.
We used constraint ID2 (equation A.4) to normalize the B̂k values, normalizing
the B̂k for the controls together, and the B̂k for the cases together.
We chose to include the sij adjustment step for several reasons. It moves the
metabolites further away from the axis of Q̂ and therefore helps make the grouping
more clear. Additionally, the step makes it it so fewer metabolites are truncated
because of low loadings.
After applying the method, 6 lipids were removed for having Q̂i1 = Q̂i2 = 0, and
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additional 15 lipids and one FFA removed for having |Q̂i1| < 0.2 and |Q̂i2| < 0.2,
leaving us with 445 metabolites.
A.5 Enrichment and differential abundance analysis
For the over representation/enrichment analysis, we tested whether a particular
class of metabolite or saturation level was over represented in a given group - (ie: if
there were more saturated lipids in group 1 than we would expect by chance, given
the total number of saturated lipids in the set of all metabolites, and the size of
group 1) by using the hypergeometric distribution (see [78] for a good review on the
hypergeometric test in enrichment analysis). These results are summarized in Table
A.2.
To test whether a higher expression in a given group was correlated with one of
the two conditions in our two-way contrasts of interests (the same two-way contrasts
as in the t-tests), we used the GSA function from the GSA package in R. We used the
”maxmean” method, with s0 = 0 and no restandardization. P -values for these tests
can be seen in Table A.3.
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Group 1 2 3 4 a b c d
Saturated 0.0022 0.9277 0.7693 0.9872 0.9277 0.3887 0.7693 0.3887
Monounsaturate 0.9913 0.0196 0.9913 0.9913 0.9913 0.0038 0.0244 0.2723
Polyunsaturated 0.9984 0.9984 0.015 1e-04 0.1471 0.9984 0.9984 0.9984
ffa 4e-04 0.9573 0.9573 0.342 0.4839 0.89 0.89 0.4102
CE 4e-04 0.9941 0.9941 0.342 0.8384 0.4496 0.4496 0.4102
CL 0.9878 0.0575 0.5414 0.8454 0.3212 0.5414 0.8454 0.8454
DG 0.9913 2e-04 0.0919 0.9913 0.9913 0.8252 0.9913 0.9913
lysoPC 0.9741 0.9741 1e-04 0.9741 0.9741 0.0462 0.1548 0.9741
lysoPE 0.8906 0.8906 0.0894 0.8906 0.0894 0.0045 0.8906 0.8886
MG 0.2613 0.7406 0.2613 0.2613 0.2876 0.194 0.2876 0.2822
PA 0.0362 0.953 0.5367 0.5367 0.2786 0.5367 0.0774 0.5367
PC 0.9997 0.9997 0.0291 0.5607 0.1042 0.1193 0.4632 0.0291
PE 0.7149 0.0174 0.9558 0.9576 0.9558 0.3951 0.7149 0.9558
PG 0.0014 0.7695 0.7695 0.7695 0.7063 0.7063 0.7063 0.0175
PI 0.3613 0.3613 0.7622 0.9248 0.0652 0.7622 0.4065 0.3613
plasmenyl-PC 0.5366 0.7406 0.3355 0.3355 0.3355 0.3355 0.3355 0.0028
plasmenyl-PE 0.5582 0.9941 0.5582 0.0079 0.5359 0.5359 0.3145 0.596
SM 0.0648 1 1 0.2449 0.9608 0.9608 4e-04 0.0026
TG 0.9995 0 0.9995 0.0382 0.9995 0.9995 0.9995 0.9995
eico 0 0.953 0.9241 0.9241 0.4179 0.7697 0.7697 0.7697
LA 0.0053 0.0408 0.9982 0.9982 0.984 0.984 0.984 0.984
ALA 0.9889 0.11 0.0436 0.3093 0.9889 0.9889 0.9889 0.9889
Table A.2: Enrichment analysis for AI data set. Variables are partitioned into 8
groups (1, 2, 3, 4, a, b, c, d), based on their loadings onto Q̂. Each group is
then tested for over representation in a class or saturation level. P -values
presented in the table are adjusted row-wise for multiple comparisons,
using the Benjamini-Hochberg procedure [1]
Group 1 2 3 4 a b c d
higher exp corr w/ controls at t 3 vs t 0 0.99 0.2 0.99 0.99 0.99 0.99 0.99 0.99
higher exp corr w/ cases at t 3 vs t 0 0.91 0.91 0.91 0.91 0.91 0.91 0.91 0.91
higher exp corr w/ controls vs cases at t 0 0.8571 0.925 0.8571 0.8571 0.8571 0.8571 0.8571 0.16
higher exp corr w/ controls vs cases at t 3 0.67 0.67 0.67 0.67 0.67 0.67 0.67 0.67
lower exp corr w/ controls at t 3 vs t 0 0.27 0.975 0.27 0.06 0.3543 0.336 0.3543 0.06
lower exp corr w/ cases at t 3 vs t 0 0.72 0.4333 0.32 0.32 0.4333 0.32 0.32 0.72
lower exp corr w/ controls vs cases at t 0 0.8457 0.6 0.68 0.8457 0.68 0.68 0.792 0.98
lower exp corr w/ controls vs cases at t 3 0.68 0.5543 0.5543 0.5543 0.5543 0.5543 0.5543 0.5543
Table A.3: GSA analysis for AI data set. P -values for using GSA to test for group
level differences of abundance in AI data. Variables are partitioned as in
Table A.2. P -values are adjusted row-wise using the Benjamini-Hochberg
procedure.
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APPENDIX B
Supplementary material for Chapter III
B.1 Module nomenclature
The jth module from CGi is referred to as Mi:j (i.e. M21u:2 refers to the second
identified module from CG21u.)
B.2 PCST node and edge frequencies
PCST solution set 0 (0.0,0.05] (0.05,0.1] (0.1,0.15] (0.15,0.2] (0.2,0.25] (0.25,0.3] (0.3,0.35] (0.35,0.4] (0.4,0.45] (0.45,0.5] (0.5,0.55] (0.55,0.6] (0.6,0.65] (0.65,0.7] (0.7,0.75] (0.75,0.8] (0.8,0.85] (0.85,0.9] (0.9,0.95] (0.95,1]
G42d edges 77128 836 347 135 130 50 59 42 37 15 22 20 31 9 15 15 16 9 16 15 56
G21d edges 59640 445 145 60 64 37 46 27 32 15 30 13 12 13 12 8 18 11 10 20 68
G42u edges 96321 929 340 120 139 60 66 30 45 33 26 16 21 12 24 10 23 9 22 25 75
G21d edges 89209 496 185 68 79 36 57 28 36 21 36 19 23 14 21 18 24 26 18 27 84
G42d nodes 27 11 6 6 6 6 3 5 0 9 4 7 2 3 6 6 2 6 11 272
G21d nodes 26 14 10 8 4 7 9 5 5 5 5 4 6 7 5 5 5 5 7 207
G42u nodes 36 7 4 3 4 8 2 3 2 4 3 4 2 10 1 5 4 6 8 328
G21d nodes 26 17 4 7 5 4 6 9 2 3 2 3 3 4 5 3 6 7 6 304
Table B.1: Prize Collecting Steiner Tree output summary. Prize Collecting Steiner
Tree node and edge frequencies over all 50 noisy runs on each graph. Table
contains the total number of nodes/edges contained in > 50X and ≤ 50Y
solutions for column (X, Y ]. In each scenario, all terminal nodes are chose
in 100% of the runs.
B.3 Module differential abundance
B.4 Full enrichment/depletion tables
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Comparison tested M21u:1 M21u:2 M21u:3 M21u:4 M21u:6 M21u:7 M21u:20 M42u:2 M42u:3 M42u:4 M42u:5 M42u:6 M42u:7 M42u:14 M42u:15 M42u:16
d21 < d0 0.000 0.000 0.000 0.000 0.997 0.000 0.000 0.000 0.000 0.000 0.032 0.000 0.000 0.000 0.000 0.000
d42 < d0 0.993 0.993 0.993 0.013 0.993 0.013 0.013 0.993 0.993 0.021 0.993 0.013 0.100 0.061 0.027 0.993
d42 < d21 1.000 1.000 1.000 1.000 0.000 1.000 1.000 1.000 1.000 1.000 1.000 0.027 1.000 1.000 1.000 1.000
d21 > d0 1.000 1.000 1.000 1.000 0.053 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000
d42 > d0 0.018 0.107 0.018 0.993 0.200 0.993 0.993 0.018 0.064 0.993 0.064 0.993 0.993 0.993 0.993 0.190
d42 > d21 0.000 0.000 0.000 0.000 1.000 0.000 0.000 0.000 0.000 0.000 0.000 1.000 0.000 0.000 0.000 0.000
Table B.2: Complete module DA results. Modules from CG21u and CG42u were tested
for differential abundance using GSA. End of PUFA (d21) and end of CHO
(d42) tested against baseline (d0), and each other. Values presented are
row-wise fdr adjusted p-values for all of modules from CG21u and CG42u.
Comparison Tested M21u:2 M21u:3 M21u:4 M21u:6 M21u:20 M42u:2 M42u:5 M42u:14 M42u:15 M42u:16
HCR-AL < LCR-AL 0.17 0.011 0.025 0.108 0.000 0.090 0.089 0.040 0.011 0.170
HCR-CR < LCR-CR 0.4933 0.381 0.278 0.278 0.493 0.278 0.278 0.278 0.278 0.493
LCR-CR < LCR-AL 0.0286 0.000 0.000 0.033 0.013 0.000 0.017 0.000 0.063 0.033
HCR-CR < HCR-AL 0.2125 0.213 0.213 0.213 0.870 0.213 0.213 0.200 0.748 0.213
HCR-AL < LCR-CR 0.8533 0.853 0.511 0.853 0.483 0.853 0.783 0.853 0.133 0.853
Table B.3: Complete module dynamics in animal model. Modules from CG21u and
CG42u which had at least 70% overlap with animal data were tested for
differential abundance in animal data using GSA. None of the tests in
the opposite direction (HCR-AL > LCR-AL, HCR-CR > LCR-CR, etc)
were significant. Values presented are row-wise fdr adjusted p-values for
all modules with requisite coverage.
Module CE DG lysoPC lysoPE MG PC PE PI plasmenyl-PC plasmenyl-PE SM TG untarg SFA MUFA PUFA
M21u:1 0.211 0.707 0.921 0.714 0.583 0.338 0.001 0.733 0.008 0.632 0.615 0.990 1.000 0.887 0.922 0.001
M21u:2 0.795 0.106 0.921 0.728 0.595 0.338 0.886 0.585 0.523 0.928 0.859 0.000 1.000 0.426 0.008 0.366
M21u:3 0.648 0.000 0.921 0.627 0.595 0.558 0.886 0.746 0.523 0.928 0.404 0.137 1.000 0.977 0.922 0.004
M21u:4 0.441 0.707 0.000 0.361 0.057 0.251 0.886 0.746 0.523 0.860 0.429 0.990 1.000 0.009 0.017 0.720
M21u:6 0.441 0.735 0.921 0.465 0.282 0.595 0.886 0.585 0.523 0.860 0.810 0.000 1.000 0.856 0.922 0.001
M21u:7 0.183 0.735 0.921 0.361 0.129 0.297 0.593 0.000 0.523 0.860 0.404 0.990 1.000 0.856 0.008 0.720
M21u:20 0.211 0.953 0.921 0.465 0.208 0.131 0.593 0.733 0.612 0.000 0.404 0.990 1.000 0.856 0.253 0.002
M42u:2 0.485 0.000 0.920 0.602 0.567 0.923 0.950 0.551 0.790 0.816 0.965 0.000 1.000 0.860 0.192 0.009
M42u:3 0.614 0.909 0.936 0.602 0.589 0.036 0.000 0.352 0.790 0.816 0.965 0.998 1.000 0.860 0.472 0.000
M42u:4 0.614 0.958 0.755 0.602 0.589 0.000 0.950 0.352 0.790 0.000 0.486 0.998 1.000 0.397 0.557 0.039
M42u:5 0.485 0.225 0.755 0.602 0.192 0.923 0.950 0.551 0.320 0.685 0.965 0.000 1.000 0.906 0.472 0.000
M42u:6 0.123 0.958 0.755 0.602 0.192 0.923 0.950 0.538 0.205 0.482 0.000 0.998 1.000 0.397 0.192 0.960
M42u:7 0.499 0.225 0.755 0.602 0.310 0.036 0.950 0.516 0.175 0.762 0.002 0.998 1.000 0.469 0.245 0.106
M42u:14 0.383 0.958 0.000 0.602 0.192 0.923 0.950 0.551 0.394 0.224 0.965 0.097 1.000 0.823 0.609 0.001
M42u:15 0.485 0.958 0.055 0.000 0.192 0.644 0.950 0.352 0.175 0.816 0.965 0.998 0.290 0.469 0.472 0.960
M42u:16 0.712 0.958 0.755 0.602 0.567 0.605 0.950 0.551 0.790 0.816 0.965 0.000 1.000 0.457 0.245 0.029
Table B.4: Complete enrichment analysis of identified modules. Modules from CG21u
and CG42u were tested for enrichment in the classes and saturation levels
listed (SFA: saturated fatty acids, MUFA: monounsaturated fatty acids,
PUFA: polyunsaturated fatty acids). P -values are adjusted for multiple
comparisons column-wise.
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Table C.1: Summary details for PCST results. Saturation levels (sat) are abbreviated as
SFA (saturated fatty acid), MUFA (monounsaturated fatty acid) and PUFA (polyunsat-
urated fatty acid). Columns d21 − d0 and d42 − d21 contain the sign of this difference.
Consensus graph nodes are terminal (T), or steiner (S). Columns labeled M21u and similar
contain module numbers from associated consensus graph. A 1 in the column HCR/LCR
indicates the compound was present in HCR/LCR data, 0 indicates otherwise.
Compound Name class sat d21 − d0 d42 − d21 CG42d node CG21d node CG42u node CG21u node M42d M21d M42u M21u HCR/LCR
(-)-salsolinol untarg -1 -1 0
(s)-3-methyl-2-oxopentanoate untarg -1 1 0
1-aminocyclopropane-1-carboxylate untarg 1 -1 1
1,7-dimethyl uric acid untarg -1 -1 S 10 0
11-deoxycortisol untarg -1 1 1
2-acetylpyrrolidine untarg 1 -1 0
2-deoxy-d-glucose untarg 1 1 0
2-hydroxy-3-methylbutyric acid untarg -1 1 T T T 4 4 2 1
2-hydroxybutyrate untarg 1 -1 1
2-piperidinone untarg -1 1 T T T 10 6 3 0
3-(4-hydroxyphenyl)lactate untarg -1 1 1
3-dehydroxycarnitine untarg 1 -1 0
3-hydroxy-3-methylglutarate untarg -1 1 S 3 1
3-methoxytyrosine untarg 1 -1 S 7 0
3,4-dihydroxybenzoate untarg 1 -1 0
3beta-hydroxyandrost-5-en-17-one untarg 1 -1 0
3beta-hydroxyandrost-5-en-17-one 3-sulfate untarg 1 1 0
4-acetamidobutanoate untarg -1 1 S 3 1
4-methyl-2-oxovaleric acid untarg -1 1 0
4-nitrophenol untarg -1 1 1
4-pyridoxate untarg 1 -1 1
5-hydroxytryptophan untarg -1 1 0
5-oxoproline untarg -1 1 S 6 1
5-tetradecenoylcarnitine (myristoyl) untarg -1 -1 0
5-valerolactone untarg 1 1 1
5’-methylthioadenosine untarg 1 -1 1
allose untarg -1 1 0
alpha-tocopherol untarg 1 -1 0
ascorbate untarg 1 1 1
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Table C.1: Summary details for PCST results. Saturation levels (sat) are abbreviated as
SFA (saturated fatty acid), MUFA (monounsaturated fatty acid) and PUFA (polyunsat-
urated fatty acid). Columns d21 − d0 and d42 − d21 contain the sign of this difference.
Consensus graph nodes are terminal (T), or steiner (S). Columns labeled M21u and similar
contain module numbers from associated consensus graph. A 1 in the column HCR/LCR
indicates the compound was present in HCR/LCR data, 0 indicates otherwise.
Compound Name class sat d21 − d0 d42 − d21 CG42d node CG21d node CG42u node CG21u node M42d M21d M42u M21u HCR/LCR
betaine untarg 1 -1 0
biliverdin untarg -1 1 1
butyrylcarnitine untarg -1 -1 0
c17 sphinganine untarg 1 -1 0
carnitine untarg 1 -1 T T T 3 4 2 1
CE 16:0 CE SFA 1 -1 1
CE 16:1 CE MUFA -1 1 T T T T 1 1 1 1 0
CE 16:2 CE PUFA -1 1 0
CE 17:1 CE MUFA -1 1 T T T T 4 6 8 4 1
CE 18:0 CE SFA -1 1 S S 6 6 1
CE 18:1 CE MUFA -1 1 S 5 1
CE 18:2 CE PUFA 1 -1 T T T 6 14 20 1
CE 18:3 CE PUFA -1 1 T T T T 4 21 4 20 1
CE 20:1 CE MUFA -1 1 0
CE 20:2 CE PUFA 1 -1 T T T 4 6 7 1
CE 20:3 CE PUFA -1 1 T T T T 3 9 15 4 1
CE 20:4 CE PUFA 1 -1 T T T 16 2 3 1
CE 20:5 CE PUFA -1 1 T T T T 3 21 3 1 0
CE 22:2 CE PUFA 1 -1 T T T 7 14 7 1
CE 22:4 CE PUFA -1 1 1
CE 22:5 CE PUFA -1 1 1
CE 22:6 CE PUFA 1 -1 0
CerP 32:1 CerP MUFA 1 -1 T T T 4 4 7 0
CerP 34:1 CerP MUFA -1 -1 1
cholate untarg 1 -1 1
cholesterol untarg 1 -1 T T T 6 4 0
choline untarg -1 -1 1
cis-7,10,13,16-docosatetraenoic acid untarg -1 1 1
citramalate untarg 1 1 1
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Table C.1: Summary details for PCST results. Saturation levels (sat) are abbreviated as
SFA (saturated fatty acid), MUFA (monounsaturated fatty acid) and PUFA (polyunsat-
urated fatty acid). Columns d21 − d0 and d42 − d21 contain the sign of this difference.
Consensus graph nodes are terminal (T), or steiner (S). Columns labeled M21u and similar
contain module numbers from associated consensus graph. A 1 in the column HCR/LCR
indicates the compound was present in HCR/LCR data, 0 indicates otherwise.
Compound Name class sat d21 − d0 d42 − d21 CG42d node CG21d node CG42u node CG21u node M42d M21d M42u M21u HCR/LCR
citrate untarg 1 -1 0
CL 70:5 CL PUFA -1 1 T T T 3 3 1 0
CL 72:7 CL PUFA -1 1 T T T T 3 9 3 1 1
CL 74:3 CL PUFA 1 -1 S S 3 3 0
CL 74:7 CL PUFA 1 -1 S S 3 3 0
CL 78:3 CL PUFA -1 1 1
corticosterone untarg 1 -1 0
cortisol untarg 1 1 S 3 0
cortisone untarg -1 1 1
cycloheptanecarboxylic acid untarg 1 1 1
decanoate untarg -1 1 S S 21 12 0
decanoyl-l-carnitine untarg 1 -1 S S 6 15 0
deoxyadenosine untarg -1 1 1
deoxycholic acid untarg -1 1 1
deoxyuridine untarg -1 1 1
DG 30:0 DG SFA -1 1 T T T T 16 21 2 1 0
DG 30:1 DG MUFA -1 1 1
DG 32:0 DG SFA 1 1 1
DG 32:1 DG MUFA -1 1 T T T T 16 3 2 2 1
DG 32:2 DG PUFA -1 1 T T T 16 2 3 0
DG 33:0 DG SFA -1 1 T T T 3 3 7 0
DG 33:1 DG MUFA -1 1 T T T 16 2 2 1
DG 33:2 DG PUFA -1 1 T S T T 4 4 4 3 1
DG 34:0 DG SFA 1 -1 1
DG 34:2 DG PUFA -1 1 T T T 16 2 3 1
DG 34:3 DG PUFA -1 1 T T T 16 2 2 0
DG 34:4 DG PUFA -1 1 T T T 2 16 4 0
DG 35:0 DG SFA 1 -1 0
DG 35:1 DG MUFA -1 1 T T T 16 2 3 1
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Table C.1: Summary details for PCST results. Saturation levels (sat) are abbreviated as
SFA (saturated fatty acid), MUFA (monounsaturated fatty acid) and PUFA (polyunsat-
urated fatty acid). Columns d21 − d0 and d42 − d21 contain the sign of this difference.
Consensus graph nodes are terminal (T), or steiner (S). Columns labeled M21u and similar
contain module numbers from associated consensus graph. A 1 in the column HCR/LCR
indicates the compound was present in HCR/LCR data, 0 indicates otherwise.
Compound Name class sat d21 − d0 d42 − d21 CG42d node CG21d node CG42u node CG21u node M42d M21d M42u M21u HCR/LCR
DG 35:2 DG PUFA -1 1 T T T T 16 3 2 2 1
DG 35:3 DG PUFA -1 1 T T T 16 2 2 1
DG 36:0 DG SFA 1 -1 1
DG 36:1 DG MUFA -1 1 1
DG 36:2 DG PUFA -1 1 T T T T 16 4 2 3 1
DG 36:3 DG PUFA 1 1 S T T T 16 4 2 3 1
DG 36:4 DG PUFA 1 -1 T T T T 3 4 2 3 0
DG 36:5 DG PUFA 1 -1 S 2 0
DG 36:6 DG PUFA -1 1 0
DG 37:0 DG SFA 1 -1 0
DG 37:5 DG PUFA -1 1 0
DG 38:0 DG SFA 1 -1 1
DG 38:1 DG MUFA -1 1 T T T T 6 21 5 4 0
DG 38:2 DG PUFA -1 1 T T T T 3 17 3 3 1
DG 38:3 DG PUFA -1 1 T T T 16 2 3 1
DG 38:4 DG PUFA -1 1 T T T T 3 4 3 3 1
DG 38:5 DG PUFA -1 1 T T T 16 2 3 1
DG 38:6 DG PUFA 1 1 S S 6 5 0
DG 38:7 DG PUFA 1 1 T T T 6 5 1 0
DG 39:0 DG SFA 1 -1 S 4 0
DG 40:0 DG SFA 1 -1 T T T 8 7 4 0
DG 40:1 DG MUFA -1 1 S S 7 4 0
DG 40:2 DG PUFA -1 1 S 3 0
DG 40:5 DG PUFA -1 1 T T T 16 2 2 0
DG 40:6 DG PUFA -1 1 T T T T 8 3 14 2 1
DG 40:7 DG PUFA -1 1 T T T 7 5 3 1
DG 40:8 DG PUFA -1 1 T T T 7 2 3 0
DG 41:0 DG SFA 1 -1 T T T 8 7 1 0
DG 42:0 DG SFA -1 1 0
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Table C.1: Summary details for PCST results. Saturation levels (sat) are abbreviated as
SFA (saturated fatty acid), MUFA (monounsaturated fatty acid) and PUFA (polyunsat-
urated fatty acid). Columns d21 − d0 and d42 − d21 contain the sign of this difference.
Consensus graph nodes are terminal (T), or steiner (S). Columns labeled M21u and similar
contain module numbers from associated consensus graph. A 1 in the column HCR/LCR
indicates the compound was present in HCR/LCR data, 0 indicates otherwise.
Compound Name class sat d21 − d0 d42 − d21 CG42d node CG21d node CG42u node CG21u node M42d M21d M42u M21u HCR/LCR
DG 42:10 DG PUFA -1 1 T T T T 2 7 16 3 0
dodecenoylcarnitine untarg 1 -1 1
gamma-butyrolactone untarg -1 1 S S 3 4 0
gamma-l-glutamyl-l-cysteine untarg 1 1 0
glu-ile/leu / l-gamma-glutamyl-l-isoleucine untarg 1 -1 0
gluconic acid untarg 1 -1 1
glucose untarg -1 1 1
glutamate untarg 1 1 0
glutamine untarg 1 1 0
glutamyl-phenylalanine untarg -1 1 1
glutarate untarg -1 1 S S 10 7 0
glyceraldehyde untarg -1 1 0
glycochenodeoxycholate untarg 1 1 1
glycocholate untarg 1 1 0
guanosine untarg -1 1 T T T 4 4 4 1
heptadecanoate untarg -1 1 0
hexadecasphinganine untarg 1 1 0
hexanoylcarnitine untarg 1 -1 T T T 5 15 1 1
hippurate untarg 1 -1 0
histidinyl-tryptophan untarg -1 -1 0
hypaphorine untarg -1 -1 T T T 7 4 7 0
hypoxanthine untarg -1 1 S S 7 1 0
ile-ile untarg -1 1 1
indole-3-acetate untarg 1 1 0
inosine untarg -1 1 T T T 4 4 3 1
isoleucine untarg 1 -1 1
isovalerylcarnitine untarg 1 -1 1
krynurenic acid untarg -1 -1 S 4 1
kynurenine untarg -1 1 T T T 3 15 3 0
107
Table C.1: Summary details for PCST results. Saturation levels (sat) are abbreviated as
SFA (saturated fatty acid), MUFA (monounsaturated fatty acid) and PUFA (polyunsat-
urated fatty acid). Columns d21 − d0 and d42 − d21 contain the sign of this difference.
Consensus graph nodes are terminal (T), or steiner (S). Columns labeled M21u and similar
contain module numbers from associated consensus graph. A 1 in the column HCR/LCR
indicates the compound was present in HCR/LCR data, 0 indicates otherwise.
Compound Name class sat d21 − d0 d42 − d21 CG42d node CG21d node CG42u node CG21u node M42d M21d M42u M21u HCR/LCR
l-carnitine untarg 1 -1 1
l-histidine untarg 1 -1 0
l-rhamnose untarg 1 1 1
lauroylcarnitine untarg -1 -1 S S 6 15 1
leucine untarg -1 1 1
lignoceric acid untarg 1 -1 T T T 2 6 3 1
lysine untarg 1 1 1
lysoPC 14:0 lysoPC SFA -1 1 T T T T 2 10 16 3 1
lysoPC 15:0 lysoPC SFA -1 1 T T T T 7 9 15 4 1
lysoPC 16:0 lysoPC SFA -1 1 T T T 9 14 4 1
lysoPC 16:1 lysoPC MUFA -1 1 T T T T 7 13 15 9 1
lysoPC 17:1 lysoPC MUFA -1 1 T T T T 7 8 15 4 1
lysoPC 18:0 lysoPC SFA -1 1 T T T 4 14 3 1
lysoPC 18:1 lysoPC MUFA -1 -1 S T T T 7 9 14 4 1
lysoPC 18:2 lysoPC PUFA 1 -1 T T T 7 14 4 1
lysoPC 18:3 lysoPC PUFA -1 1 T T T T 7 9 14 4 1
lysoPC 19:0 lysoPC SFA -1 -1 T T T 9 15 4 1
lysoPC 20:0 lysoPC SFA 1 -1 T T T T 7 9 14 4 1
lysoPC 20:1 lysoPC MUFA -1 -1 T T T 7 5 4 1
lysoPC 20:2 lysoPC PUFA 1 -1 T T T 7 14 4 1
lysoPC 20:3 lysoPC PUFA -1 1 T T T T 7 9 14 4 1
lysoPC 20:4 lysoPC PUFA -1 1 T T T 9 14 4 1
lysoPC 20:5 lysoPC PUFA 1 -1 T T T 7 14 4 1
lysoPC 22:0 lysoPC SFA 1 -1 T T T 4 4 4 1
lysoPC 22:1 lysoPC MUFA -1 1 S T T T 7 9 14 4 1
lysoPC 22:4 lysoPC PUFA -1 1 T T T T 7 9 14 4 1
lysoPC 22:5 lysoPC PUFA -1 1 T T T T 7 9 14 4 1
lysoPC 22:6 lysoPC PUFA -1 1 S 4 1
lysoPC 23:0 lysoPC SFA -1 -1 1
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Table C.1: Summary details for PCST results. Saturation levels (sat) are abbreviated as
SFA (saturated fatty acid), MUFA (monounsaturated fatty acid) and PUFA (polyunsat-
urated fatty acid). Columns d21 − d0 and d42 − d21 contain the sign of this difference.
Consensus graph nodes are terminal (T), or steiner (S). Columns labeled M21u and similar
contain module numbers from associated consensus graph. A 1 in the column HCR/LCR
indicates the compound was present in HCR/LCR data, 0 indicates otherwise.
Compound Name class sat d21 − d0 d42 − d21 CG42d node CG21d node CG42u node CG21u node M42d M21d M42u M21u HCR/LCR
lysoPC 24:0 lysoPC SFA -1 -1 T T T 4 4 20 1
lysoPC 24:1 lysoPC MUFA -1 -1 S 4 0
lysoPC 26:0 lysoPC SFA -1 1 1
lysoPC 26:1 lysoPC MUFA -1 -1 0
lysoPC 26:2 lysoPC PUFA 1 -1 S S 5 4 1
lysoPE 16:0 lysoPE SFA -1 1 T T T T 4 9 4 16 0
lysoPE 16:1 lysoPE MUFA 1 1 1
lysoPE 18:0 lysoPE SFA -1 1 T T T 19 15 15 1
lysoPE 18:1 lysoPE MUFA -1 -1 S 4 1
lysoPE 18:2 lysoPE PUFA 1 -1 T T T 7 15 4 0
lysoPE 18:3 lysoPE PUFA -1 1 T T T T 5 7 3 9 1
lysoPE 20:3 lysoPE PUFA -1 1 T T T T 2 10 16 3 1
lysoPE 20:4 lysoPE PUFA -1 1 T T T T 7 10 15 7 0
lysoPE 20:5 lysoPE PUFA -1 -1 0
lysoPE 22:4 lysoPE PUFA -1 1 T T T T 3 9 3 4 0
lysoPE 22:5 lysoPE PUFA -1 1 T T T T 7 8 15 5 1
lysoPE 22:6 lysoPE PUFA -1 1 T T T T 7 15 15 20 0
lysoPE 24:1 lysoPE MUFA -1 1 0
lysoPE 26:0 lysoPE SFA 1 -1 1
malate untarg -1 -1 1
mandelic acid untarg 1 1 1
methionine untarg 1 1 1
methyl beta-d-galactoside untarg 1 1 T T T 7 4 1 0
methyl indole-3-acetate untarg -1 1 0
MG 16:0 MG SFA -1 1 T T T T 6 20 6 7 1
MG 17:0 MG SFA -1 -1 1
MG 18:0 MG SFA -1 -1 T T T 9 5 4 0
MG 18:1 MG MUFA -1 -1 T T T 9 15 4 0
MG 18:2 MG PUFA 1 -1 T T T T 6 16 14 4 0
109
Table C.1: Summary details for PCST results. Saturation levels (sat) are abbreviated as
SFA (saturated fatty acid), MUFA (monounsaturated fatty acid) and PUFA (polyunsat-
urated fatty acid). Columns d21 − d0 and d42 − d21 contain the sign of this difference.
Consensus graph nodes are terminal (T), or steiner (S). Columns labeled M21u and similar
contain module numbers from associated consensus graph. A 1 in the column HCR/LCR
indicates the compound was present in HCR/LCR data, 0 indicates otherwise.
Compound Name class sat d21 − d0 d42 − d21 CG42d node CG21d node CG42u node CG21u node M42d M21d M42u M21u HCR/LCR
MG 18:4 MG PUFA 1 -1 T T T 10 9 20 0
MG 19:0 MG SFA 1 -1 0
MG 24:0 MG SFA 1 1 0
myo-inositol untarg -1 1 0
n-acetyl-d-tryptophan untarg 1 1 1
n-acetyl-dl-methionine untarg -1 1 T T T 6 15 3 0
n-acetyl-dl-serine untarg -1 1 S S 6 15 1
n-acetyl-l-alanine (-h+na) untarg -1 1 0
n-acetyl-l-aspartic acid untarg -1 1 S 3 0
n-acetyl-l-leucine untarg -1 1 1
n-acetyl-l-phenylalanine untarg -1 1 T T T 7 15 1 1
n-acetylglycine untarg -1 1 1
n-alpha-acetyl-l-lysine untarg 1 -1 0
n-cyclohexylformamide untarg 1 -1 0
n-gamma-l-glutamyl-l-methionine untarg -1 1 0
n-methyl-l-glutamate untarg 1 1 1
n2 n2-dimethylguanosine untarg -1 1 0
n6,n6,n6-trimethyl-l-lysine untarg 1 -1 1
nicotinamide untarg -1 1 1
o-acetylcarnitine untarg 1 -1 0
octanoylcarnitine untarg 1 -1 S S 6 15 1
octenoylcarnitine untarg 1 -1 0
oleoylcarnitine untarg -1 -1 S 15 1
PA 34:0 PA SFA -1 -1 0
PA 34:2 PA PUFA -1 -1 0
PA 40:1 PA MUFA 1 1 0
palmitoylcarnitine untarg -1 1 T T T 9 15 4 1
pantothenate untarg -1 1 1
paraxanthine untarg -1 1 T T T 7 14 15 0
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Table C.1: Summary details for PCST results. Saturation levels (sat) are abbreviated as
SFA (saturated fatty acid), MUFA (monounsaturated fatty acid) and PUFA (polyunsat-
urated fatty acid). Columns d21 − d0 and d42 − d21 contain the sign of this difference.
Consensus graph nodes are terminal (T), or steiner (S). Columns labeled M21u and similar
contain module numbers from associated consensus graph. A 1 in the column HCR/LCR
indicates the compound was present in HCR/LCR data, 0 indicates otherwise.
Compound Name class sat d21 − d0 d42 − d21 CG42d node CG21d node CG42u node CG21u node M42d M21d M42u M21u HCR/LCR
PC 19:2 PC PUFA -1 -1 S 4 1
PC 21:0 PC SFA -1 -1 0
PC 26:0 PC SFA -1 1 T T T T 4 3 4 2 0
PC 28:0 PC SFA -1 1 T T T T 5 7 4 2 0
PC 29:0 PC SFA -1 1 T T T T 5 3 4 2 0
PC 30:0 PC SFA -1 1 T T T T 1 8 4 18 1
PC 30:1 PC MUFA -1 1 T T T T 4 3 4 2 1
PC 30:2 PC PUFA -1 1 T T T T 4 10 4 3 1
PC 30:3 PC PUFA -1 1 T T T T 4 7 4 4 0
PC 31:0 PC SFA -1 1 T T T 7 15 3 1
PC 31:1 PC MUFA 1 -1 T T T 3 3 7 0
PC 32:0 PC SFA -1 1 T T T T 3 7 3 6 1
PC 32:1 PC MUFA -1 1 S S 3 2 1
PC 32:2 PC PUFA -1 1 S T T T 2 4 16 3 1
PC 32:3 PC PUFA -1 1 T T T T 3 9 4 4 1
PC 32:4 PC PUFA -1 1 T T T T 4 3 4 2 0
PC 33:0 PC SFA 1 1 1
PC 33:1 PC MUFA -1 1 T T T T 3 13 3 20 1
PC 33:2 PC PUFA -1 -1 T T T 7 4 3 1
PC 33:3 PC PUFA -1 1 T T T T 2 7 16 4 1
PC 34:0 PC SFA 1 -1 0
PC 34:1 PC MUFA -1 1 T T T T 3 7 3 7 1
PC 34:2 PC PUFA -1 1 T T T T 2 8 5 20 1
PC 34:3 PC PUFA -1 -1 1
PC 34:4 PC PUFA -1 1 T T T T 5 9 4 1 1
PC 34:5 PC PUFA -1 1 T T T T 2 4 4 3 1
PC 35:0 PC SFA -1 1 T S T T 4 6 4 10 1
PC 35:1 PC MUFA -1 1 T T T T 6 3 15 2 1
PC 35:2 PC PUFA -1 -1 1
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Table C.1: Summary details for PCST results. Saturation levels (sat) are abbreviated as
SFA (saturated fatty acid), MUFA (monounsaturated fatty acid) and PUFA (polyunsat-
urated fatty acid). Columns d21 − d0 and d42 − d21 contain the sign of this difference.
Consensus graph nodes are terminal (T), or steiner (S). Columns labeled M21u and similar
contain module numbers from associated consensus graph. A 1 in the column HCR/LCR
indicates the compound was present in HCR/LCR data, 0 indicates otherwise.
Compound Name class sat d21 − d0 d42 − d21 CG42d node CG21d node CG42u node CG21u node M42d M21d M42u M21u HCR/LCR
PC 35:3 PC PUFA 1 -1 T T T 4 4 1 1
PC 35:4 PC PUFA -1 1 T T T T 11 9 3 3 1
PC 35:5 PC PUFA -1 1 0
PC 35:6 PC PUFA -1 1 T T T 3 3 1 0
PC 36:0 PC SFA -1 1 T T T T 6 21 15 4 1
PC 36:1 PC MUFA -1 1 T T T T 2 21 16 20 1
PC 36:2 PC PUFA -1 -1 T T T 2 16 4 1
PC 36:3 PC PUFA 1 -1 T T T 7 15 1 1
PC 36:4 PC PUFA -1 1 S S 6 7 1
PC 36:5 PC PUFA -1 1 T T T T 2 3 5 2 1
PC 36:6 PC PUFA -1 1 1
PC 36:7 PC PUFA -1 1 S T T T 2 9 4 3 0
PC 37:1 PC MUFA 1 -1 T S T T 6 9 6 4 1
PC 37:2 PC PUFA 1 1 1
PC 37:3 PC PUFA -1 1 1
PC 37:4 PC PUFA -1 -1 S S 8 14 1
PC 37:5 PC PUFA -1 1 T T T T 4 4 4 1
PC 37:6 PC PUFA -1 1 T T T 3 4 14 1
PC 37:7 PC PUFA -1 1 T T T 3 3 1 1
PC 38:0 PC SFA 1 -1 T T T T 3 9 3 4 0
PC 38:1 PC MUFA -1 1 1
PC 38:2 PC PUFA -1 -1 S S 3 3 1
PC 38:3 PC PUFA -1 1 T T T T 2 4 16 2 1
PC 38:4 PC PUFA -1 1 T T T T 8 7 7 1 1
PC 38:5 PC PUFA -1 1 T T T T 6 15 7 20 1
PC 38:6 PC PUFA -1 1 T T T 3 14 14 1
PC 38:7 PC PUFA -1 1 T T T 21 4 3 1
PC 38:8 PC PUFA -1 1 T T T T 2 9 16 3 1
PC 38:9 PC PUFA -1 1 T T T T 4 14 4 13 0
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Table C.1: Summary details for PCST results. Saturation levels (sat) are abbreviated as
SFA (saturated fatty acid), MUFA (monounsaturated fatty acid) and PUFA (polyunsat-
urated fatty acid). Columns d21 − d0 and d42 − d21 contain the sign of this difference.
Consensus graph nodes are terminal (T), or steiner (S). Columns labeled M21u and similar
contain module numbers from associated consensus graph. A 1 in the column HCR/LCR
indicates the compound was present in HCR/LCR data, 0 indicates otherwise.
Compound Name class sat d21 − d0 d42 − d21 CG42d node CG21d node CG42u node CG21u node M42d M21d M42u M21u HCR/LCR
PC 39:2 PC PUFA 1 -1 0
PC 39:3 PC PUFA -1 1 1
PC 39:4 PC PUFA -1 1 T T T T 6 7 4 1 1
PC 39:5 PC PUFA -1 1 T T T T 3 18 3 19 1
PC 39:6 PC PUFA -1 1 T T T T 7 9 8 4 1
PC 39:7 PC PUFA -1 1 0
PC 39:8 PC PUFA -1 1 0
PC 40:1 PC MUFA 1 -1 T T T 4 7 4 0
PC 40:10 PC PUFA -1 1 S S 4 4 1
PC 40:2 PC PUFA 1 -1 T T T 5 13 4 1
PC 40:3 PC PUFA -1 1 T T T 8 14 20 1
PC 40:4 PC PUFA -1 1 T T T T 2 7 16 7 1
PC 40:5 PC PUFA -1 1 T T T T 16 6 2 20 1
PC 40:6 PC PUFA -1 1 T T T T 8 3 7 20 1
PC 40:7 PC PUFA -1 -1 1
PC 40:8 PC PUFA -1 -1 T T T 14 11 4 1
PC 41:6 PC PUFA -1 1 1
PC 42:1 PC MUFA -1 1 1
PC 42:10 PC PUFA -1 1 T T T T 3 10 3 4 1
PC 42:11 PC PUFA -1 -1 S 10 1
PC 42:2 PC PUFA 1 -1 T T T 3 3 20 1
PC 42:3 PC PUFA 1 -1 T T T T 6 15 20 1
PC 42:4 PC PUFA -1 -1 S S 6 20 0
PC 42:5 PC PUFA -1 1 T T T T 4 7 3 7 1
PC 42:6 PC PUFA -1 1 T T T 12 2 11 0
PC 42:7 PC PUFA -1 -1 S S 4 4 1
PC 42:8 PC PUFA 1 -1 T T T 3 3 7 1
PC 42:9 PC PUFA 1 -1 T T T T 8 9 14 16 0
PC 44:4 PC PUFA -1 -1 1
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Table C.1: Summary details for PCST results. Saturation levels (sat) are abbreviated as
SFA (saturated fatty acid), MUFA (monounsaturated fatty acid) and PUFA (polyunsat-
urated fatty acid). Columns d21 − d0 and d42 − d21 contain the sign of this difference.
Consensus graph nodes are terminal (T), or steiner (S). Columns labeled M21u and similar
contain module numbers from associated consensus graph. A 1 in the column HCR/LCR
indicates the compound was present in HCR/LCR data, 0 indicates otherwise.
Compound Name class sat d21 − d0 d42 − d21 CG42d node CG21d node CG42u node CG21u node M42d M21d M42u M21u HCR/LCR
PC 44:5 PC PUFA -1 1 1
PC 46:5 PC PUFA -1 1 0
PE 32:1 PE MUFA 1 1 T T T 3 3 20 0
PE 32:2 PE PUFA 1 1 0
PE 33:0 PE SFA 1 -1 0
PE 33:1 PE MUFA -1 1 T T T 3 3 8 0
PE 33:2 PE PUFA -1 1 S S 3 3 0
PE 34:0 PE SFA 1 -1 1
PE 34:1 PE PUFA -1 -1 T S T T 7 6 5 20 0
PE 34:2 PE PUFA -1 -1 0
PE 34:3 PE PUFA -1 1 T T T T 4 21 4 3 1
PE 35:0 PE MUFA 1 1 0
PE 35:1 PE PUFA -1 1 0
PE 35:2 PE PUFA -1 1 1
PE 35:3 PE PUFA -1 1 S S 4 4 0
PE 35:4 PE SFA -1 1 S S 3 3 0
PE 36:0 PE MUFA 1 1 1
PE 36:1 PE PUFA -1 -1 S S 8 20 0
PE 36:2 PE PUFA -1 -1 1
PE 36:3 PE PUFA 1 -1 S S 3 3 1
PE 36:4 PE PUFA -1 1 T T T 3 3 1 0
PE 36:5 PE PUFA -1 1 T T T T 3 14 3 2 1
PE 37:2 PE PUFA -1 -1 S 4 0
PE 37:3 PE PUFA -1 1 T T T 3 3 7 0
PE 37:4 PE PUFA -1 1 T T T T 3 9 3 1 0
PE 37:6 PE PUFA -1 1 S S S S 4 7 4 4 0
PE 38:1 PE MUFA -1 1 T T T 7 10 7 0
PE 38:2 PE PUFA -1 1 1
PE 38:3 PE PUFA -1 -1 0
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Table C.1: Summary details for PCST results. Saturation levels (sat) are abbreviated as
SFA (saturated fatty acid), MUFA (monounsaturated fatty acid) and PUFA (polyunsat-
urated fatty acid). Columns d21 − d0 and d42 − d21 contain the sign of this difference.
Consensus graph nodes are terminal (T), or steiner (S). Columns labeled M21u and similar
contain module numbers from associated consensus graph. A 1 in the column HCR/LCR
indicates the compound was present in HCR/LCR data, 0 indicates otherwise.
Compound Name class sat d21 − d0 d42 − d21 CG42d node CG21d node CG42u node CG21u node M42d M21d M42u M21u HCR/LCR
PE 38:4 PE PUFA -1 1 T T T T 3 5 3 1 1
PE 38:5 PE PUFA -1 1 T T T 3 3 1 0
PE 38:6 PE PUFA -1 1 T T T 3 3 1 0
PE 38:7 PE PUFA -1 1 0
PE 39:6 PE PUFA -1 1 T T T T 3 7 3 3 0
PE 40:3 PE PUFA -1 1 T T T 21 3 1 0
PE 40:4 PE PUFA -1 1 S S S S 3 4 3 1 1
PE 40:5 PE PUFA -1 1 T T T T 3 4 3 1 1
PE 40:6 PE PUFA -1 1 T T T 3 3 1 0
PE 40:7 PE PUFA 1 -1 S S 3 3 0
PE 40:8 PE PUFA 1 -1 S S 3 3 1
PE 42:8 PE PUFA -1 1 S S S 9 4 4 0
PE 42:9 PE PUFA 1 -1 0
PG 33:0 PG SFA -1 -1 1
PG 34:1 PG MUFA -1 1 0
PG 34:2 PG PUFA 1 -1 0
PG 36:0 PG SFA -1 1 T T T 8 4 20 0
PG 36:3 PG PUFA -1 1 0
PG 38:4 PG PUFA -1 -1 S 7 0
phenyl acetate untarg -1 1 1
phenylalanine untarg 1 1 1
phenylephrine untarg 1 -1 S S 9 3 0
phytanate untarg -1 1 T T T 7 15 3 0
PI 34:1 PI MUFA -1 1 T T T T 4 7 4 7 0
PI 34:2 PI PUFA 1 1 1
PI 36:1 PI MUFA 1 -1 0
PI 36:2 PI PUFA 1 -1 T S T T 3 7 3 7 1
PI 36:3 PI PUFA 1 -1 T T T T 4 7 4 7 0
PI 36:4 PI PUFA -1 1 T T T 2 3 7 1
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Table C.1: Summary details for PCST results. Saturation levels (sat) are abbreviated as
SFA (saturated fatty acid), MUFA (monounsaturated fatty acid) and PUFA (polyunsat-
urated fatty acid). Columns d21 − d0 and d42 − d21 contain the sign of this difference.
Consensus graph nodes are terminal (T), or steiner (S). Columns labeled M21u and similar
contain module numbers from associated consensus graph. A 1 in the column HCR/LCR
indicates the compound was present in HCR/LCR data, 0 indicates otherwise.
Compound Name class sat d21 − d0 d42 − d21 CG42d node CG21d node CG42u node CG21u node M42d M21d M42u M21u HCR/LCR
PI 38:3 PI PUFA -1 1 1
PI 38:4 PI PUFA -1 1 1
PI 38:5 PI PUFA -1 1 1
PI 40:5 PI PUFA -1 1 T T T 6 15 2 1
PI 40:6 PI PUFA 1 1 0
pipecolate untarg 1 1 1
piperine untarg -1 1 T T T 8 8 1 0
plasmenyl-PC 18:0 plasmenyl-PC SFA -1 1 T T T 9 14 4 1
plasmenyl-PC 20:0 plasmenyl-PC SFA 1 -1 S S 10 9 1
plasmenyl-PC 29:0 plasmenyl-PC SFA -1 1 T T T 12 8 1 0
plasmenyl-PC 34:1 plasmenyl-PC MUFA -1 -1 0
plasmenyl-PC 34:2 plasmenyl-PC PUFA -1 1 T T T 9 7 4 0
plasmenyl-PC 36:3 plasmenyl-PC PUFA -1 -1 S S 3 2 0
plasmenyl-PC 36:4 plasmenyl-PC PUFA 1 -1 0
plasmenyl-PC 38:1 plasmenyl-PC MUFA -1 -1 T T T 9 5 3 0
plasmenyl-PC 38:3 plasmenyl-PC PUFA 1 -1 T T T 6 15 1 0
plasmenyl-PC 38:5 plasmenyl-PC PUFA -1 -1 T T T 3 15 1 0
plasmenyl-PC 40:5 plasmenyl-PC PUFA 1 -1 0
plasmenyl-PC 40:6 plasmenyl-PC PUFA 1 -1 S 8 0
plasmenyl-PC 42:5 plasmenyl-PC PUFA 1 -1 S T T T 6 5 6 1 0
plasmenyl-PC 44:4 plasmenyl-PC PUFA -1 1 0
plasmenyl-PE 32:1 plasmenyl-PE MUFA -1 1 0
plasmenyl-PE 34:0 plasmenyl-PE SFA 1 -1 0
plasmenyl-PE 34:1 plasmenyl-PE MUFA -1 -1 T T T 14 20 1
plasmenyl-PE 34:2 plasmenyl-PE PUFA -1 -1 T T T 4 4 20 1
plasmenyl-PE 34:3 plasmenyl-PE PUFA -1 -1 T T T 6 6 1 0
plasmenyl-PE 36:0 plasmenyl-PE SFA -1 1 S T T T 3 16 3 4 0
plasmenyl-PE 36:1 plasmenyl-PE MUFA -1 -1 T T T 8 4 20 1
plasmenyl-PE 36:2 plasmenyl-PE PUFA -1 -1 T T T 4 14 20 0
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Table C.1: Summary details for PCST results. Saturation levels (sat) are abbreviated as
SFA (saturated fatty acid), MUFA (monounsaturated fatty acid) and PUFA (polyunsat-
urated fatty acid). Columns d21 − d0 and d42 − d21 contain the sign of this difference.
Consensus graph nodes are terminal (T), or steiner (S). Columns labeled M21u and similar
contain module numbers from associated consensus graph. A 1 in the column HCR/LCR
indicates the compound was present in HCR/LCR data, 0 indicates otherwise.
Compound Name class sat d21 − d0 d42 − d21 CG42d node CG21d node CG42u node CG21u node M42d M21d M42u M21u HCR/LCR
plasmenyl-PE 36:3 plasmenyl-PE PUFA -1 -1 T T T 4 4 20 1
plasmenyl-PE 36:4 plasmenyl-PE PUFA -1 -1 T T T 4 4 20 1
plasmenyl-PE 36:5 plasmenyl-PE PUFA -1 1 T T T 9 4 1 0
plasmenyl-PE 38:1 plasmenyl-PE MUFA -1 1 1
plasmenyl-PE 38:2 plasmenyl-PE PUFA 1 -1 1
plasmenyl-PE 38:3 plasmenyl-PE PUFA -1 1 T T T T 4 8 4 20 1
plasmenyl-PE 38:4 plasmenyl-PE PUFA -1 -1 T T T 8 4 20 1
plasmenyl-PE 38:5 plasmenyl-PE PUFA -1 -1 S T T T 4 8 4 20 1
plasmenyl-PE 38:6 plasmenyl-PE PUFA -1 -1 T T T 4 4 20 1
plasmenyl-PE 40:3 plasmenyl-PE PUFA 1 -1 S S 4 4 0
plasmenyl-PE 40:4 plasmenyl-PE PUFA -1 -1 1
plasmenyl-PE 40:5 plasmenyl-PE PUFA -1 -1 T T T 8 14 20 1
plasmenyl-PE 40:6 plasmenyl-PE PUFA -1 -1 T T T 7 4 20 1
plasmenyl-PE 42:5 plasmenyl-PE PUFA -1 -1 1
plasmenyl-PE 42:6 plasmenyl-PE PUFA 1 -1 T T T 7 5 4 0
possible peptide-262.1341-6.151 untarg -1 1 0
possible peptide-310.1151-2.804 untarg -1 1 0
possible peptide-414.2046-18.389 untarg 1 -1 0
proline untarg -1 1 S 8 1
propionylcarnitine untarg -1 1 1
pyridoxamine untarg 1 1 S S 3 3 0
raffinose untarg -1 1 0
s-allyl-l-cysteine untarg -1 1 0
sarcosine untarg 1 -1 1
serine untarg 1 1 1
serinyl-leucine untarg -1 1 S S 10 6 0
SM 21:0 SM SFA -1 -1 0
SM 21:1 SM MUFA -1 -1 T S T T 7 9 14 4 1
SM 29:1 SM MUFA -1 1 T T T 14 15 17 0
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Table C.1: Summary details for PCST results. Saturation levels (sat) are abbreviated as
SFA (saturated fatty acid), MUFA (monounsaturated fatty acid) and PUFA (polyunsat-
urated fatty acid). Columns d21 − d0 and d42 − d21 contain the sign of this difference.
Consensus graph nodes are terminal (T), or steiner (S). Columns labeled M21u and similar
contain module numbers from associated consensus graph. A 1 in the column HCR/LCR
indicates the compound was present in HCR/LCR data, 0 indicates otherwise.
Compound Name class sat d21 − d0 d42 − d21 CG42d node CG21d node CG42u node CG21u node M42d M21d M42u M21u HCR/LCR
SM 30:0 SM SFA -1 1 T T T T 14 3 4 2 0
SM 30:1 SM MUFA -1 1 T T T T 4 7 4 3 0
SM 31:1 SM MUFA -1 1 T T T T 4 7 4 7 1
SM 32:0 SM SFA -1 1 S T T T 4 6 4 20 1
SM 32:1 SM MUFA -1 1 T T T T 4 7 4 7 1
SM 32:2 SM PUFA -1 1 T T T T 4 7 4 3 1
SM 33:0 SM SFA -1 -1 S S 8 20 0
SM 33:1 SM MUFA -1 1 T T T 7 4 20 1
SM 33:2 SM PUFA -1 -1 0
SM 34:1 SM MUFA 1 1 1
SM 34:2 SM PUFA -1 -1 1
SM 35:0 SM SFA -1 1 0
SM 35:1 SM MUFA 1 -1 T S T T 3 5 3 3 1
SM 35:2 SM PUFA -1 1 T T T 7 7 1 1
SM 36:0 SM SFA -1 1 1
SM 36:1 SM MUFA -1 1 T T T T 9 7 7 1 1
SM 36:2 SM PUFA -1 -1 S S S 9 16 3 1
SM 37:0 SM SFA -1 1 0
SM 37:1 SM MUFA -1 -1 T T T 7 7 7 1
SM 37:2 SM PUFA -1 1 T T T 8 7 20 1
SM 38:0 SM SFA -1 -1 1
SM 38:1 SM MUFA 1 -1 1
SM 38:2 SM PUFA -1 -1 T T T 9 8 3 1
SM 38:4 SM PUFA 1 -1 T T T 8 7 1 0
SM 39:0 SM SFA -1 -1 0
SM 39:1 SM MUFA -1 -1 T T T T 6 7 6 3 1
SM 39:2 SM PUFA -1 -1 T T T 6 15 10 1
SM 39:4 SM PUFA -1 -1 0
SM 39:5 SM PUFA -1 1 0
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Table C.1: Summary details for PCST results. Saturation levels (sat) are abbreviated as
SFA (saturated fatty acid), MUFA (monounsaturated fatty acid) and PUFA (polyunsat-
urated fatty acid). Columns d21 − d0 and d42 − d21 contain the sign of this difference.
Consensus graph nodes are terminal (T), or steiner (S). Columns labeled M21u and similar
contain module numbers from associated consensus graph. A 1 in the column HCR/LCR
indicates the compound was present in HCR/LCR data, 0 indicates otherwise.
Compound Name class sat d21 − d0 d42 − d21 CG42d node CG21d node CG42u node CG21u node M42d M21d M42u M21u HCR/LCR
SM 40:0 SM SFA 1 -1 T T T 6 6 4 0
SM 40:1 SM MUFA -1 -1 T T T 6 6 3 1
SM 40:2 SM PUFA -1 -1 T T T T 3 3 3 2 1
SM 40:4 SM PUFA 1 1 1
SM 40:5 SM PUFA -1 1 0
SM 41:1 SM MUFA -1 -1 T T T 6 3 4 1
SM 41:2 SM PUFA -1 -1 S 6 1
SM 41:4 SM PUFA -1 -1 T T T 7 6 4 1
SM 41:5 SM PUFA 1 -1 0
SM 42:0 SM SFA 1 -1 T T T 6 6 4 0
SM 42:1 SM MUFA -1 -1 T T T 6 6 4 1
SM 42:2 SM PUFA 1 -1 1
SM 42:4 SM PUFA 1 1 T T T 6 6 4 1
SM 42:5 SM PUFA 1 1 1
SM 43:1 SM MUFA -1 -1 T T T 7 3 20 1
SM 43:2 SM PUFA -1 1 1
SM 43:4 SM PUFA -1 -1 0
SM 43:5 SM PUFA -1 1 0
SM 44:1 SM MUFA -1 1 1
SM 44:2 SM PUFA -1 -1 1
stearoylcarnitine untarg -1 -1 S 15 1
succinate untarg -1 1 1
sucrose untarg -1 1 1
TG 40:0 TG SFA -1 -1 1
TG 42:0 TG SFA -1 1 T T T 3 16 2 1
TG 42:1 TG MUFA -1 1 S T T T 16 3 2 2 1
TG 42:2 TG PUFA -1 1 S S 16 2 1
TG 44:1 TG MUFA -1 1 T T T T 2 11 16 2 1
TG 44:2 TG PUFA -1 1 T T T T 16 4 2 2 1
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Table C.1: Summary details for PCST results. Saturation levels (sat) are abbreviated as
SFA (saturated fatty acid), MUFA (monounsaturated fatty acid) and PUFA (polyunsat-
urated fatty acid). Columns d21 − d0 and d42 − d21 contain the sign of this difference.
Consensus graph nodes are terminal (T), or steiner (S). Columns labeled M21u and similar
contain module numbers from associated consensus graph. A 1 in the column HCR/LCR
indicates the compound was present in HCR/LCR data, 0 indicates otherwise.
Compound Name class sat d21 − d0 d42 − d21 CG42d node CG21d node CG42u node CG21u node M42d M21d M42u M21u HCR/LCR
TG 46:0 TG SFA -1 1 T T T T 2 3 16 2 1
TG 46:1 TG MUFA -1 1 T T T T 16 3 16 2 1
TG 46:2 TG PUFA -1 1 T T T T 16 3 16 2 1
TG 46:3 TG PUFA -1 1 T T T T 16 4 16 2 1
TG 48:0 TG SFA -1 1 T T T T 2 3 16 2 1
TG 48:1 TG MUFA -1 1 T T T T 2 3 16 2 1
TG 48:2 TG PUFA -1 1 T T T T 2 3 16 2 1
TG 48:3 TG PUFA -1 1 T T T T 2 3 16 2 1
TG 49:0 TG SFA -1 1 T T T T 2 3 16 2 1
TG 49:1 TG MUFA -1 1 T T T T 2 3 16 2 1
TG 49:2 TG PUFA -1 1 T T T T 2 3 16 2 1
TG 49:3 TG PUFA -1 1 T T T T 2 3 16 2 1
TG 50:0 TG SFA -1 1 T T T T 16 3 16 2 1
TG 50:1 TG MUFA -1 1 T T T T 16 3 2 2 1
TG 50:2 TG PUFA -1 1 T T T T 5 3 4 2 1
TG 50:3 TG PUFA -1 1 T T T T 2 3 16 2 1
TG 50:4 TG PUFA -1 1 T S T T 16 4 16 3 1
TG 50:5 TG PUFA -1 1 T S T T 2 4 16 3 1
TG 51:1 TG MUFA -1 1 T T T T 2 3 16 2 1
TG 51:2 TG PUFA -1 1 T T T T 2 3 16 2 1
TG 51:3 TG PUFA -1 1 T T T T 2 3 16 2 1
TG 51:4 TG PUFA -1 1 S S S S 2 4 16 3 1
TG 51:5 TG PUFA -1 1 1
TG 52:0 TG SFA -1 1 T T T T 16 10 2 4 1
TG 52:1 TG MUFA -1 1 T T T T 16 3 2 2 1
TG 52:2 TG PUFA -1 1 T T T T 3 3 3 2 1
TG 52:3 TG PUFA -1 1 T S T T 15 4 1 3 1
TG 52:4 TG PUFA 1 -1 T T T 4 3 3 1
TG 52:5 TG PUFA -1 1 T T T 13 5 2 1
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Table C.1: Summary details for PCST results. Saturation levels (sat) are abbreviated as
SFA (saturated fatty acid), MUFA (monounsaturated fatty acid) and PUFA (polyunsat-
urated fatty acid). Columns d21 − d0 and d42 − d21 contain the sign of this difference.
Consensus graph nodes are terminal (T), or steiner (S). Columns labeled M21u and similar
contain module numbers from associated consensus graph. A 1 in the column HCR/LCR
indicates the compound was present in HCR/LCR data, 0 indicates otherwise.
Compound Name class sat d21 − d0 d42 − d21 CG42d node CG21d node CG42u node CG21u node M42d M21d M42u M21u HCR/LCR
TG 52:6 TG PUFA 1 -1 S S 2 5 1
TG 52:7 TG PUFA 1 1 S S S 2 16 3 1
TG 53:0 TG SFA -1 1 T T T 2 16 4 1
TG 53:1 TG MUFA -1 1 T T T T 2 3 16 2 1
TG 53:2 TG PUFA -1 1 T T T T 16 3 16 2 1
TG 53:3 TG PUFA -1 1 T S T T 2 4 16 2 1
TG 53:4 TG PUFA 1 -1 T T T T 6 4 5 3 1
TG 53:5 TG PUFA 1 1 1
TG 53:6 TG PUFA -1 1 T T T 6 5 3 1
TG 53:7 TG PUFA -1 1 1
TG 54:1 TG MUFA -1 1 T T T T 2 4 2 3 1
TG 54:2 TG PUFA -1 1 T T T T 16 4 2 3 1
TG 54:3 TG PUFA 1 -1 S S 2 16 1
TG 54:4 TG PUFA 1 -1 T T T T 16 6 16 6 1
TG 54:5 TG PUFA 1 -1 T T T T 6 6 5 6 1
TG 54:6 TG PUFA 1 -1 T T T T 6 6 5 6 1
TG 54:7 TG PUFA 1 -1 T T T T 6 6 5 6 1
TG 54:8 TG PUFA 1 1 S S S 2 5 6 1
TG 54:9 TG PUFA -1 1 T T T 6 5 3 0
TG 55:0 TG SFA -1 1 1
TG 55:1 TG MUFA -1 1 T T T T 6 13 6 9 1
TG 55:2 TG PUFA -1 1 T T T T 16 10 2 20 1
TG 55:3 TG PUFA -1 1 1
TG 55:4 TG PUFA 1 -1 1
TG 55:5 TG PUFA 1 -1 0
TG 55:6 TG PUFA -1 1 T T T T 6 2 5 15 1
TG 55:7 TG PUFA 1 1 S 14 1
TG 55:8 TG PUFA -1 1 T T T T 6 2 5 1 1
TG 56:0 TG SFA 1 1 1
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Table C.1: Summary details for PCST results. Saturation levels (sat) are abbreviated as
SFA (saturated fatty acid), MUFA (monounsaturated fatty acid) and PUFA (polyunsat-
urated fatty acid). Columns d21 − d0 and d42 − d21 contain the sign of this difference.
Consensus graph nodes are terminal (T), or steiner (S). Columns labeled M21u and similar
contain module numbers from associated consensus graph. A 1 in the column HCR/LCR
indicates the compound was present in HCR/LCR data, 0 indicates otherwise.
Compound Name class sat d21 − d0 d42 − d21 CG42d node CG21d node CG42u node CG21u node M42d M21d M42u M21u HCR/LCR
TG 56:1 TG MUFA -1 1 T T T T 16 10 2 4 1
TG 56:10 TG PUFA 1 1 S S 6 5 1
TG 56:2 TG PUFA -1 1 T T T T 16 4 2 3 1
TG 56:3 TG PUFA -1 1 S S 3 3 1
TG 56:4 TG PUFA 1 1 S S 16 2 1
TG 56:5 TG PUFA 1 1 S S S 7 6 5 1
TG 56:6 TG PUFA 1 -1 S S S S 7 6 14 6 1
TG 56:7 TG PUFA 1 1 1
TG 56:8 TG PUFA 1 -1 T T T 6 5 6 1
TG 56:9 TG PUFA 1 -1 S T T T 6 6 5 6 1
TG 57:1 TG MUFA -1 1 1
TG 57:2 TG PUFA -1 1 T T T 16 12 4 1
TG 57:3 TG PUFA 1 1 1
TG 57:6 TG PUFA -1 1 T T T 20 4 15 0
TG 57:8 TG PUFA -1 1 0
TG 58:0 TG SFA -1 1 T T T 16 2 4 1
TG 58:1 TG MUFA -1 1 1
TG 58:10 TG PUFA 1 -1 T T T T 4 6 14 6 1
TG 58:11 TG PUFA 1 1 S T T T 6 7 5 6 1
TG 58:12 TG PUFA -1 1 T T T 6 5 4 0
TG 58:2 TG PUFA -1 -1 S S S S 16 4 2 3 1
TG 58:3 TG PUFA 1 -1 T T T 16 2 3 1
TG 58:4 TG PUFA 1 1 S S 3 3 1
TG 58:5 TG PUFA -1 1 0
TG 58:6 TG PUFA -1 1 1
TG 58:7 TG PUFA -1 1 T T T 7 14 6 1
TG 58:8 TG PUFA 1 1 S S 7 14 1
TG 58:9 TG PUFA 1 -1 S T T T 7 6 14 6 1
TG 60:10 TG PUFA -1 1 S S 7 14 1
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Table C.1: Summary details for PCST results. Saturation levels (sat) are abbreviated as
SFA (saturated fatty acid), MUFA (monounsaturated fatty acid) and PUFA (polyunsat-
urated fatty acid). Columns d21 − d0 and d42 − d21 contain the sign of this difference.
Consensus graph nodes are terminal (T), or steiner (S). Columns labeled M21u and similar
contain module numbers from associated consensus graph. A 1 in the column HCR/LCR
indicates the compound was present in HCR/LCR data, 0 indicates otherwise.
Compound Name class sat d21 − d0 d42 − d21 CG42d node CG21d node CG42u node CG21u node M42d M21d M42u M21u HCR/LCR
TG 60:11 TG PUFA -1 1 T T T T 7 8 14 20 1
TG 60:12 TG PUFA 1 1 1
TG 60:13 TG PUFA -1 1 S 2 1
TG 60:3 TG PUFA 1 -1 S S 16 2 1
TG 60:8 TG PUFA -1 1 T S T T 7 8 14 20 0
TG 60:9 TG PUFA -1 1 T T T 7 14 3 1
TG 62:1 TG MUFA -1 1 S 16 1
TG 62:12 TG PUFA -1 1 0
TG 62:13 TG PUFA -1 1 T T T 4 4 1 1
TG 62:14 TG PUFA 1 1 1
theobromine untarg -1 1 T T T 7 14 7 0
theophylline untarg -1 1 0
threonine untarg -1 -1 S S 7 4 1
thymine-d4(methyl-d3,6-d1) [istd] untarg -1 1 0
thyroxine untarg -1 1 S S 4 3 1
tryptophan untarg 1 1 1
tyrosine untarg -1 1 1
urate untarg 1 1 1
uridine untarg -1 -1 1
ursodiol untarg -1 1 T T T 4 3 3 1
valine untarg 1 1 1
xanthine untarg -1 1 0
xylose untarg 1 -1 0
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